

In vitro biomimetic models for glioblastoma-a promising tool for drug response studies

Tijana Stanković^{a,1}, Teodora Randelović^{b,d,1}, Miodrag Dragoj^a, Sonja Stojković Burić^a, Luis Fernández^{b,c,d}, Ignacio Ochoa^{b,c,d}, Victor M. Pérez-García^e, Milica Pešić^{a,*}

^a Department of Neurobiology, Institute for Biological Research "Siniša Stanković"- National Institute of Republic of Serbia, University of Belgrade, Despota Stefana 142, 11060, Belgrade, Serbia

^b Tissue Microenvironment Lab (TME), Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Aragon 50018, Spain

^c Centro Investigación Biomédica en Red. Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, Aragon 50018, Spain

^d Institute for Health Research Aragón (IIS Aragón), Instituto de Salud Carlos III, Zaragoza, Spain

^e Departamento de Matemáticas, E.T.S.I. Industriales and Instituto de Matemática Aplicada a la Ciencia y la Ingeniería (IMACI), Universidad de Castilla-La Mancha, Ciudad Real, 13071, Spain

ARTICLE INFO

Keywords:

Glioblastoma
3D cell culture
Drug screening
Chemoresistance
Blood-brain barrier
Mathematical models
Biomimetic models

ABSTRACT

The poor response of glioblastoma to current treatment protocols is a consequence of its intrinsic drug resistance. Resistance to chemotherapy is primarily associated with considerable cellular heterogeneity, and plasticity of glioblastoma cells, alterations in gene expression, presence of specific tumor microenvironment conditions and blood-brain barrier. In an attempt to successfully overcome chemoresistance and better understand the biological behavior of glioblastoma, numerous tri-dimensional (3D) biomimetic models were developed in the past decade. These novel advanced models are able to better recapitulate the spatial organization of glioblastoma in a real time, therefore providing more realistic and reliable evidence to the response of glioblastoma to therapy. Moreover, these models enable the fine-tuning of different tumor microenvironment conditions and facilitate studies on the effects of the tumor microenvironment on glioblastoma chemoresistance.

This review outlines current knowledge on the essence of glioblastoma chemoresistance and describes the progress achieved by 3D biomimetic models. Moreover, comprehensive literature assessment regarding the influence of 3D culturing and microenvironment mimicking on glioblastoma gene expression and biological behavior is also provided. The contribution of the blood-brain barrier as well as the blood-tumor barrier to glioblastoma chemoresistance is also reviewed from the perspective of 3D biomimetic models. Finally, the role of mathematical models in predicting 3D glioblastoma behavior and drug response is elaborated. In the future, technological innovations along with mathematical simulations should create reliable 3D biomimetic systems for glioblastoma research that should facilitate the identification and possibly application in preclinical drug testing and precision medicine.

1. Introduction

Glioma is the most common and aggressive type of malignant brain tumors. High-grade gliomas, including WHO grade III (anaplastic astrocytoma and oligodendroglioma) and WHO grade IV (glioblastoma) gliomas, are hardest to treat and have the worst survival prognosis of all brain tumors (Louis et al., 2016; Moore and Kim, 2010; Ostrom et al., 2019; Wesseling and Capper, 2018). Among high-grade gliomas, glioblastoma multiforme (GBM) is the most frequently diagnosed type that

commonly occurs between the fifth and the seventh decade of life (Moore and Kim, 2010; Ostrom et al., 2019; Wen et al., 2020). GBM is also the most aggressive brain tumor type with only 5-year survival rate of 6.8 % which renders it one of the cancers with the worst prognosis (Ostrom et al., 2019). The aggressiveness of this tumor is even more distressing given that it does not metastasize to other organs, like other solid tumors, but remains a rather brain-localized primary tumor which kills the patient.

The standard clinical protocol for GBM treatment includes surgical

* Corresponding author.

E-mail address: camala@ibiss.bg.ac.rs (M. Pešić).

¹ These authors equally contributed to the paper.

resection and radiation with concomitant and adjuvant chemotherapy (Stupp protocol). The only approved chemotherapeutic drug currently used in Stupp protocol is temozolomide (TMZ) that improves patient survival by only 2.5 months compared to radiotherapy alone (Stupp et al., 2005). Multiple new targeted therapies have been tested but also failed to prolong patients' survival (Mrugala, 2013; Wen et al., 2020). The latest FDA approved electrical device that generates tumor treating fields (Optune/NOVOTTF-100A System) improved patients' quality of life, but could not extend their survival beyond 3 months (Mrugala et al., 2017).

The evident stagnation in GBM treatment and the implementation of new therapeutic strategies is due to a number of factors including: (i) specific, hardly reachable, tumor location in the brain, (ii) highly invasive potential, (iii) presence of the blood-brain barrier (BBB), and (iv) considerable cellular heterogeneity and plasticity. All these factors contribute to prominent intrinsic, as well as acquired, resistance to both radiotherapy and chemotherapy. GBMs are generally large tumors, mainly located deep within the white matter of the supratentorial part of the brain. It commonly spreads into cortex, deep nuclei or even to contralateral hemisphere which is seen in images as a characteristic "butterfly" shape (Tataranu et al., 2018). Apart from the delicate position within the brain, GBMs are also extremely diffuse and highly infiltrative tumors which make them even more difficult to remove, in spite of improvements in neurosurgery procedures. GBM invasiveness is reflected by the infiltration of tumor cells into the surrounding brain parenchyma. Unlike other tumors that disseminate through the bloodstream and lymphatic system, GBM cells spread along white matter tracts and basal lamina of blood vessels (Bernstein and Woodard, 1995; Liu et al., 2019; Mair et al., 2018). Moreover, glioma cells' ability to undergo intravasation into the blood or lymphatic vessels has been rarely evidenced (Krol et al., 2018) and therefore distant GBM metastases are very rare (Hamilton et al., 2014). Although GBM remains localized within the brain, tumor cells invade different brain sections, affecting normal functions of the central nervous system. Hence, this life-threatening brain tumor is extremely difficult to completely resect. In addition, GBM cells show a dichotomous "go or grow" behavior. Depending on the interaction with stromal cells, communication with the extracellular matrix (ECM) and surrounding extracellular factors, such as oxygen level and nutrients availability, GBM cells can switch between a migratory and proliferative state (Giese and Westphal, 1996; Hatzikirou et al., 2012; Oliveira et al., 2017). This dichotomous phenotype has important implications for the efficiency of chemotherapy and acquisition of chemoresistance (Kathagen-Buhmann et al., 2016; Tiek et al., 2018).

Although many GBM characteristics contribute to the resistance to current therapeutic regimens, limited and varied drug delivery across the BBB can be considered a considerable reason for the slow progress in the development of more effective therapies (Agarwal et al., 2011; Haumann et al., 2020; Khaddour et al., 2020). The structure of the BBB comprises of physical, transport and biochemical barriers. Brain capillary endothelial cells prevent paracellular diffusion due to their tight junctions. Therefore, molecules from the bloodstream can pass the BBB only through luminal and abluminal plasma membranes of endothelial cells (Dyrna et al., 2013). Many anticancer drugs that do not readily cross lipid bilayers cannot pass this physical barrier. On the other hand, lipophilic drug diffusion is prevented by transmembrane efflux transporters that constitute a drug extrusion barrier on the endothelial cells. These transporters including P-glycoprotein (P-gp; ABCB1), multidrug resistance associated protein 1 (MRP1/ABCC1) and breast cancer resistance protein (BCRP/ABCG2) actively expel drugs into the capillaries (Begley, 2004; Li et al., 2016b; Wang et al., 2021). Among them, P-gp is the most abundant (Bicker et al., 2014; Zhang et al., 2021). Thus, the BBB limits the penetration into the brain of more than 98 % of small-molecule drugs, including for example paclitaxel, doxorubicin, methotrexate and vincristine (He et al., 2018).

Drug resistance due to cellular heterogeneity and plasticity is mainly

attributed to a small subpopulation of cells with stem cell-like properties commonly designated as "glioma stem cells" (GSC) (Sharifzad et al., 2019). These cells possess self-renewal capacity *in vitro* and *in vivo* and the ability to form tumors upon intracranial implantation in immunodeficient mice (Singh et al., 2004). These cells express a number of stem cell specific markers including for example Nestin, SOX2, ID1, CD15, and CD44 that maintain stem-like properties and have the ability to differentiate into multiple lineages of neuronal and non-neural cells (Aum et al., 2014). For example, as observed by live-imaging, glioblastoma stem cells may differentiate into endothelial cells and contribute to angiogenesis in GBM (Mei et al., 2017). On the other hand, differentiated glioblastoma cells can switch to a stem-like phenotype by reprogramming the expression of major neuro-developmental transcription factors, such as POU3F2 (BRN2), SOX2, SALL2 and OLIG2 (Suvà et al., 2014). Both acquisition and loss of stemness contribute to considerable plasticity of glioblastomas (Dirkse et al., 2019; Kondo, 2021). This diversity of cells gives rise to complex and pronounced intratumoral heterogeneity involved in chemoresistance, making glioblastoma a very difficult to treat malignancy.

Resistance to chemotherapy is mediated by multiple signaling pathways that are activated through different factors, either intracellular or originating from the tumor microenvironment (TME) (Assaraf et al., 2019; Gacche and Assaraf, 2018; Gonen and Assaraf, 2012; Jiang et al., 2020; Leonetti et al., 2019; Lepeltier et al., 2020; Li et al., 2016b; Mosca et al., 2021; Niewerth et al., 2015; Wijdeven et al., 2016; Zhitomirsky and Assaraf, 2016). Increasing evidence emphasizes the role of the TME in glioblastoma pathogenesis and response to therapy (DeCordova et al., 2020; Dirkse et al., 2019; Perrin et al., 2019; Son et al., 2017). However, classical 2D, monolayer cultures on plastic or glass surface do not mimic complex structure of brain tissue and glioblastoma cell behavior (Gómez-Oliva et al., 2021; Luo and Weiss, 2020; Pine et al., 2020). On the other hand, animal studies with human xenografts and orthotopic models do not adequately reproduce the disease status present in GBM patients (Gómez-Oliva et al., 2021; Kijima and Kanemura, 2017). Therefore, recent studies are focused on developing tridimensional (3D) *in vitro* cultures to study glioblastoma pathogenesis and response to therapy more realistically considering all the effects of cell surrounding.

In this review we summarize and discuss mechanisms involved in glioblastoma chemoresistance and recent progress in the development of 3D glioblastoma models to study their response to chemotherapy.

2. Intracellular factors contributing to glioblastoma chemoresistance

The majority of common chemotherapeutics, as well as radiotherapy, inflict severe DNA damage, predominantly DNA double strand breaks (DSB). (Borrego-Soto et al., 2015; de Almeida et al., 2021; Huang and Zhou, 2020; Woods and Turchi, 2013). It was shown that glioblastoma cells, particularly their CD133+ stem-like subpopulation, have enhanced activation of DNA damage checkpoint proteins (ATM, Rad17, Chk1 and Chk2) and subsequent DNA repair upon treatment, therefore causing therapy failure (Ali et al., 2020; Bao et al., 2006a; Bighetti-Trevisan et al., 2019). However, resistance to TMZ, as an alkylating agent, is mediated by another set of DNA repair proteins, involving increased expression of MGMT (Sun et al., 2013), and deficiency in components of base excision and mismatch repair systems (Cahill et al., 2007; Felsberg et al., 2011; Montaldi and Sakamoto-Hojo, 2013).

Apart from causing direct DNA damage, chemotherapy also generates reactive oxygen species (ROS) that cause additional DNA breaks and damage of important cellular proteins and lipids (Cui et al., 2018a; Yang et al., 2018). Unfortunately, glioblastoma cells have developed the ability to resist such therapeutic assault by lowering ROS production and increasing expression of components of their scavenging system including superoxide dismutase (SOD), catalase, glutathione peroxidase (GPX), glutathione reductase (GR), Solute Carrier Family 7 Member 11

(SLC7A11) (Lee et al., 2004; Oliva et al., 2011; Polewski et al., 2016).

Normally, cells damaged upon chemotherapy would undergo autophagy (to self-repair) and/or apoptosis (to self-destruct) (Hou et al., 2020; Knizhnik et al., 2013; Pawlowska et al., 2018; Russo and Russo, 2018). However, glioblastoma cells have developed additional defense mechanisms against therapy based on these two processes. They have enhanced pro-survival autophagy pathways (increased expression of VPS34, Beclin1, ATG5, LC3, BNIP3) and developed the ability to evade apoptosis (Chen et al., 2015; Hu et al., 2012b; Ruano et al., 2008), contributing to further tumor mass growth despite significant cellular impairments. High grade glioma stem cells were shown to have increased expression of anti-apoptotic proteins (Fanfone et al., 2020; Jin et al., 2008), while pro-apoptotic molecules were downregulated (Capper et al., 2009; Daniele et al., 2018). Such alterations in apoptotic machinery eventually contribute to glioma resistance to therapy (Ma et al., 2002; Trejo-Solís et al., 2018; Valdés-Rives et al., 2017).

In the very essence of the abovementioned mechanisms of chemoresistance is the deregulation of numerous signaling pathways. The most commonly altered signaling molecules in chemoresistance are involved in maintaining stem-like phenotype (Notch and Wnt/ β -catenin pathways) and have pro-survival and anti-apoptotic effect (PI3K/Akt/mTOR and RAS/MAPK pathways) (Hombach-Klonisch et al., 2018; Valdés-Rives et al., 2017; Yamada et al., 2011). In addition, ATP-binding cassette (ABC) transporter superfamily is another class of molecules particularly important for the anti-glioma chemotherapy resistance. Glioma cells have predominantly overexpressed multidrug resistance-associated proteins (MRPs) conferring intrinsic chemoresistance (Calatuzzolo et al., 2005). High MRP1 and BCRP expression is characteristic of glioma stem-like cell population and high grade gliomas (Calatuzzolo et al., 2005; Garrido et al., 2014; Jin et al., 2008, 2009). P-gp, as the best characterized ABC transporter, is also reported to be expressed to some extent in gliomas but its role in chemoresistance is still controversial. Its presence, together with that of BCRP, in the BBB appears to be the most responsible for reduced drug efficacy in glioblastoma (de Trizio et al., 2020; Declèves et al., 2006).

3. Microenvironment factors contributing to glioblastoma chemoresistance

Sensitivity to anti-glioma therapy also considerably depends on different microenvironment factors, primarily hypoxia. Severe hypoxia is a major characteristic of high grade gliomas. It causes formation of pseudopalisade structures with necrotic areas, thrombotic vessels and a characteristic rim of highly migratory cells that are moving away from hypoxic regions (Brat et al., 2004). In response to low oxygen levels, glioma cells undergo phenotypic and genetic changes that allow them to survive and even proliferate in a hypoxic environment. Hypoxic conditions predominantly promote stem-like properties of both stem and non-stem glioma cells by stimulating their self-renewal and neurosphere formation (Colwell et al., 2017; Heddlestone et al., 2009; Li et al., 2009). This hypoxia-induced response is driven by changes in the expression of hypoxia-induced factors (HIF1 α and HIF2 α), various downstream pro-survival signaling molecules (PI3K-Akt or ERK1/2 pathways) and numerous stemness markers (CD133, CXCR4, CD44, A2B5, OCT4, NANOG and c-MYC) (Heddlestone et al., 2009; Li et al., 2009; Soeda et al., 2009). Such stemness-like phenotype, promoted by hypoxia, additionally contributes to therapy resistance (Kolenda et al., 2011; Raz et al., 2014). Moreover, hypoxia can have direct negative effect on anti-glioma therapy efficacy, by eliminating free radicals or slowing down tumor cell proliferation = as well as indirect effect mainly through HIF-1 α activation. Specifically, increased HIF activity up-regulates the expression of MDR efflux transporters of the ABC superfamily which mediate chemoresistance (Chou et al., 2012; Uribe et al., 2017). Moreover, HIF-1 α affects glioma sensitivity to therapy by regulating autophagy/apoptosis, metabolism, proliferation, and the tumor vasculature (Amberger-Murphy, 2009; Huang et al., 2019). Sanzey and colleagues

showed that severe hypoxia strongly upregulated the expression of glycolysis-related genes in patient-derived GBM cells that resulted in increased glycolytic activity and promoted tumor invasiveness (Sanzey et al., 2015).

Apart from modulating glioma cell phenotype and treatment response, hypoxia affects other microenvironment factors which additionally contribute to therapy resistance (Gacche and Assaraf, 2018). Due to the hypoxic conditions, tumor cells switch to anaerobic metabolism causing acidification of the TME. This acidic stress promotes and maintains glioma stem-like phenotype (Hjelmeland et al., 2011). Specifically, increased expression of HIF-1 α , in response to hypoxia, enhances survival of nearby endothelial cells and induces the expression of vascular endothelial growth factor (VEGF) that further stimulates formation of new blood vessels (angiogenesis) (Bao et al., 2006b; Ezhilarasan et al., 2007; Tamura et al., 2020; Zhang et al., 2015). Reciprocally, endothelial cells induce glioma stem cell state and stimulate sphere formation via Notch signaling (Xu et al., 2015; Zhu et al., 2012). They also release different factors, such as bFGF or nitric oxide, which additionally favor glioma plasticity and induction of stem-like phenotype (Charles et al., 2010; Fessler et al., 2015).

In addition to interaction with surrounding cells and different factors they secrete, the ECM is another important component of the perivascular niche that determines glioblastoma cell behavior and response to therapy. The composition of brain ECM is quite unique and distinct from other tissues. Its abundant components are glycosaminoglycans, predominantly hyaluronic acid, and proteoglycans, such as heparan sulfate, while the presence of fibrous glycoproteins collagen, laminin and fibronectin is scarce and mainly restricted to blood vessels basement membrane (Belousov et al., 2019). In glioblastoma, most of these components are overexpressed and contribute to GBM invasion (Virga et al., 2017), as well as acquisition of stem-like phenotype and chemoresistance (Farace et al., 2015; Hu et al., 2012a). Moreover, changes in the ECM composition modulate its physicochemical properties, in the first place stiffness and rigidity, which additionally contribute to increased invasiveness and chemoresistance (Coppola et al., 2017; Erickson et al., 2018; Ulrich et al., 2009).

4. *In vitro* 3D models of glioblastoma

Different glioblastoma 3D cell culture models were developed with the intention to recreate a TME and mimic interactions between tumor cells, different cellular components and ECM (Fig. 1). The aim is to create biomimetic systems that are user-friendly, cost-effective and compatible with downstream analysis, to finally obtain a reliable GBM model which could be used for therapy response studies in personal medicine.

4.1. Types of 3D GBM cell cultures

One of the highly biomimetic GBM models, used for drug testing, is growing a tumor tissue explant in a collagen-coated Petri dish. It conserves a real structure of the tumor with all components of its microenvironment (Freeman and Hoffman, 1986). A similar model, which includes growing GBM cells on an organotypic brain slice, enables investigation of tumor invasion in healthy brain tissue (Jung et al., 2001). Disadvantages of these models are low reproducibility and difficulties with the preservation of the tissue.

Therefore, more reproducible models of 3D cell culture were introduced and widely used in GBM research. Depending on the cell culture environment, we can distinguish between scaffold-free and scaffold-based cultures (Saji Joseph et al., 2019).

4.1.1. Scaffold-free models

Scaffold-free cultures are spherical multicellular aggregates that well represent different biochemical gradients, as the diffusion within them is limited. Larger aggregates develop gradients of oxygen, nutrients,




Fig. 1. 3D GBM cell culture models: (A) Multicellular tumor spheroid (MCTS) formation: (1) Hanging drop method – Growing cells in a small volume of medium on a lid of a Petri dish permits the cells to fall to the tip of a drop, aggregate and form MCTS; (2) Non-adherent surface method – Seeding cells on a surface that is not suitable for cell attachment, leads to cell accumulation on the bottom of the well and formation of MCTS; (3) Magnetic levitation – Incorporation of magnetic nanoparticles within the cells allows magnetic-induced cell floating and formation of MCTS on the liquid-air interface; (B) Cultures made from patient samples: (1) Neurospheres – Primary cells obtained by enzymatic dissociation of tumor tissue are grown in medium without serum and supplemented with growth factors, which promote sphere formation; (2) Organotypic multicellular spheroids – Fragments of fresh tissue, grown under non-adherent conditions, round up and form spheroids; (3) Organoids – Primary cells or tumor tissue fragments can form complex 3D structures, when embedded in matrigel or grown in special medium on orbital shaker; (C) Scaffold-based models: (1) Hydrogels – Cell suspension can be mixed with liquid polymer precursor which after cross-linking converts to solid scaffold with encapsulated cells; (2) Porous scaffolds – Cells seeded on the top of the solid scaffold enter within the scaffold and form 3D structures; (3) Fibrous scaffolds – Organized scaffold that mimics GBM invasion pathways; (D) Cultures with medium flow: (1) Bioreactors: (a) Stirring bioreactor – Constant agitation of cells prevents cell attachment to the surface and promotes spheroid formation; (b) Perfusion bioreactor – Scaffold based culture connected to peristaltic pump permits the simulation of physiological mass transport; (2) Microfluidic devices: (a) Simple microfluidic device connected to syringe pump for investigation of shear stress effects; (b) Gradient microdevice – Hydrogel with embedded cells is filled within the central chamber, while lateral channels are perfused with medium, that way permitting formation of different gradients. Created with BioRender.com.

growth factors, signaling molecules and molecular waste and can simulate drug penetration within a solid tumor. Scaffold-free models include spheroids and organoids.

4.1.1.1. Spheroids. Spheroids are the most frequently used 3D models. They successfully mimic cell-to-cell interactions. Limited diffusion within spheroids causes formation of different cellular zones: proliferating zone on the surface (sufficient level of oxygen, nutrients and signals), necrotic zone in the central part of the spheroid (lack of oxygen and nutrients, higher concentration of the waste) and quiescent zone between these two zones (Bell et al., 2001; Nath and Devi, 2016).

Depending on the cell line type, spheroid complexity and the method for its formation, one can distinguish between different types of glioblastoma spheroid cultures: multicellular tumor spheroids (MCTS), neurospheres, tissue-derived tumor spheres and organotypic multicellular spheroids (Weiswald et al., 2015). Growing tumor cell lines under non-adherent conditions leads to cell aggregation and formation of

spherical multicellular structures. here are different ways for the MCTS formation: non-adherent surface method, hanging drop method, suspension culture and magnetic levitation (Hoarau-Véchet et al., 2018). It is also possible to create spheroids within scaffolds and microfluidic devices, which will be discussed later.

Neurospheres (also called tumor spheres and gliomaspheres) are a special type of spheroid cultures generated from patient-derived primary GBM cells. Primary cells from GBM patients, obtained by dissociation of tumor tissue, are normally grown under suspension culture conditions, in serum-free medium, supplemented with B27, bFGF and EGF (Gómez-Oliva et al., 2021; Lee et al., 2006; Lenting et al., 2017). This enables spontaneous formation of neurospheres. Glioblastoma stem-like cells are a predominant component of the neurosphere, while the rest of cell subtypes are being lost (Lee et al., 2006; Xiao et al., 2017).

Fragments of fresh tumor tissue from patients can be grown *in vitro* in agar coated flasks, without prior dissociation. Differing from tumor tissue explant mentioned above, anti-adherence agar coating allows the

tissue to round up and form organotypic multicellular spheroids. This model properly represents the tumor. It conserves the TME with all cell types and ECM and better preserves the *in vivo* phenotype. On the other hand, its reproducibility is low and different results can be obtained, as they depend on the fraction of tumor cells that is successfully grown (Bjerkvig et al., 1990; Christensen et al., 2010; De Witt Hamer et al., 2009; Mahesparan et al., 1999).

4.1.1.2. Organoid culture. Organoids are complex 3D structures that better represent the heterogeneous structure of the tissue (Andreatta et al., 2020; Gómez-Oliva et al., 2021; Klein et al., 2020; Zhang et al., 2020). They are usually obtained by growing primary stem cells or pluripotent stem cells, which are able to differentiate in various cell subtypes and to self-organize, creating specific tissue structures. A growth medium containing specific factors or ECM components are needed to promote cell differentiation and organization (Lancaster and Knoblich, 2014). The first glioblastoma organoids were formed by embedding tumor cells in matrigel and growing them in a stem cell medium on orbital shaker (Hubert et al., 2016). The disadvantages of these organoid cultures are the long formation time, lack of vascularization and the absence of complete maturation of the reproduced organ (Lancaster and Knoblich, 2014; Saji Joseph et al., 2019). Recently, Jacob et al., developed a new method for organoid formation (Jacob et al., 2020). Patient derived tumor tissue is cut into small pieces and grown on an orbital shaker in serum-free medium without exogenous addition of growth factors and ECM, hence preventing cell selection and allowing conservation of molecular signatures of parental tumor and different cellular components of TME for prolonged time. Limitations of this model are decreased rate of organoid formation from IDH-1 mutant and recurrent tumors as well as decrease of vasculature and immune cells after long culture (Jacob et al., 2020).

4.1.2. Scaffold-based models

Scaffold-based models comprise of different components of GBM microenvironment in an *in vitro* system. They are based on diverse biocompatible materials that give support to cells and mimic biochemical and mechanical properties of ECM. Within scaffolds we can study cell growth, invasion, cellular interactions with its microenvironment and the effects of potential therapy.

Scaffolds can be made from natural and synthetic materials (Hoarau-Véhot et al., 2018; Lv et al., 2017; Saji Joseph et al., 2019). Natural material-based scaffolds consist of ECM-derived biomolecules, such as hyaluronic acid (HA) (Ananthanarayanan et al., 2011), collagen (Cheng et al., 2015; Rao et al., 2013a; Ulrich et al., 2010), fibrinogen (Bayat et al., 2018), basement membrane extracts (Ahmed et al., 2018; Musah-Eroje and Watson, 2019) and even decellularized patient tissue (Koh et al., 2018). Cells grown in these scaffolds are able to receive transduction signals and to respond to changes in the microenvironment. The disadvantage of these materials is that, as they originate from mammalian organisms, they can contain pathogens, variations in soluble factors and protein concentrations, so the results obtained in such scaffolds can vary. In order to overcome these problems, non-mammalian polymers are used (alginate and chitosan) (Benson et al., 2014; Kievit et al., 2010; Zustiak et al., 2016), as they are also biocompatible with GBM cells, but are non-immunogenic. Also, different synthetic polymers are being developed. These polymers are inert, their properties can be highly controlled and they give reproducible results. As they do not have cellular adhesion sites, bioactive proteins can be attached, such as RGD functionalized proteins (with the adhesive peptide of tri-amino acid sequence, arginine-glycine-aspartate), in order to enable cellular adhesion or biodegradation (Pedron et al., 2013; Wang et al., 2014). Some of the synthetic polymers used are polystyrene (Gomez-Roman et al., 2016), polydimethylsiloxane (PDMS) (Rao et al., 2013b), polylactic acid (Ma et al., 2018), poly(ethylene-glycol) (PEG) (Li et al., 2016a; Wang et al., 2014, 2017a), polycaprolactone (PCL)

(Martínez-Ramos and Lebourg, 2015).

Depending on the 3D structure of the scaffold they can be divided into hydrogels, fibrous scaffolds and porous scaffolds (Cha and Kim, 2017; Saji Joseph et al., 2019). Hydrogels are microporous polymer networks that have high water absorption capacity. Physical or chemical cross-linking of liquid precursors leads to the creation of solid scaffolds. This permits the encapsulation of the cells within the scaffold at the beginning of the fabrication process. As hydrogels are rich in water, the transport of oxygen, nutrients and growth factors is possible. Depending on their composition, hydrogels can have similar biophysical and biochemical characteristics to ECM, hence presenting a more realistic *in vitro* model and the most frequently used one (Caliari and Burdick, 2016; Xiao et al., 2017).

Fibrous scaffolds mimic fibrous structures of white matter tract or blood vessels, which serve as invasion routes for GBM cells (Cha and Kim, 2017). They are made by electrospinning of synthetic polymer solutions, such as PCL (Johnson et al., 2009; Unal et al., 2020), polystyrene (Sharma et al., 2013), polyacrylonitrile (Saleh et al., 2019) or PDMS (Rao et al., 2013b). Cells are seeded on the top of the scaffold, they attach on the surface of the material and their migration along scaffold can be followed.

Porous scaffolds are solid scaffolds, composed of interconnected pore network. They provide a physical support to cells and permit formation of 3D structures. Cells are seeded on the top of the scaffold and they enter it passively or by migration, attach to the walls, proliferate, cluster and form spheroids. Different techniques can be used for scaffold fabrication. Some of them are freeze drying, micro molding, gas foaming, solvent casting/particulate leaching and bioprinting, as the most advanced method (Lv et al., 2017; Saji Joseph et al., 2019).

3D bioprinting is a manufacturing process that enables creation of tissues and organs using different hydrogel-based biomaterials (bioinks) and cells. The fabrication process requires digital design of the desired structure and segmentation of the image, in order to enable printing of successive layers of material and cells and formation of 3D systems (Shafiee and Atala, 2016). This process is highly controlled and facilitates precise distribution of different cell types and ECM, thereby mimicking TME with its cellular, biochemical and biophysical components. Using 3D bioprinting, one is able to obtain complex, highly reproducible 3D cell cultures. However, depending on the parameters of the printing processes, it can provoke cell death or changes of phenotype; thus, it is important to optimize the conditions (Hoarau-Véhot et al., 2018; Zhang et al., 2016). Recently, more bioprinted models of GBM are being developed, as the technique has great potential for GBM studies (Dai et al., 2016; Heinrich et al., 2019; Hermida et al., 2020; Lee et al., 2019; Maloney et al., 2020; Smits et al., 2020; Tang et al., 2020; Wang et al., 2018b, 2020c; Yi et al., 2019). Furthermore, additional components of TME were added to GBM bioprinted models, oxygen gradients were created (Yi et al., 2019) and different cell types were included, such as macrophages (Heinrich et al., 2019; Hermida et al., 2020; Tang et al., 2020), astrocytes (Smits et al., 2020; Tang et al., 2020) and vascular endothelial cells (Yi et al., 2019).

4.1.3. 3D GBM cell cultures with media flow

In order to reconstitute real tumor conditions more faithfully, researchers have developed complex 3D cell cultures that introduce media flow through the system. Depending on the design of these perfusion 3D cultures, the presence of media flow, mimics blood flow through the vessels and/or interstitial fluid flow. Bioreactors and microfluidic devices are examples of these complex 3D cell cultures, developed also for GBM studies.

Bioreactors are closed systems in which biological and biochemical processes are under a strictly controlled environmental and operating conditions (e.g., temperature, pH, pressure, shear stress, nutrient supply, oxygen and CO₂ concentration, metabolites and regulatory molecules) (Hoyle et al., 2020; Martin et al., 2004; Selden and Fuller, 2018; Wang et al., 2020a). Since bioreactors provide us with a high degree of control,

reproducibility and automation, they have found applications in various fields. Bioreactors are also designed and used for growing cancer cells and scaffold-based tumor tissues as a new 3D model of malignant neoplasms.

Bioreactors for tumor tissue engineering have to be made from bio-inert and biocompatible materials. The whole system should operate under sterile culture conditions and allow specific mass transport and nutrient supply. Also, it should be transparent to allow visualization and use of fluorescence and optical imaging of tumor tissue (Bregenzner et al., 2019; Guller et al., 2016).

Depending on the physicochemical parameters to be controlled and the desired outcome of the experiment, many different types of bioreactors have been developed and used for tumor tissue engineering. They can be grouped into the following types: bioreactors with static cultivation systems, stirring bioreactors, rotary bioreactors, hollow-fiber bioreactors and perfusion bioreactors. Detailed description of these bioreactors and their application in tumor tissue engineering have been previously reviewed (Guller et al., 2016).

Bioreactors have been mainly used to cultivate a large amount of human GBM-derived cancer stem cells (GSCs), hence circumventing the limitations of massive cell propagation in conventional *in vitro* 2D cell cultures (Serra et al., 2012). The type of bioreactor most commonly used for expansion of CSCs of various tumors, including GBM, is the stirring bioreactor. This type of bioreactor provides dynamic mixing of the growth medium and significantly improves mass transfer between cells and the culture medium. However, these conditions place the cells under the constant influence of fluid-induced shear stress (Bregenzner et al., 2019; Guller et al., 2016). Recently, perfusion bioreactors have been used as a new strategy for improving the 3D *in vitro* models of the GBM. This type of bioreactors achieves the most accurate simulation of mass transfer in a living organism (Ahmed et al., 2019). Combining scaffold-based 3D cell culture and perfusion bioreactor has found application in producing large amounts of glioblastoma tumor-initiating cells (TICs) required for drug screening, as well as for basic cancer research (Li et al., 2016a, 2018).

Microfluidic platforms or chips are microfabricated bioreactors that enable growing cells in micrometric chambers within well controlled physiological-like conditions. They consist of one or more fluidic channels where small volumes of liquid and low number of cells can be handled (Whitesides, 2006). Depending on the characteristics of the device, we can mimic interactions between cells, between cells and ECM, as well as to mimic biophysical and biochemical characteristics of the TME, such as gradients of nutrients, oxygen and signaling molecules (Ayuso et al., 2016). As the laminar flow is present within the channels of the microdevice, there is no fluid mixing and molecules travel through the device by diffusion (Paguirigan and Beebe, 2008).

The simplest microfluidic devices consist of a simple channel that permits the 2D growth of cells. They are used to investigate flow-induced shear stress effects, migration, nutrient gradients and drug effects (Han et al., 2016; Huang et al., 2011; Jo et al., 2018; Liu et al., 2010; Rezk et al., 2020). As mentioned above, microfluidic platforms can be used for spheroid formation. These devices are made from anti-adherent materials and their geometry promotes capturing of the cells within microwells, their aggregation and spheroid formation (Vadivelu et al., 2017). Within some devices, cells are embedded in hydrogels and thus, by providing physical and biochemical components of ECM, a more adequate biomimetic model is created (Ayuso et al., 2017, 2016; Lee et al., 2014; Qazi et al., 2011; Samiei et al., 2020).

Microfluidic devices permit a real time monitoring of cell culture. They can be used for different purposes, to investigate cell proliferation, metabolism, migration and invasion, angiogenesis, immune system function and most importantly therapy response (Andrei et al., 2019; Ayuso et al., 2017, 2016; Logun et al., 2018; Samiei et al., 2020).

4.2. 3D glioblastoma models specifically used for anti-glioblastoma drug screening

Most of the studies that examined anti-glioblastoma effects of different chemotherapeutic drugs, as well as novel compounds in a 3D setting used spheroids grown in medium as a model system. Some examples of drugs/compounds tested for their anticancer effect in gliomaspheres are listed in Table 1.

Recently, Quereda and collaborators developed a high-throughput spheroid-based proliferation assay for testing cytotoxicity of up to 3,300 compounds simultaneously on GSC cells (Quereda et al., 2018).

Although simple spheroid systems in growth media are widely used for drug screening in 3D GBM cultures they have significant limitations, primarily the simplified architecture that lacks complex TME conditions. Therefore, in several publications drug effects on glioblastoma cells were tested in different 3D scaffolds mimicking natural ECM (Table 1). In most of these studies the authors examined the invasion of 3D culture in response to various compounds, such as inflammatory cytokines IL-1 β and TNF α (Sarkar and Yong, 2009), FasL neutralizing antibody (Merz et al., 2015) or drug combination of imatinib and docetaxel (Kinsella et al., 2011). However, two research groups, An et al. (2010) and Iwasaki et al. (1993), performed more comprehensive studies and investigated then effects of vorinostat (histone deacetylase inhibitor) and TNF α , respectively, on 3D cell culture growth and viability, morphological and adhesive characteristics and gene expression in addition to invasive properties.

Lee et al., constructed a type of 3D platform with alginate matrix for high-throughput drug cytotoxicity and efficacy testing on both GBM cells and normal astrocytes (Lee et al., 2017). This 3D chip with micropillars (for growing cells in alginate matrix) and microwells (containing drugs) is suitable for simultaneous screening of 72 compounds in 7 replicates (Lee et al., 2017). Recently, technological advances enabled us to perform more accurate and reliable drug testing in complex 3D cultures, such as in microfluidic devices, which more faithfully recapitulate glioblastoma TME and its conditions observed in patients. Examples of microfluidic devices specifically developed for anti-glioblastoma drug screening are summarized in Table 1. Fan and colleagues developed microfluidics-based brain cancer chip for high-throughput testing of multiple-simultaneous drug response on GBM spheroids in PEGDA hydrogel (Fan et al., 2016). They validated generation of drug concentration in chip by testing single and combined effects of pitavastatin and irinotecan on U87 spheroid cell viability. Recently, the same group of authors engineered an improved version of the brain cancer chip that prevents the diffusion of any drug molecule across channels (Akay et al., 2018). As a proof-of-concept experiment, they tested viability effects of concentration gradient generated by simultaneous application of temozolomide and bevacizumab on three GBM patient-derived cell spheroids. To consider effect of cellular heterogeneity on drug treatment response, Pang and collaborators designed a microfluidic platform for single-cell separation based on cell biomechanical properties. In this system, the authors were able to determine the level of vincristine sensitivity according to the cell size and degree of deformability (Pang et al., 2016).

5. Effects of 3D culture on GBM gene expression and phenotype

Cell culture dimensionality significantly affects glioblastoma cell phenotype, such as morphology, migration, proliferation, differentiation and stemness (Table 2). Numerous studies have shown that glioma cells have an altered morphology in 3D systems compared to 2D cell cultures. In 3D matrices, cells are present in a spindle or round form compared to flattened epithelioid shape when grown in monolayers (Gomez-Roman et al., 2016; Huang et al., 2018; Jia et al., 2018; Jiguet Jiglaire et al., 2014; Kievit et al., 2010, 2014; Wang et al., 2016, 2018a; Wang et al., 2019b). Unlike cells in 2D cultures that lack polarity, spindle cells of 3D cultures contain one or two oriented spindly

Table 1
3D GBM cell cultures used to study anti-glioblastoma drug activity.

3D cell cultures	GBM cell types	Drugs	Reference
Scaffold-free cultures			
Spheroids grown in media	U251, primary cell lines	Acetazolamide with TMZ	(Amiri et al., 2016)
	U87, primary cell lines	RO4929097 with TMZ and radiotherapy	(Yahyanejad et al., 2016)
	U87	Curcumin and DOX in micellar carrier	(Sarisozen et al., 2016)
	U251	Pyrrolidine-2 and curcumin	(Zhang et al., 2016)
	T-98G	Curcumin and TMZ in magnetic nanoparticles	(Dilnawaz and Sahoo, 2013)
	U251	Metformin and Ara-a	(Mouhieddine et al., 2015)
	LN229, U87, T-98 G	Sodium Selenite with TMZ	(Berthier et al., 2017)
	U87	²²⁵ Ac in polymersomes	(de Kruijff et al., 2018)
	Primary cell lines	Niclosamide with TMZ	(Oh et al., 2020)
	U87, primary cell lines	Simultaneous cytotoxicity testing up to 3300 compounds	(Quereda et al., 2018)
Organoids grown in media	Patient tissue	TMZ with radiotherapy, gefitinib, trametinib, everolimus	(Jacob et al., 2020)
Scaffold-based cultures			
Single cells in Type I collagen 3D matrix	U178	IL-1 β and TNF- α	(Sarkar and Yong, 2009)
Spheroids in Matrigel	U87, U251	APG101	(Merz et al., 2015)
Spheroids in collagen gel	SNB-19, primary cell lines	Imatinib and Docetaxel	(Kinsella et al., 2011)
Spheroids in collagen type I 3D gel	LN18, F98, C6, F98EGFR-vIII, U87	Vorinostat	(An et al., 2010)
Single cells in Matrigel	Primary cell lines	TNF- α	(Iwasaki et al., 1993)
Organoids in hyaluronic acid-collagen hydrogel	Patient derived cells	Dacomitinib	(Maloney et al., 2020)
Single cells in collagen gel	U251, U87	Simvastatin with TMZ	(Shojaei et al., 2020)
3D platforms			
High-throughput alginate micropillar and microwell chip platform	Patient derived cells and normal human astrocyte cell line	70 compounds simultaneously tested	(Lee et al., 2017)
Spheroids forming microfluidic device with PEGDA hydrogel	U87	Pitavastatin and Irinotecan	(Fan et al., 2016)
Spheroids forming microfluidic device with PEGDA hydrogel	Patient derived cells	TMZ and bevacizumab	(Akay et al., 2018)
Single cell separation microfluidic device	U251	Vincristine	(Pang et al., 2016)

TMZ-temozolomide; DOX-doxorubicin; Acetazolamide-carbonic anhydrase IX inhibitor; RO4929097- NOTCH/ γ -secretase inhibitor; Pyrrolidine-2-cytoplasmic phospholipase A2 α inhibitor; ²²⁵Ac-Actinium; APG101-CD95 ligand neutralizing agent; Vorinostat - suberoylanilide hydroxamic acid.

protrusions (Huang et al., 2018). This is particularly evident for highly invading cells that present a neural progenitor-like phenotype with a round small cell body and a long leading process, as shown in experiments with tumor spheres grafted into a 3D collagen matrix (Fayzullin et al., 2019). Moreover, in 3D scaffolds, glioblastoma cells tend to form multi-cellular clusters and to aggregate into tumor cell spheroids (Florczyk et al., 2013; Lv et al., 2016), while cells cultured on 2D surfaces have an epithelium-like morphology and grow into sheets (Wang et al., 2018a). This colony formation ability in 3D culture depends on the GBM cell type and characteristics of 3D scaffold, such as pore size (Jia et al., 2018). As observed in the study of Wang et al., cells form tighter spheroids in 3D scaffolds with closer connections and have more abundant secretory granules on the cell surface (Wang et al., 2018b). Those cells were also richer in mitochondria and rough endoplasmic reticulum and had a higher number of longer microvilli.

Apart from influencing cell morphology, 3D culture environment also enhances the migration ability of the glioma cells, compared with the 2D plated cultures (Jia et al., 2018). The movement pattern in 3D cultures significantly depends on the presence of the tumor core; without a tumor core, cells migrate randomly, while existence of tumor sphere induces oriented cell migration (Fayzullin et al., 2019). It was shown that migration of U87 glioblastoma cells in 3D environment is driven by mesenchymal-amoeboid transition (MAT) upon Rac1 GTPase inhibitor treatment (Huang et al., 2018).

Glioblastoma cell proliferation is generally slower in 3D compared to 2D cultures (Dai et al., 2016; Florczyk et al., 2013; Gomez-Roman et al., 2016; He et al., 2014; Jia et al., 2018; Jiguet Jiglaire et al., 2014; Kievit et al., 2010, 2014; Lv et al., 2016; Wang et al., 2016), and it is accompanied by decreased expression of the proliferative marker Ki67 (Jia et al., 2018). According to the Gomez-Roman study, this behavior can be changed in response to VEGF supplementation which increases 3D cell proliferation but has no effect on 2D growth conditions (Gomez-Roman et al., 2016). It was observed that in a 3D environment, GBM cells accumulate in G0/G1 cell cycle phase but without significant difference in apoptosis rate compared to 2D culture, suggesting their decreased proliferation and increased quiescence in 3D scaffolds (Lv et al., 2016). Although 2D culture initially had higher proliferative capacity, it was shown that upon prolonged 2D cultures (longer than 10 days), cellular proliferation decreases after some point of time and then proliferation rate of 3D bioprinted cultures becomes higher (Dai et al., 2016; Wang et al., 2018a, 2019b).

Fernandez-Fuente and colleagues first showed that there is no difference in GBM cell differentiation level (GFAP level) between 2D and 3D cultures (Fernandez-Fuente et al., 2014). However, a later study of Lv et al., reported decreased GFAP level as a marker of increased dedifferentiation of glioblastoma cells in 3D compared to 2D culture (Lv et al., 2016). Several observations are consistent with the later finding and show that cultures in different 3D scaffolds have a greater proportion of stem cell-like cells, with CD133 positive phenotype, compared to monolayer cultures (Kievit et al., 2014; Wang et al., 2018a, 2018b; Wang et al., 2019b).

Along with increased stem-like phenotype, angiogenic potential of GBM cells is also altered in 3D compared to 2D cultures. For example, accelerated vasculature formation, with enhanced recruitment of CD31 positive cells, was observed in U87 tumors from cells pre-cultured in 3D chitosan alginate scaffolds (Kievit et al., 2010). Moreover, complexity of 3D culture can affect angiogenic potential as well. Wang et al., reported that 3D bioprinted GSC culture had increased VEGFA secretion and formed more tube-like structures than conventional GSC suspension culture (Wang et al., 2018b).

Corresponding to increased stemness, three-dimensionally grown glioblastoma cells also have increased *in vivo* tumorigenic potential. They form larger tumors that are developing much faster, compared to tumors derived from monolayer cell cultures (Kievit et al., 2014; Wang et al., 2018a, 2019b). However, Kievit et al., reported that this initial rapid tumor growth is not sustainable and after some time tumors

Table 2
Effects of 3D cell culture and microenvironment on GBM cell phenotype.

Cell characteristics	Properties of 3D cell culture									
	Third dimension	Inclusion of ECM components in 3D scaffold	Stiffer scaffold	Interstitial flow	Hypoxia	Nutrient supply	Endothelial cells	Astrocytes	Mesenchymal cells	Immune cells
Morphology	Spindle/round ¹	Spindle/round ²	More round	More homogeneous	ND	ND	Round/elongate ²	Round	ND	ND
Proliferation	–	ND	–	ND	+/- ³	+	–	+/- ^{2,4}	+	+
Migration	+	+/- ²	–	ND	+	ND	ND	+	ND	ND
Invasion	ND	+	–	+	+	ND	+	+	+/- ⁵	+
Stemness	+	+	ND	ND	ND	+	+	+	ND	+
Angiogenic potential	+	ND	+	ND	ND	ND	+	ND	ND	+
Tumorigenic potential	+	+	ND	ND	ND	ND	ND	ND	ND	ND
Therapy resistance markers expression	+	+	ND	ND	ND	ND	ND	ND	ND	ND
Apoptotic factors expression	Pro – Anti +	ND	ND	ND	Pro +	ND	ND	ND	ND	ND

+ increased; - decreased; ND – not determined; ¹ depending on 3D cell culture model; ² depending on scaffold composition; ³ depending on O₂ concentration; ⁴ depending on seeding ratio; ⁵ depending on cell type.

developed from 3D pre-cultured cells began to grow at a similar rate as the 2D pre-cultured tumors (Kievit et al., 2010).

As cell appearance and behavior is determined by gene expression, it was reasonable to assume that the dimensionality of cell culture would also significantly affect regulation of gene expression. Indeed, when grown in 3D cultures, glioblastoma cells showed different levels of expression of various genes compared to culturing in monolayers (He et al., 2014; Levin et al., 2012). Numerous studies have observed altered expression of several classes of markers (mRNA and/or protein) in 3D cultures, including:

- Stemness related markers - most frequently general stemness markers such as CD133 (Jia et al., 2018; Kievit et al., 2014; Lv et al., 2016; Martínez-Ramos and Lebourg, 2015; Wang et al., 2018a, 2018b; Yang et al., 2015), CD44 (Kievit et al., 2014; Martínez-Ramos and Lebourg, 2015; Wang et al., 2018a), Nestin (Dai et al., 2016; Florczyk et al., 2013; Jia et al., 2018; Kievit et al., 2014; Martínez-Ramos and Lebourg, 2015; Wang et al., 2018a; Yang et al., 2015), Nanog (Jia et al., 2018; Lv et al., 2016), SOX2 (Jia et al., 2018; Lv et al., 2016); Oct4 (Jia et al., 2018; Yang et al., 2015); Snail (Kievit et al., 2014; Wang et al., 2018a), as well as less frequently observed Frizzled 4, GLI, HES (Kievit et al., 2014), LIN28A, LIN28B, CXCR4 and CSPG4 (Ma et al., 2016b), RHAMM (Martínez-Ramos and Lebourg, 2015), Musashi-1 (Florczyk et al., 2013); interestingly, the degree of overexpression of some stem-related genes, such as MSI1, MSI2 and BMI-1 and c-Myc, was shown to be cell type dependent in 3D environment (Jia et al., 2018);
- Markers of glial differentiation and neural development - β -tubulin III (Dai et al., 2016) and GFAP (Dai et al., 2016; Florczyk et al., 2013); however, there is inconsistency in the literature regarding GFAP because some authors reported no difference in its level between 2D and 3D cultures (Kievit et al., 2014);
- DNA damage repair genes – MGMT (Lv et al., 2016);
- ABC transporters - ABCG2 (Florczyk et al., 2013) and ABCB1 (Ma et al., 2016b), although Lv et al., reported no significant alterations in ABC transporter gene expression in 3D compared to 2D environment (Lv et al., 2016)
- Markers related to invasion and EMT - MMP1 (Jia et al., 2018), MMP-2 (Florczyk et al., 2013; Jia et al., 2018; Kievit et al., 2010; Pedron and Harley, 2013), MMP3 (Jia et al., 2018), MMP7 (Jia et al., 2018), MMP-9 (Florczyk et al., 2013; Pedron and Harley, 2013), N-cadherin (Jia et al., 2018; Kievit et al., 2014), TWIST1 (Florczyk et al., 2013), Twist2, Snai1 and Snai2 (Kievit et al., 2014), vimentin

(Jia et al., 2018); it is worth mentioning that E-cadherin levels is suppressed upon 3D cultures (Kievit et al., 2014)

- Markers of angiogenesis and response to hypoxia - HIF-1 α (Florczyk et al., 2013; Pedron and Harley, 2013; Wang et al., 2018a, 2018b; Yang et al., 2015), VEGF (Dai et al., 2016; Kievit et al., 2010; Pedron and Harley, 2013), laminin (Kievit et al., 2010), fibronectin (Kievit et al., 2010; Pedron and Harley, 2013), VEGFR2, and CD31 (Wang et al., 2018b)
- Cell-cycle related genes - p21, p27, CCNA1, CCNB1, CCND1 and CCNE1 (Jia et al., 2018)

Excluding specific genes/proteins, whole signaling pathways are also differentially regulated in 3D compared to 2D GBM cellular systems. Specifically, it was reported that components of pro-apoptotic signaling cascade (caspases, poly (ADP-ribose) polymerase (PARP) and p53) were downregulated, while anti-apoptotic signaling factors (PDL-1 and Livin) were upregulated in 3D collagen scaffold (Jia et al., 2018). In addition, key proteins of Wnt, SHH and Notch signaling pathways (Notch1, 2 and 3, Wnt3a, Wnt5a and SHH) were also highly expressed in this 3D system (Jia et al., 2018).

6. Effects of the TME on GBM cell phenotype in 3D models

Besides dimensionality, other characteristics of 3D culture, also significantly shape glioblastoma phenotype (Table 2).

6.1. Composition of 3D scaffolds

In the first place, the type of 3D scaffold material, its composition and formulation, considerably determines glioblastoma behavior and gene expression. For example, patient-derived primary GSC exhibited opposite migratory profile in Matrigel and collagen scaffolds, moving in spherical multicellular aggregates in Matrigel *versus* single elongated cells within collagen matrix (Herrera-Perez et al., 2015). The type of collagen used for scaffold fabrication also affects GBM cell morphology. Cells gain a round morphology in collagen-IV, while in collagen-I/III, with the strong fibrillary structure, they acquire spindle shape and prominent migratory phenotype (Rao et al., 2013a).

Addition of ECM components to 3D scaffolds considerably influences GBM cell characteristics. Incorporation of HA in 3D collagen-hydrogels causes cells to get a more rounded morphology and to decrease migration (Herrera-Perez et al., 2015; Rao et al., 2013a). Pedron et al., showed that addition of methacrylated hyaluronic acid (HAMA) to adhesive

(GelMA) and non-adhesive (PEG) 3D hydrogels induced cell clustering and increased expression of invasion-related genes (VEGF, HIF-1, MMP-9, and Fn) (Pedron et al., 2013). Several groups also reported that the presence of HA in 3D scaffolds increased expression of stem cell markers, particularly CD133, and EMT-related genes in GBM cell lines (Kievit et al., 2016; Martínez-Ramos and Lebourg, 2015; Wang et al., 2018a), also leading to increased tumorigenicity in nude mice (Wang et al., 2018a). Accordingly, Li et al., developed 3D HA scaffold-based bioreactor (AlgTubes) for scalable culturing of high quality and high quantity glioblastoma TICs (Li et al., 2018). They made coaxial alginate tubes filled with HA and dispersed primary glioblastoma cells. Such a bioreactor system with a high HA content ensured efficient mass transport, protection from the hydrodynamic pressure, efficient expansion of glioblastoma TICs and maintenance of stem phenotype (Li et al., 2018).

Similar to HA, addition of agarose to collagen matrices also promoted a round morphology and amoeboid motility and slowed down migration of GBM cells due to increased elasticity, reduced porosity and presence of steric barriers within such composite 3D scaffold (Ulrich et al., 2010). Excluding HA, the presence of other ECM components, such as laminin, contribute to altered GBM behavior in 3D cultures. Coating of electrospun polystyrene (ESPS) scaffolds with different laminin isoforms was shown to increase expression of integrin alpha 6 and beta 4, as well as several stem markers and ABC transporters in U251 cells (Ma et al., 2016b). Additionally, including of laminin in polyacrylonitrile scaffold leads to higher migration and lower proliferation (Saleh et al., 2019).

6.2. Biomechanical properties of 3D scaffolds

The addition of ECM components and ligands to 3D scaffolds, as well as crosslinking 3D scaffold material, alters biomechanical properties, stiffness and porosity, of the scaffold causing changes in GBM cell behavior. For example, Kaphle et al., showed that 8S-StarPEG, used to crosslink collagen, could increase hydrogel viscosity and decrease collagen degradation and cell migration (Kaphle et al., 2019). Generally, increasing hydrogel stiffness causes cells to be more rounded and proliferate less and it also inhibits their motility and invasion (Heffernan et al., 2015; Rao et al., 2013a; Unal et al., 2020; Wang et al., 2014, 2020b; Zhu et al., 2020). It is interesting to note that, in spite of the general behavior pattern, different glioblastoma cells may act differentially in the same 3D matrix (Ananthanarayanan et al., 2011), which is particularly evident for primary glioblastoma cells (Grundy et al., 2016).

Altering scaffold stiffness and crosslinking also affects gene expression. Increased expression of HIF-1, VEGF, and MMP-9, as well as reduced CD44 expression, was observed in response to greater stiffness and/or crosslinking density (Pedron and Harley, 2013; Wang et al., 2014). Apart from stiffness, varying scaffold porosity may influence GBM cell gene expression. In the Jia et al., study, pore size of the 3D collagen scaffold significantly and differentially affected expression of malignancy, stemness, cell cycle and EMT-related markers in three glioblastoma cell lines. This effect was mainly observed at the protein level rather than at the mRNA level, but without clear influence on their biological functions (proliferation, colony formation, migration and invasion) (Jia et al., 2018).

In more complex 3D systems, media perfusion is introduced to mimic interstitial flow (IF) in tumors. Presence of IF generates fluid shear stress (SS) which can alter glioblastoma cell behavior and gene expression, even though it is of lesser magnitude in tumor tissue than in vasculature system. Panchalingam et al., developed stirred-suspension bioreactor protocols for growing human-GSCs in suspension culture under low- and high-shear stress forces (Panchalingam et al., 2010). High SS conditions resulted in a higher cell expansion and lower mean diameter of neurospheres. Also, the size of the neurospheres formed under high-shear stress conditions was more uniform, suggesting that high-shear GSC tissue may lead to homogeneous cell culture morphology. It was

previously shown using a 3D Modified Boyden chamber with media perfusion that SS either induced cell death or decreased cell motility which was accompanied by downregulation of MMP-1 and MMP-2 activity (Qazi et al., 2011). However, later studies have shown that IF stimulates glioblastoma cell invasion, mediated by CXCR4-CXCL12 chemotactic signaling and/or HA receptor (CD44)-dependent mechanosensing (Kingsmore et al., 2016; Munson et al., 2013).

6.3. Induction of hypoxia

Hypoxia, as one of the major hallmarks of glioblastoma as well as solid tumors, is an important microenvironment factor that should be mimicked in 3D cultures in order to study GBM behavior and response to therapy in the most comprehensive way (Li Petri et al., 2020; Raz et al., 2014). Therefore, several studies have investigated its effects on 3D GBM cell culture phenotype. Xu and colleagues studied the effects of 1% and 0.2 % oxygen levels on GBM cells in PDMS microfluidic chip with collagen hydrogel (Xu et al., 2015). They observed increased induction of EMT and migration under hypoxic conditions, as well as upregulated expression of HIF-responsive and EMT-associated genes. However, the effects on cell proliferation depended on the degree of oxygen levels. At an environment of 1% O₂, cell proliferation was increased whereas under highly hypoxic conditions (0.2 % O₂) it was decreased. Similar results, namely increased invasion, mesenchymal transition and spheroid growth and expansion, were observed by mimicking *in vivo* hypoxia conditions using a genetic approach, by transfecting HIF1α or HIF2α into GBM cells (Ma et al., 2016a). However, long incubation (in 7 days) of hypoxic 3D culture of patient-derived glioblastoma cells, the size of spheroids did not change over time albeit they were dramatically smaller than under normoxia at the end of cultivation period (Rosenberg et al., 2018). In these 7-day spheroid cultures, cellular proliferation marker was mainly decreased, and hypoxia-induced markers (HIF-1α, carbonic anhydrase IX, VEGF) were upregulated under hypoxic conditions compared to normoxic conditions, while expression of stem cell markers varied across spheroid cultures in response to hypoxia. Furthermore, Ayuso et al., developed a microfluidic device that enabled generation of both oxygen and nutrient gradients within 3D cultures with the possibility to monitor cell death, viability, proliferation and ROS production (Ayuso et al., 2016). Using this platform they were able to mimic blood-vessel obstruction and consequently oxygen and nutrient deprivation, therefore inducing cell migration and formation of the characteristic pseudopalisade structure within 3D cell culture (Ayuso et al., 2017). Detailed proteomic analysis of 3D GBM cell cultures revealed that proteins and phosphoproteins are differentially expressed in response to hypoxic conditions (Levin et al., 2012). Namely, both pro-survival and pro-apoptotic proteins were activated, as well as migration-associated proteins, while the amount of proteins promoting cell cycle was reduced.

6.4. Nutrient deprivation

Effects of nutrient supply on GBM cell phenotype were also examined in the study of Panchalingam et al. (2010). In their stirred-suspension bioreactor-based culture of human GSCs, the authors introduced different feeding strategies and examined the effect that the 2-day and 6-day fed-batch (40 % medium replacement every 2 or 6 days) had on the expansion and phenotype of human GSC expanded cells. The results showed that the 2-day fed-batch mode resulted in the highest expansion after 32 days of culture (90 -fold cell expansion, larger neurosphere diameter, enrichment of CD133+ cells and maintenance of their genomic and phenotypic characteristics (Panchalingam et al., 2010).

6.5. Introduction of stromal cells

The complexity of the GBM TME is particularly reflected in the presence of various stromal cells and their intense interaction with

tumor cells. Therefore, numerous models were developed to study GBM co-cultures with various stromal constituents in a 3D setting. So far, most extensively were investigated the 3D GBM co-cultures with endothelial cells. Co-culturing glioblastoma and HUVEC cells in 3D hydrogels was shown to stimulate overall co-culture growth throughout the time, especially when the proportion of GBM cells in co-culture was increased (Avci et al., 2015). The presence of glioblastoma cells in 3D hydrogels enhanced proliferation, sprouting and migration of HUVEC cells (Chen et al., 2009; Nguyen et al., 2016a, 2016b). Such stimulation of angiogenesis is mediated through VEGF secretion by glioblastoma cells or exogenously added VEGF at low concentrations (Chen et al., 2009). This effect was even more pronounced under hypoxic conditions (Chen et al., 2009). On the other hand, HUVEC cells slowed down the growth rate of GBM cells, caused them to form spheres around or on the top of endothelial cells (Kievit et al., 2016) and promoted their invasive phenotype (Chonan et al., 2017). In the novel 3D model of Wang et al., adult patient-derived GBM tumor xenograft cells were shown to have significantly increased cell proliferation in the presence of mouse brain microvascular endothelial cells encapsulated in alginate microfibers mimicking microvessels in hydrogel (Wang et al., 2019a). Co-culturing GBM and endothelial cells in 3D models induced the acquisition of GBM stem-like phenotype with increasing expression of corresponding markers CD133, CD44 and Id1 (Kievit et al., 2016). Recently, McCoy and colleagues showed that enrichment in GBM stem cell population and their increased invasiveness were mediated by interleukin-8 signaling in 3D models of patient-derived GBM spheroids co-cultured with brain endothelial cells (McCoy et al., 2019), while Truong et al., proved in 3D organotypic microfluidic platform that these effects of microvasculature environment on patient-derived glioblastoma cells involved activity of CXCL12-CXCR4 signaling (Truong et al., 2019). Similarly, Wang et al., reported that endothelial cells increased the expression of CXCR4 in GBM cells in their 3D co-culture system (Wang et al., 2019a). Co-culturing also affected the expression of several other groups of genes and proteins: induced expression of angiogenesis related genes, such as PECAM1/CD31, KDR/VEGFR2, and PIK3R1 (Avci et al., 2015), induced the expression of differentiated cell marker tubulin β 3 (TUBB3), upregulated expression of cell-ECM adhesion-associated proteins (integrin α 2, integrin β 3, type II collagen α 1 and vitronectin) and downregulated the expression of genes associated with cell-cell adhesion such as cadherin 1 and catenin α 2 (Chonan et al., 2017). Ngo and Harley established a tri-culture comprising of U87 cells, HUVECs and normal human lung fibroblasts (NHLFs) and explored their interaction in 3D hydrogel depending on the ECM composition (Ngo and Harley, 2017). This study revealed that U87 cells arranged in close proximity to endothelial cells and their morphology changed from rounded in the absence of HA to elongated in its presence. On the other hand, U87 cells induced the regression of the microvasculature network in a cell density- and time-dependent manner, irrespectively of HA presence.

Other stromal cells also significantly influenced GBM cells behavior in 3D co-culture models and *vice versa*. According to Kievit and collaborators, astrocytes affect GBM cells similarly to HUVEC cells. They slowed down GBM cell growth rate when cultured in a higher cell ratio (astrocytes:GBM 5:1), stimulated them to form spheres and promoted their stem-like phenotype (Kievit et al., 2016). On the other hand, when grown in a ratio 1:1 in HA-gelatin hydrogel, astrocytes promoted tumor cell proliferation (Civita et al., 2019). 3D GBM co-cultures with normal astrocytes showed that ECM molecules secreted by GBM cells increased glial fibrillary acidic protein (GFAP) expression in astrocytes, while astrocytes secreted soluble factors that increased GBM cell migration (Grudecki et al., 2015). Moreover, it was demonstrated in the study of Gritsenko et al., that 3D astrocyte scaffold stimulated GBM cell invasion, both along astrocyte layers and through the scaffold (Gritsenko et al., 2017). In more complex 3D systems developed by Herrera-Perez et al., human endothelial colony forming cells were introduced to co-culture of various patient-derived cell lines and astrocytes to investigate their mutual effect on GBM cell invasion (Marisol Herrera-Perez et al., 2018).

Astrocytes significantly induced invasion of all three examined GBM cell lines. However, addition of endothelial precursor cells had diverse effects on invasion depended on the cell type and their genetic background.

Mesenchymal stem cells (MSC) also modulated the GBM phenotype in corresponding 3D co-culture models. MSC promoted GBM cell proliferation in transwell chamber system either through a TGF β 1-mediated paracrine signaling or by direct interaction, independently of TGF β 1 cytokine secretion (Oliveira Rodini et al., 2018). Breznik et al., observed that glioblastoma cell lines increased MSC motility when co-cultured in collagen I or matrigel. On the other hand, MSC had a differential effect on GBM cell invasion depending on the cell type, suppressed the invasion of U87 cells but increased the invasion of U373 cells (Breznik et al., 2017).

Immune cells as important constituents of the tumor stroma also influence GBM cell invasion. For example, Coniglio et al., showed that tumor associated macrophages (THP-1 cells) significantly induced invasion of human glioblastoma cell line U87 and similarly rat microglia stimulated invasion of murine glioblastoma cell line GL261 in 3D matrices (Coniglio et al., 2016). Besides, human microglial cells were shown to promote GBM cell proliferation (Leite et al., 2020). Cui and colleagues went a step further and developed 3D tri-culture microfluidic angiogenesis platform to investigate the interaction between GBM, endothelial cells and immune cells (Cui et al., 2018b). They observed that GBM cells switched uncommitted macrophages into macrophages with immunosuppressive phenotype. These tumor-associated macrophages further stimulated sprouting and angiogenesis of co-cultured endothelial cells (Cui et al., 2018b). Tang et al., developed a tetra-culture model with GSC, astrocytes, neural precursor cells and macrophages. This system supports the upregulation of different glioblastoma signatures, such as invasion, angiogenesis, hypoxia and stemness. On the other hand, macrophages in a co-culture system are polarized to M2 phenotype, showing that way mutual effect of cellular components of TME (Tang et al., 2020).

7. Effects of drug treatment on GBM cells in 3D models

Regardless of the type of 3D GBM culture is used in drug screening, they are generally more resistant to drug treatments than monolayer cultures and therefore more closely resemble chemotherapy response in GBM patients. A number of studies has investigated the difference in response to drugs between 2D and 3D cultures and some examples are listed in Table 3. Regarding drug resistance development, Han et al., constructed a specific microfluidic device for the detection and study of drug resistance acquisition in GBM (Han et al., 2016). This so called, Cancer Drug Resistance Accelerator (CDRA) chip consists of 488 hexagonal microchambers with two microchannels for antiparallel supply with drug and media. It was designed to generate a drug concentration gradient and observe the emergence of drug resistant cell population throughout the time. Different mechanisms were reported to underlie the development of drug resistance in 3D cell cultures. Ayuso et al., observed that TMZ had a mild effect on U-251 cell viability in their microfluidic system. They explained this resistance as a consequence of reduced GBM cell proliferation in 3D hydrogel that affects TMZ activity, which is dependent on DNA replication (Ayuso et al., 2016). Pang and collaborators observed that biomechanical properties of GBM cells significantly affected sensitivity to vincristine in their microfluidic platform for single-cell separation based on cell (Pang et al., 2016). They revealed that smaller and/or more deformable tumor cells were more resistant to the drug.

According to data of Wang et al., several groups of genes demonstrated increased expression in 3D cell cultures, contributing to a higher degree of drug resistance (Wang et al., 2016). These included genes associated with drug detoxification, drug efflux (ABCC5, ABCC3, and MVP), resistance to apoptosis (ESR1, RARG, ERBB4, MET), anti-apoptotic genes (BCL2, B2M), resistance against oxidative stress (NFKB

Table 3
Studies showing drug resistance in 3D compared to 2D cell cultures.

3D cell cultures	GBM cell types	Drugs	Relative resistance (3D vs 2D)	Reference
3D culture with chitosan-hyaluronic acid scaffolds	U-118	DOX, TMZ	no difference for DOX, 2-fold for TMZ	(Florczyk et al., 2013)
3D bioprinted cell culture with gelatin/alginate/fibrinogen hydrogel	U87, SU3 patient-derived cell line	TMZ	1.5-fold for SU3 cells, 2.2-fold for U87	(Dai et al., 2016)
3D culture with collagen scaffolds	U87, primary GBM cells	TMZ, CCNU, Cisplatin	U87 cells: 3-fold for DDP, 42-fold for CCNU, 6-fold for TMZ primary cells: 3-fold for DDP, 18-fold for CCNU, 6-fold for TMZ	(Lv et al., 2016)
3D culture with chitosan-hyaluronic acid scaffolds	Primary GBM cells	TMZ, BCNU, CCNU, Everolimus	3-fold for TMZ, 9-fold for BCNU, 16-fold for CCNU, no difference for Everolimus	(Wang et al., 2017a)
3D bioprinted culture with gelatin/alginate/fibrinogen hydrogel	U118	TMZ	2.5-fold	(Wang et al., 2019a)
3D aggregates on agarose hydrogels	BMG-1	Cisplatin, Bleomycin	1.3-fold for cisplatin, no difference for bleomycin	(Ravi et al., 2017)
Spheroids and 3D culture with gelatin foam	Patient-derived cells	Irinotecan, 5-Fluorouracil	about 10-fold for both drugs	(Yang et al., 2015)
3D bioprinted culture with alginate/HA/collagen I	U87, primary cell line	TMZ, cisplatin	2-fold for TMZ, 8-fold for cisplatin for U87, 24-fold for cisplatin for primary cells	(Hermida et al., 2020)

TMZ-temozolomide; DOX-doxorubicin; CCNU-comustine; BCNU-carmustine.

family members, PPAR, SOD1, HIF1A), DNA repair (MGMT, XPC, TOP2B and BRCA2) and DNA replication arrest (CDKN13 and CCND1). Interestingly, the authors did not observe a significant difference between 3D scaffold and 2D cultures in the expression of genes mainly involved in multidrug resistance (e.g., ABCB1) and detoxification (e.g., CYP3A4). In line with these findings are results published by Lv and colleagues that observed upregulated expression of MGMT, as a possible mechanism of resistance to alkylating agents in 3D environment, but no changes in the expression of major ABC transporters (ABCB1, ABCC1, ABCC2, ABCC4, and ABCG2) (Lv et al., 2016). However, some authors have reported increased expression of ABCG2 in GBM cell lines resistant to drug treatment in 3D cultures (Florczyk et al., 2013; Kinsella et al., 2011). Florczyk et al., also observed that cell line with the highest degree of resistance to alkylating agents in 3D systems, besides upregulating ABCG2 expression, also increased the expression of ABCB1 (Florczyk et al., 2013). Moreover, results from previously described 3D system, Cancer Drug Resistance Accelerator chip, showed that increased drug efflux activity was the main cause of emerging DOX resistance in U87 cells (Han et al., 2016). The authors of this study isolated resistant U87 cells from the chip and performed exome and transcriptome sequencing and identified several mutated genes (*CHD1* and *FLNA*) related to DOX resistance, as well as significant number of differentially

expressed genes associated with immune response, DOX metabolism and NFκB signaling. Increased resistance to apoptosis is another mechanism that contributes to resistance to alkylating agents (Samiei et al., 2020; Wang et al., 2016), as well as DOX and resveratrol (Kim et al., 2011), in 3D cell cultures. Regarding the latter study, authors observed increased production of anti-apoptotic factors, survivin and Bcl2, in 3D cultures in response to DOX and resveratrol as known apoptosis inducers.

Drug resistance in 3D models may be at least partially reversed by combined drug application. Fernandez-Fuente and collaborators showed that sunitinib resistance in three-dimensional GSC culture may be reversed through the inhibition of the Akt and ERK signaling pathways, using PD98059 and LY294002, respectively (Fernandez-Fuente et al., 2014). Shojaei et al., described that simvastatin, a mevalonate biosynthesis inhibitor, can increase TMZ-induced apoptosis by inhibiting autophagy flux (Shojaei et al., 2020). Similarly, in our recent study we were able to sensitize TMZ-resistant RC6 cells by combining TMZ with coenzyme Q10 in 3D microfluidic device within collagen hydrogel (Stojković et al., 2016).

8. Effects of 3D culture microenvironment on GBM cell response to drug treatment

The effects of drug treatments on 3D glioblastoma culture are determined not only by culture dimensionality but also by the presence of various microenvironment factors, as summarized in Table 4.

Two publications reported that the efficacy of EGFR-targeted therapies in 3D GBM culture depends not only on EGFR status but also on the chemical composition and physicochemical properties of the ECM. Pedron et al., showed that EGFR mutated, patient-derived GBM cells, that are sensitive to erlotinib, had decreased response to this TKI inhibitor in the HA-containing GelMA hydrogel, due to crosstalk between CD44 and EGFR signaling pathways (Pedron et al., 2017). Xiao and colleagues made a similar observation in their 3D brain-biomimetic platform. They confirmed that patient-derived GBM cells are less responsive to erlotinib and lapatinib in the presence of HA-bound hydrogels and this effect was also dependent on the stiffness of the hydrogel (Xiao et al., 2018b). Recently, the same group showed that HA and RGD-functionalized proteins in 3D hydrogel concomitantly contributed to GBM cell resistance to the alkylating agents TMZ and carmustin (Xiao et al., 2019). This effect was mediated by Src signaling upon joint activation of CD44 and integrin. Another ECM component, fibronectin, was also shown to influence GBM cell response to targeted therapy. Efficiency of MEK inhibitor, PD0325901, on GBM cell growth, motility and dispersal from spheroid is dependent on high fibronectin concentration in the ECM (Shannon et al., 2017). Recently, two additional research groups demonstrated that growing cells in stiffer scaffolds leads to higher TMZ resistance (Wang et al., 2020b; Zhu et al., 2020).

As previously mentioned, hypoxic conditions promote an invasive phenotype of GBM upon 3D cultures, however the lack of oxygen also influences their response to therapy. Namely, Musah-Eroje and Watson showed that growing GBM cells in 3D culture increased resistance to TMZ which became even more pronounced under hypoxic conditions (Musah-Eroje and Watson, 2019).

The presence of stromal cells in composite 3D GBM cultures further contributes to tumor cells' drug resistance. Namely, astrocytes and endothelial precursor cells are able to diminish the cytotoxic effect of the STAT3 inhibitor (SH-4-54) in 3D culture of stem-like GBM cell line (Marisol Herrera-Perez et al., 2018). Earlier work of Yang and colleagues also showed that addition of the astrocytic cell line to different GBM cell spheroid cultures protected them from cytotoxic insult of TMZ and DOX (Yang et al., 2014). Additionally, Civita et al., reported that lower response to TMZ, vincristine and clomipramine can be a result of mitochondrial exchange between reactive astrocytes and GBM cells through tunneling nanotubes formed between them (Civita et al., 2019). Xiao et al., established U87 cells co-culture with rat neurons and glial

Table 4

Effects of various microenvironment conditions on drug response in 3D glioblastoma cell cultures.

3D cell cultures	GBM cell types	Drugs	Microenvironment conditions	Major findings	Reference
3D culture with HA decorated GelMA hydrogels	Patient-derived xenograft cells	Erlotinib	0, 0.3, 0.5, 0.7, 1 and 2 wt% hyaluronic acid methacrylate	EGFR mutated cells were 2 fold resistant in the presence of HA in hydrogel	(Pedron et al., 2017)
Gliomaspheres and 3D culture with HA and RGD containing hydrogels	Primary cell lines	Erlotinib, Lapatinib	0.5 % or 0.1 % (w/v) HA, with or without RGD peptide, 1 or 2 kPa compressive modulus	Cells cultured in 3D hydrogels with a high HA content (0.5 % w/v), RGD tripeptide and low compressive modulus (1 kPa) were the most resistant to erlotinib	(Xiao et al., 2018b)
Gliomaspheres and 3D culture with HA and RGD containing hydrogels	Primary cell lines	TMZ, carmustine	0.5 % and 0.1 % (w/v) HA, with or without RGD peptide	High content HA scaffolds, particularly those with RGD peptide, were more resistant to TMZ and carmustine than low-HA hydrogel culture and gliomaspheres	(Xiao et al., 2019)
Spheroids	Primary cell lines	PD0325901	30 and 300 µg/mL serum fibronectin	PD0325901 increased spheroid stiffness and viscosity under high fibronectin serum concentration	(Shannon et al., 2017)
Neurospheres	U251, U87 SNB19	TMZ	Normoxia (20 % oxygen), hypoxia (1 % oxygen)	U87 and U251 neurospheres were more resistant to TMZ than monolayer culture, particularly under hypoxic conditions	(Musah-Eroje and Watson, 2019)
3D culture in collagen type I-hyaluronan matrix	Primary cell lines	SH-4-54	Tri-culture with normal primary astrocytes and ECFCs	Stem marker positive cells were 1.25 fold more resistant to STST3 inhibitor in 3D matrix with stromal cells than in 3D matrix only	(Marisol Herrera-Perez et al., 2018)
Spheroids	A172, U251, LN18, C6, primary cell lines	TMZ, DOX	Co-culture with TNC-1 astrocytes	Most cell lines were resistant to TMZ and DOX in the presence of astrocytes	(Yang et al., 2014)
3D culture in GCNT matrix	U87	blebbistatin	Co-culture with rat neurons and glial cells	Cortical cells reduced U87 migration velocity by 34 % in GCNT matrix	(Xiao et al., 2018a)
3D culture in HA-gelatin hydrogel	Primary cell line	TMZ, CLM, VCR	Co-culture with microglia	Cells were more resistant to all drugs in co-culture with microglia	(Leite et al., 2020)
3D culture in HA-gelatin hydrogel	Primary cell lines	TMZ, CLM, VCR	Co-culture with astrocytes	Cells were more resistant to all drugs in presence of astrocytes	(Civita et al., 2019)
3D bioprinted culture with GelMA and GMHA	Xenografted tumor cells	TMZ, Erolotinib, Gefitinib	Tetra-culture with astrocytes, neural precursor cells and macrophages	The resistance was enhanced in tri-culture and it was potentiated with addition of macrophages	(Tang et al., 2020)

HA-hyaluronic acid; GelMA-methacrylamide-functionalized gelatin; RGD-arginine-glycine-aspartate; TMZ-temozolomide; ECFCs-endothelial colony forming cells; PD0325901-MEK inhibitor; SH-4-54-STAT3 inhibitor; blebbistatin-myosin II inhibitor; GCNT-graphene-carbon nanotube, GMHA-glycidyl methacrylate-HA.

cells within 3D graphene-carbon nanotube matrix and evaluated the effect of myosin II inhibitor, blebbistatin, on tumor cell migration. They observed that the presence of cortical cells reduced blebbistatin activity reflected in decreased U87 cell motility (Xiao et al., 2018a).

9. Preclinical models of the blood-brain barrier

9.1. The blood-brain barrier limits the efficient treatment of brain tumors

The BBB consists of brain endothelial cells which form the complex network of brain capillaries. It enables the supply of brain with the essential nutrients and oxygen but at the same time, its important function is to protect the brain from any environmental insult. Besides, neurons must be protected against physiological fluctuations such as temperature oscillations, variations in O₂ or CO₂ levels, and variations in the concentrations of different factors produced by the organism. Therefore, the BBB has the least permeable capillaries also due to tight junctions between endothelial cells. The tight junctions between these endothelial cells consist of transmembrane proteins (occludin, claudin and junctional adhesion molecule), cytoplasmic attachment proteins (cingulin, zona occludens-1, -2, -3) as well as cytoskeletal proteins (He et al., 2018). Besides tight junctions, there are other physical components of the BBB such as astrocytic end-feet, pericytes and a basement membrane (Dyrna et al., 2013). The entire neurovascular unit of the BBB consists of five cell types: endothelial cells, astrocytes, pericytes, neurons, and microglia (Abbott, 2013). Among brain cells which assist the BBB, astrocytes secrete factors necessary for the BBB function (Colgan et al., 2008), pericytes decrease vascular permeability (Daneman et al., 2010), induce polarity to the astrocyte end feet (Allt and Lawrenson, 2001) and synthesize factors necessary for the differentiation of the BBB (Dore-Duffy et al., 2006), while microglia clears the cellular debris (Sumi et al., 2010).

Brain tumors and brain metastasis compromise the integrity of the BBB due to the formation of specific blood-tumor barriers. The blood-tumor barrier (BTB) possesses its individual characteristics including different and non-uniform permeability with higher activity of the multidrug efflux transporters of the ABC superfamily (Arvanitis et al., 2020). The efflux mediated by P-glycoprotein (ABCB1) can be present on membranes of both endothelial and tumor cells. P-glycoprotein extrudes toxic compounds on the expense of ATP which is essential for the P-glycoprotein function (Borgnia et al., 1996; Henderson and Piquette-Miller, 2015; Li et al., 2016b; Zhang et al., 2021). Thus, the drug cannot reach the effective concentration necessary for its anti-cancer activity. The high expression and the ATP-driven efflux mediated by P-glycoprotein is the mechanism of MDR responsible for the low intracellular penetration of chemotherapeutics.

Thus, although the presence of GBM alters the normal vascular function of BBB rendering it more permeable, disruption of barrier due to the BTB cannot provide efficient drug penetration (Dhermain et al., 2010). Rather, cell migration is increased across a more permeable BTB, thereby facilitating the spread of GBM cells in distant places within the brain parenchyma (Jia et al., 2014).

9.2. In vitro models of the blood-brain barrier

Although different approaches were used to open the BBB for the efficient treatment of brain diseases, the lack of *in vivo* validation and controlled clinical trials delayed the progress. Even if *in vivo* experiments provide the natural environment, the versatility of results obtained from animal models cannot be accurately translated into humans (Perel et al., 2007). This could be surpassed by using the results from the *in vitro* models of BBB. The quality of the *in vitro* models is usually determined by several parameters including the transendothelial electrical resistance (TEER), permeability of specific marker substances (mannitol and

sucrose) and the expression of BBB markers (Zona Occludens-1, Claudin-5, Occludin, and endothelial von Willebrands factor) (Wolff et al., 2015). The *in vivo* TEER across the functional BBB is 1500–8000 Ωcm^2 (Crone and Olesen, 1982). Therefore, achieving the approximate values for the *in vitro* models is imperative.

The most used type of *in vitro* BBB models has polystyrene or polycarbonate membranes with 400 nm pores (Colgan et al., 2008) separating the endothelial cells grown in the upper (luminal) compartment of the Transwell (Corning Inc., Corning, NY) from the astrocytes and pericytes usually cultured on the lower (abluminal) side of the membrane. To obtain the most accurate model, it is important to choose the right cell types such as brain derived endothelial cells which are almost impossible to obtain from healthy donors. As an alternative human pluripotent stem cells induced to differentiate into brain microvasculature are used (Lippmann et al., 2012). However, the majority of experimental work was performed with immortalized cell lines such as human cardiac microvascular endothelial cells (hCMEC)/D3 and human brain microvascular endothelial cells (HBMECs) (Eigenmann et al., 2013). To increase the tightness of endothelial cells grown in a monoculture, the astrocyte-conditioned medium (Siddharthan et al., 2007) as well as glia-conditioned ECM are used (Hartmann et al., 2007). Besides, it was shown that by introducing the shear stress through microfluidics, together with astrocyte conditioned medium, the TEER of primary HBMECs increased up to 1500 Ωcm^2 (Siddharthan et al., 2007).

In respect to co-cultures, two models can be studied: contact and non-contact. In the contact model, endothelial cells are grown on the luminal side of a Transwell membrane, whereas astrocytes, pericytes, or neurons are grown directly on the abluminal side of the membrane allowing a close-range impact on endothelial cells. In non-contact model, non-endothelial cells are grown on the bottom of the well making the effect on the endothelial cells solely through excreted molecules. These two models complement and provide more comprehensive understanding of the BBB functioning (Wolff et al., 2015). It was discovered that astrocytes and pericytes were more efficient in preserving BBB properties and increasing TEER in contact than in non-contact models (Al Ahmad et al., 2009; Hayashi et al., 2004). However, the permeability of endothelial cells did not change in co-culture models implying that a monolayer is sufficient for studying drug permeability (Nakagawa et al., 2007).

9.3. Microfluidic devices with neurovascular units

Although Transwell cell culture systems are affordable and relevant for the BBB studies, they lack the dynamic mechanical microenvironment and complex architecture of the BBB. Therefore, in recent years, the interest in microchip BBB models constantly increases (Booth and Kim, 2012; Griep et al., 2013; Kaisar et al., 2017; Maoz et al., 2018; Prabhakarandian et al., 2013; Wang et al., 2017b). Systems developed to resemble the neurovascular unit offer a great potential for BBB research (Achyuta et al., 2013; Bhatia and Ingber, 2014; Prabhakarandian et al., 2013). These microfluidic devices with multiple physiologic parameters of the BBB and the cytoarchitecture present *in vivo* should be able to serve as high-throughput drug screening platforms. Besides, microfluidics technology combines dynamic fluid flow and 3D setting enabling mimicking of *in vivo* situation of each patient's pathology thus having the potential to serve as a platform for the development of personalized therapy (Bhatia and Ingber, 2014).

Advantages of microfluidic devices over Transwell BBB models are better mimicking of the microenvironment with a potential to imitate organ-level functioning, ability to analyze BBB properties such as permeability, TEER and shear stress, real-time readouts, and testing of pharmacodynamics and pharmacokinetics (Chin and Goh, 2018).

However, these multi-physiological systems have some limitations that need to be overcome in the future. Dimensions of mimicking blood vessels within majority of devices are around 100 μm in diameter, while human cerebral capillaries are around 10 μm (Wiedeman, 1963). In

addition, the blood vessel compartment usually does not recapitulate the circular cross section found *in vivo*. Commonly, the geometry in the microdevices involves square or rectangular cross sections. These factors significantly impact the intensity and uniform distribution of shear stress on the endothelial cells (Phan et al., 2017). Moreover, many of the BBB models have a single channel and represent a single blood vessel (Brown et al., 2015; Deosarkar et al., 2015; Wang et al., 2017b). More appropriate and more complex devices should build a network of hierarchical branching vasculature. Another limitation is the non-natural contact among endothelial cells, basal lamina, pericytes and astrocytes that need to be integrated and incorporated in 3D milieu (Phan et al., 2017).

Xu et al., presented a newly fabricated microfluidic device which integrated the physical endothelial-astrocyte interaction, 3D ECM, and dynamic vascular flow (Xu et al., 2016). Although the authors used rat-derived brain microvascular endothelial cells (BMECs) and astrocytes to construct the BBB model, they were able to confirm key features of the BBB (the expression of the BBB markers, TEER in range of the *in vivo* values, and permeability of endothelial cells). Moreover, this multiple functional unit design mimics different BBB regions, which makes this BBB assay suitable for use in a high throughput manner. The results showed that the exposure to dynamic flow as well as presence of astrocytes significantly increased expression of endothelial tight junction proteins (ZO-1, claudin-5) and adhesive protein known as vascular endothelial cadherin (VE-cadherin) in BMECs. On the other hand, the presence of astrocytes increased the expression of P-glycoprotein and GLUT-1, while the flow alone did not alter their expression.

The presence of either dynamic flow or astrocytes increased TEER of BMECs. However, the addition of astrocytes, in the presence of dynamic flow, enhanced the TEER values up to those relevant *in vivo*. The TEER reached a steady-state within 60 h.

Interestingly, the presence of astrocytes increased the impermeability of BMECs as well as dynamic flow alone. However, when the dynamic flow was applied along with the presence of astrocytes, it was not able to enhance the already achieved impermeability.

The authors studied the potential of different human cancer cell types to cross the BBB established in their microfluidic device (Xu et al., 2016). Their results confirmed the clinical empirical findings that lung cancer, breast cancer and melanoma are able to cross the BBB, while liver cancer cells cannot migrate through BBB (Paolillo and Schinelli, 2016). Despite the inherent aggressiveness of GBM, U87 cells could not transverse the BBB. This result confirmed the already known fact that GBM almost never metastasizes out of the central nervous system (Simonetti et al., 2017).

The co-culturing of U87 cells and astrocytes resulted in a homogeneous cell layer within 72 h. However, when lung cancer, breast cancer and melanoma cells were co-cultured with astrocytes, they didn't intermix but rather formed cell spheres comprised solely of these cancer cells (Xu et al., 2016).

Another more recently developed hypoxia-enhanced BBB chip used human induced pluripotent stem brain microvascular endothelial cells (iPS-BMVECs) which enabled the maintenance of high TEER levels up to seven days (Park et al., 2019). Hypoxic conditions in the presence of human astrocytes and pericytes were used to differentiate iPS-BMVECs and thus better mimic barrier characteristics. This approach ameliorated previously identified problems with BBB models using human iPS-BMVECs which could only maintain high TEER levels for approximately two days, while the expression levels of MDR efflux pumps in iPS-BMVECs could not reach the levels observed *in vivo* (Vatine et al., 2017). Hypoxic conditions with 5% O_2 induced the expression of HIF1- α , Wnt signaling, P-glycoprotein, GLUT-1, VE-cadherin and VEGF (vascular endothelial growth factor) in iPS-BMVECs, while the expression of ZO-1, Claudin-5 as well as platelet endothelial cell adhesion molecule (PECAM-1) was detected in these cells when co-cultured with human astrocytes and pericytes in a BBB chip. Besides, hypoxia-induced iPS-BMVECs from BBB chip were able to generate their own basement

membrane ECM containing high levels of collagen IV, laminin, perlecan (a heparin sulfate proteoglycan), and fibronectin. Increased expression of some ABC transporters (BCRP, MRP1 and MRP4) as well as many solute carriers (SLC) was observed after three-day cultivation in the BBB chips. All these characteristics were not observed when iPS-BMVECs were differentiated under normoxic conditions.

9.4. Drug testing in 3D models of the blood-brain barrier

The most pragmatic way to confirm the advantages of using *in vitro* models of BBB, particularly technologically advanced microfluidic devices, is to obtain the analogous results with drugs approved for clinical use. Thus, different drugs were applied in the microfluidic device reported by Xu et al. (2016). Eight clinically approved chemotherapeutic drugs were tested on their ability to cross the BBB and their cytotoxic effects on GBM. TMZ as a lipophilic and BBB permeable pro-drug (Ramalho et al., 2019) was compared to a broad-spectrum of anticancer agents with low BBB permeability. The results showed that only TMZ was able to induce apoptosis in GBM cells when the BBB was present. The rest of the tested compounds were hydrophilic and efficient only in the absence of BBB implying that their inability to cross the BBB reduces their anticancer potential against GBM.

Importantly, 400 μ M of TMZ was able to induce apoptosis around 80 % of U87 cells in the microfluidic device with established BBB. Therefore, Xu et al., demonstrated the reliability of their microfluidic BBB model in evaluating anticancer drugs' potential (Xu et al., 2016). Even more, this platform has the ability to perform parallel experiments suggesting that it could be used for high throughput screening for anti-glioma agents.

In another study (Park et al., 2019), the functionality of the BBB in the microfluidic chip was tested using verapamil as P-glycoprotein inhibitor, Rhodamine 123 as P-glycoprotein substrate and citalopram as a serotonin-specific reuptake inhibitor - drug commonly used to treat depression. Surprisingly, the authors found that citalopram permeability was increased in the presence of verapamil indicating that P-glycoprotein suppresses the transcytosis of this drug. For the first time, results obtained in the BBB chip recapitulated the *in vivo* findings regarding citalopram (Doran et al., 2005), whereas no other *in vitro* BBB models was able to identify citalopram as a P-glycoprotein substrate (Feng et al., 2008).

Doxorubicin permeability was also tested in this BBB chip under a physiological flow of 100 μ L/h (Park et al., 2019). The authors reported that after verapamil application, doxorubicin influx significantly increased through the vascular channel of the BBB chip. This was also comparable with the P-glycoprotein activity *in vivo* (Kalvass et al., 2013). All these results point to the importance of using differentiated iPS-BMVECs, their plating under physiological flow and at the interface with human brain astrocytes and pericytes if one wishes to create the closest mimicking conditions for the investigations of the BBB functionality *in vitro*. However, BBB-on-a-chip models need considerable optimizations and therefore, they still cannot be ideally used for the high-throughput screening of drugs. Another challenge is to explore whether iPS-BMVEC based BBB chips can explain differences in patient-specific response to drugs.

10. Mathematical models as a way to complement research on biomimetic models

Mathematical models describe real systems by means of abstraction and mathematical formalism. They may enable extrapolation beyond the situations originally analyzed, allowing for quantitative predictions, inference of mechanisms, falsification of underlying biological hypotheses and quantitative descriptions of putative relationships between different components of a system. They cannot replace experimental results obtained by biomedical models, but may complement experimentation in providing a broader picture. This may help novel findings

or solutions for some cancer-related problems. Thus, a combination approach using experimental and mathematical models has the potential to provide robust findings. Interestingly, GBM is the tumor type that has attracted the most interest of applied mathematicians. Here we will describe only results integrating theory and experiments, *i.e.* validated models with the potential of having biomedical value and not those of interest for pure mathematicians because of technical reasons. The field is still in its initial stages and much progress has been made from the initial mathematical models dealing with simple biological scenarios in either 2D cultures or spheroids to the feature-rich ones in use in recent works.

One of the first studies combining mathematical models and experimental work was done by Stein et al., who proposed a continuum mathematical model describing GBM invasion observed in experiments on the patterns of growth and dispersion of U87MG tumor spheroids in a 3D collagen-I gel. The authors identified and characterized discrete cellular mechanisms underlying invasive cell motility from the experimental data (Stein et al., 2007). Another work (Kim et al., 2009) developed a mathematical method to study 2D *in vitro* experiments reported by Khain and Sander (Khain and Sander, 2006), who showed two different migration patterns: one pattern of wild type U87 cells exhibited radially symmetric migration of individual cells and another pattern of mutant U87- Δ EGFR cells exhibited formation of branches moving outward, with a slower speed. The mathematical model explained both growth patterns to be a result of the effect of cell-cell adhesion on migration.

A complementary analysis of Stein et al., experiments was performed by Kubo and Miyata (Kubo and Miyata, 2017). Another study (Jiang et al., 2014) explored different motility models to describe the U87MG GBM cell line on different substrates and found super-diffusion to provide the best fit. They explained their findings as a result of that type of invasive behavior allowing a better access to external nutrients. Further studies on the same datasets using cellular automata mathematical models were developed (Tektonidis et al., 2011). Yet, an additional study investigated mathematically with the help of a lattice-gas cellular automaton model, the impact of the migration/proliferation dichotomy on avascular glioma invasion in terms of invasion velocity and width of the infiltration zone (Böttger et al., 2012). Khain et al., studied the differential dynamics of tumor cells in spheroids and in wound-healing assays both under hypoxia and normoxia and developed a stochastic mathematical model to understand the results (Khain et al., 2011). The same group investigated, by combining theory and experiments, the effect of cell-cell adhesion on glioma front propagation and the properties of the invasive interface (Khain et al., 2012). Moreover, Aubert et al., studied migration of glioma cells on substrates of collagen and astrocytes using GL15 spheroids and constructed a mathematical model based on a cellular automaton where the various dynamic effects were introduced through adequate evolution rules (Aubert et al., 2008). Using the model, they investigated the role of homotype and heterotype gap junction communication and showed that it was possible to reproduce the experimentally observed migration patterns (Aubert et al., 2008). Related studies have explored recently the invasive patterns of primary cultures and U87 cell line with discrete, individual cell-based mathematical models to understand the relationship between cell-adhesion properties and the different invasive morphologies displayed in the experiments (Oraipoulou et al., 2018). A summary of the early mathematical modeling activity of glioma invasion in simpler *in vitro* scenarios can be found in a previous review (Alfonso et al., 2017).

Following these initial research studies focused on developing simple mathematical models involving mostly cell-motility and adhesion properties, several works have used the combination of mathematical and biomimetic models to obtain a deeper insight into other biological processes. Kingsmore et al., studied the role of interstitial fluid flow (IFF) in patient-derived GBM stem cells (Kingsmore et al., 2016). Using 3D *in vitro* assays and correlative *in vivo* studies, they demonstrated an increased invasion with flow in GSC lines. Flow-stimulated invasion was

reduced by blockade of CXCR4, CXCL12, and/or CD44, revealing that GSC invasion may be mediated simultaneously by different mechanisms. Characterization of CXCR4+, CXCL12+, and CD44+ populations in different GSC lines revealed different percentages of the subpopulations for each line. The authors developed and validated a mathematical agent-based model to identify the contributions of each subpopulation to flow-stimulated invasion. The mathematical model predicted that IFF-stimulated invasion was driven primarily by CXCR4+ and CXCL12+. Kim et al., combined a special transwell assay with a mathematical model to demonstrate that microglia can stimulate tumor cell invasion by secreting the growth factor TGF- β (Kim et al., 2017). The mathematical model was also used to make new predictions to guide future experiments aimed at the development of new therapeutic approaches. Ayuso et al., constructed an experimental model of GBM by embedding U-251 MG cells within a collagen hydrogel in a custom-designed microfluidic device (Ayuso et al., 2017). By controlling the medium flow through lateral microchannels, they could control blood-vessel obstruction events associated with this disease. They showed that nutrient and oxygen starvation triggered a strong migratory process leading to pseudopalisade generation *in vitro*. The results validated the hypothesis of pseudo-palisade formation in GBM and revealed an excellent agreement with a partial-differential equation mathematical model based on a hypoxia-driven phenomenon (Ayensa-Jiménez et al., 2020; Ayuso et al., 2017).

Mathematical models in combination with *in vitro* experiments have been also used for drug-response studies in GBM. A very interesting work parametrized a partial-differential equation-based computational model of GBM growth and treatment response using *in vitro* data from SF268 during lapatinib exposure (Stein et al., 2018). Then, the authors explored *in silico* what would be the most effective treatment strategy within the clinical toxicity limits of lapatinib. Despite the inability of lapatinib to induce tumor regression with a continuous daily schedule, the modeling approach predicted that continuous dosing would be the best strategy to slow down tumor growth and to decrease overall tumor burden, compared to pulsatile schedules currently known to be tolerated. This was found to hold even when considering drug resistance, reduced lapatinib tumor concentrations due to the BBB, and the phenotypic switch from proliferative to migratory cell phenotypes that occur under the hypoxic TME. Rabé et al., studied the development of drug resistance in glioblastoma using an integrated approach involving experimentation and mathematical models (Rabé et al., 2020). They did not use advanced biomimetic devices but a longitudinal study including a combination of mathematical models, RNA sequencing, single cell analyses, functional and drug assays in a human glioma cell line (U251). However, the methodology shows the potential of the combination of mathematical modelling with *in vitro* studies for unveiling mechanisms in complex situations. The model suggested the presence of a transient state. The experimental analysis found it to be characterized by slow growth, a distinct morphology and a shift of metabolism. The specific gene expression pattern associated with this population revealed chromatin remodeling. Indeed, the histone deacetylase inhibitor trichostatin (TSA), specifically eliminated this population and thus prevented the appearance of rapidly growing TMZ-resistant cells. Thus, the study allowed the identification of a population with tolerant features, which could constitute a therapeutic target.

A different line of research is the use of mathematical models for the improvement of the design of biomimetic devices. For instance, a recent study (Marino et al., 2018), reported the use of different fluid-mechanical models to optimize the construction of a 1:1 scale, biomimetic, and biohybrid model of the BBB fabricated through two-photon lithography and used as scaffolds for the co-culturing of endothelial-like bEnd.3 and U87 glioblastoma cells. Another research group (Koens et al., 2020) used a computational model to adjust parameters and understand oxygen heterogeneities in a new double-layer microfluidic device.

Finally, a recent paper combining mathematical models and

patient's imaging data has underlined the substantial role played by evolutionary dynamics in tumor growth dynamics (Pérez-García et al., 2020). The mathematical models predicted that three spatial dimensions would be necessary to capture the rich evolutionary dynamics observed in genuine cancers with experimental systems. The idea behind the calculations is that evolutionary dynamics typically take places in peripheral spatial locations where phenotypic and/or genetic alterations can consolidate in macroscopic populations and 3D is the only configuration allowing for a sufficient space for those changes to occur and consolidate.

In summary, mathematical models, when used in combination with GBM *in vitro* biomimetic models, have a substantial potential to aid in hypothesis generation and falsification, interpretation of experimental results and the design of better devices. As they become more mature they can help in better understanding the complex interplay arising in rich 3D biomimetic systems and to extrapolate the experimental observations on those *in vitro* systems and translate them to *in vivo* scenarios.

11. Future perspectives and directions

In the past decade researchers have made a great effort to develop a variety of 3D glioblastoma cell models. These models are valuable tools for *in vitro* studies of glioblastoma pathogenesis and also represent good platforms for drug screenings. 3D glioblastoma models are physiologically more relevant and reliable than conventional 2D cell cultures and they are increasingly replacing monolayer cultures in laboratory practice. They should ultimately substitute animal models in preclinical drug characterization, reduce the costs of drug discovery and development, avoiding at the same time ethical concerns regarding *in vivo* experiments. However, there are still important issues to be considered and properties to be improved in order to fully adopt 3D glioblastoma cell culture models as standard platforms for preclinical drug screening and development. The greatest challenge in developing 3D glioblastoma models is to mimic the full temporal and spatial complexity of the tumor: organization of its structures, heterogeneity of cell types, specificity of ECM composition, dynamics of TME conditions, and simulation of different cancer-related processes, such as metastasis.

As reviewed above, spheroids represent the first step in making more complex cell cultures. They have cell-cell and cell-ECM interactions and established biochemical gradient, but are still lacking the 3D architecture of the tumor. On the other hand, organoids, as miniature organs, appear to most closely resemble native tumor structure *in vitro* but lack reproducibility and have limitations in continuously providing tumor-related physicochemical conditions and preserving long-term culture. Introducing 3D bioprinting technology also gives an opportunity to achieve structural complexity of tumor tissue in a controlled manner. However, bioprinted cultures, as with organoids, lack an important physicochemical component namely fluid flow. Therefore, in the future, organoids and bioprinted cultures should be combined with other approaches and platforms that provide a dynamic microenvironment, for example perfusion bioreactors and microfluidic devices, for establishing a complete mimic of 3D glioblastoma cell culture. In this regard, microfluidic devices are so far the most comprehensive of all 3D cell culture models. Yet, there are several challenges to be addressed in the future development and use of microfluidic-based 3D glioblastoma cell cultures. In the first place, the choice of biomaterials remains a great challenge and requires further development by biomaterial and tissue engineering. Focus should be put on improving biomaterial characteristics for 3D GBM cell culture scaffolds, on increasing their long-term stability, mimicking the specific composition of GBM ECM (e.g. enriched in HA), maintaining consistency of their composition and physicochemical properties, particularly in response to the presence of GBM cells and their dynamic interaction with scaffold. Particular attention should be paid to the choice of biomaterials- regarding the type of drugs applied in studies to avoid false positive or false negative

results on chemosensitivity due to variable drug permeability and absorption. Other challenges, which also affect drug efficiency in GBM, remain to be addressed in the future design of microfluidic-based 3D GBM platforms. Those include establishing heterogeneity of GBM cells, mimicking interactions between GBM cells and other brain cell types, as well as modeling GBM motility.

Development of composite 3D glioblastoma cell culture platforms can be an expensive and time consuming process and their operation often requires the use of additional specialized equipment (e.g. peristaltic pumps). Therefore, improvements in design and engineering of 3D glioblastoma cell cultures should be made in the future, particularly to ensure easy handling and widespread use. Moreover, in the near future, 3D glioblastoma cell cultures should be designed to be applicable for high-throughput and high-content screening, to enable their wider and more frequent commercial usage.

An important aspect in the application of 3D glioblastoma cell platforms is monitoring processes within them, not only on phenotypic but also on molecular level. So far, end-point analyses or time-lapse fluorescent and confocal microscopy were mainly used to analyze cancer cell behavior in 3D platforms. However, in order to obtain as much relevant data, particularly as a function of time, it is necessary to couple 3D cultures with more advanced monitoring techniques such as MRI and MALDI imaging that will enable long-term real time monitoring of 3D cell cultures and identify the spatial distributions of biomolecules within cells.

3D cancer cell culture analyses generate large amounts of data that will further increase with the development of high-throughput and high-content 3D screening platforms. Fast development of machine-learning software and their implementation for 3D cancer cell culture analyses will provide quick and automated evaluation of the obtained results which will further increase applicability of 3D cell cultures for widespread commercial use.

Regardless of how complex 3D GBM cell cultures will be made in the future, they will still represent simplified models of the real tumors. Application of mathematical modeling can help to overcome this problem of reductionism in *in vitro* conditions. Mathematical simulations based on the obtained *in vitro* data could predict GBM behavior *in vivo*, particularly response to treatment and potential development of chemoresistance, thereby increasing usefulness of 3D glioblastoma cell cultures for drug screening and precision medicine.

Overall, upgraded 3D GBM models, that will be developed in the future with integrated advanced imaging techniques, cutting-edge artificial intelligence-based analyses and mathematical simulations will be invaluable and irreplaceable tool for better understanding of GBM, its response to therapy and overcoming chemoresistance, as well as for commercial application in preclinical drug screening, drug development and personalized medicine.

Although *in vitro* BBB models cannot fully recapitulate the activity of the BBB *in vivo*, they help us studying BBB development and BBB function under pathological conditions. Particularly useful BBB models are iPSC-based models offering the possibility to understand the individual changes that can be crucial for defining drug concentrations in GBM patients. Other advances in the BBB-on-a-chips include introduction of appropriate ECM, all cellular components of the neurovascular unit and shear stress due to the dynamic flow. These advanced BBB models were developed in order to evaluate drug permeability and toxicity aiming to help in the determination of new GBM therapeutic approaches.

Declaration of Competing Interest

Ignacio Ochoa and Luis Fernández are promoters and consultants for BeOnChip S.L. and EBERS Medical Technology S.L. (Zaragoza, Spain). Both cited companies have had no role in the decision to publish nor were involved in the writing of this manuscript.

Acknowledgements

This research was funded by James S. Mc. Donnell Foundation 21st Century Science Initiative in Mathematical and Complex Systems Approaches for Brain Cancer (Collaborative award 220020560); Ministry of Education, Science and Technological Development, Republic of Serbia (ref. number 451-03-68/2020-14/200007); Ministerio de Ciencia e Innovación, Spain (grant number PID2019-110895RB-I00); Junta de Comunidades de Castilla-La Mancha, Spain (grant number (SBPLY/17/180501/000154). This work has also received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 829010 (PRIME). T.R. studentship was supported by Instituto de Salud Carlos III (i - PFIS IFI16/00050).

References

- Abbott, N.J., 2013. Blood-brain barrier structure and function and the challenges for CNS drug delivery. *J. Inher. Metab. Dis.* <https://doi.org/10.1007/s10545-013-9608-0>.
- Achyuta, A.K.H., Conway, A.J., Crouse, R.B., Bannister, E.C., Lee, R.N., Katnik, C.P., Behensky, A.A., Cuevas, J., Sundaram, S.S., 2013. A modular approach to create a neurovascular unit-on-a-chip. *Lab Chip* 13, 542–553. <https://doi.org/10.1039/c2lc41033h>.
- Agarwal, S., Sane, R., Oberoi, R., Ohlfest, J.R., Elmquist, W.F., 2011. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. *Expert Rev. Mol. Med.* <https://doi.org/10.1017/S1462399411001888>.
- Ahmed, E.M., Bandopadhyay, G., Coyle, B., Grabowska, A., 2018. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. *Cell. Oncol.* 41, 319–328. <https://doi.org/10.1007/s13402-018-0374-8>.
- Ahmed, S., Chauhan, V.M., Ghaemmaghami, A.M., Aylott, J.W., 2019. New generation of bioreactors that advance extracellular matrix modelling and tissue engineering. *Biotechnol. Lett.* <https://doi.org/10.1007/s10529-018-2611-7>.
- Akay, M., Hite, J., Avci, N.G., Fan, Y., Akay, Y., Lu, G., Zhu, J.-J., 2018. Drug screening of human GBM spheroids in brain cancer chip. *Sci. Rep.* 8, 15423. <https://doi.org/10.1038/s41598-018-33641-2>.
- Al Ahmad, A., Gassmann, M., Ogunshola, O.O., 2009. Maintaining blood-brain barrier integrity: pericytes perform better than astrocytes during prolonged oxygen deprivation. *J. Cell. Physiol.* 218, 612–622. <https://doi.org/10.1002/jcp.21638>.
- Alfonso, J.C.L., Talkenberger, K., Seifert, M., Klink, B., Hawkins-Daarud, A., Swanson, K. R., Hatzikirou, H., Deutsch, A., 2017. The biology and mathematical modelling of glioma invasion: a review. *J. R. Soc. Interface.* <https://doi.org/10.1098/rsif.2017.0490>.
- Ali, M.Y., Oliva, C.R., Noman, A.S.M., Allen, B.G., Goswami, P.C., Zakharia, Y., Monga, V., Spitz, D.R., Buatti, J.M., Griguer, C.E., 2020. Radiosensitivity in glioblastoma and the development of radiosensitizers. *Cancers (Basel)*. <https://doi.org/10.3390/cancers12092511>.
- Allt, G., Lawrenson, J.G., 2001. Pericytes: cell biology and pathology. *Cells Tissues Organs (Print)* 169, 1–11. <https://doi.org/10.1159/000047855>.
- Amberger-Murphy, V., 2009. Hypoxia helps glioma to fight therapy. *Curr. Cancer Drug Targets* 9, 381–390. <https://doi.org/10.2174/156800909788166637>.
- Amiri, A., Le, P.U., Moquin, A., Machkalyan, G., Petrecca, K., Gillard, J.W., Yoganathan, N., Maysinger, D., 2016. Inhibition of carbonic anhydrase IX in glioblastoma multiforme. *Eur. J. Pharm. Biopharm.* 109, 81–92. <https://doi.org/10.1016/j.ejpb.2016.09.018>.
- An, Z., Gluck, C.B., Choy, M.L., Kaufman, L.J., 2010. Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. *Cancer Lett.* 292, 215–227. <https://doi.org/10.1016/j.canlet.2009.12.006>.
- Ananthanarayanan, B., Kim, Y., Sanjay, K., 2011. Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform. *Biomaterials* 32, 7913–7923. <https://doi.org/10.1016/j.biomaterials.2011.07.005>.
- Andreata, F., Beccaceci, G., Fortuna, N., Celotti, M., De Felice, D., Lorenzoni, M., Foletto, V., Genovesi, S., Rubert, J., Alaimo, A., 2020. The organoid era permits the development of new applications to study glioblastoma. *Cancers (Basel)*. <https://doi.org/10.3390/cancers12113303>.
- Andrei, L., Kasas, S., Ochoa Garrido, I., Stanković, T., Suárez Korsnes, M., Vlacikova, R., Assaraf, Y.G., Pešić, M., 2019. Advanced technological tools to study multidrug resistance in cancer. *Drug Resist. Updat.*, 100658 <https://doi.org/10.1016/j.drup.2019.100658>.
- Arvanitis, C.D., Ferraro, G.B., Jain, R.K., 2020. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. *Nat. Rev. Cancer.* <https://doi.org/10.1038/s41568-019-0205-x>.
- Assaraf, Y.G., Brozovic, A., Gonçalves, A.C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmiento-Ribeiro, A.B., Xavier, C.P.R., Vasconcelos, M.H., 2019. The multi-factorial nature of clinical multidrug resistance in cancer. *Drug Resist. Updat.* 46 <https://doi.org/10.1016/j.drup.2019.100645>.
- Aubert, M., Badoual, M., Christov, C., Grammaticos, B., 2008. A model for glioma cell migration on collagen and astrocytes. *J. R. Soc. Interface* 5, 75–83. <https://doi.org/10.1098/rsif.2007.1070>.
- Aum, D.J., Kim, D.H., Beaumont, T.L., Leuthardt, E.C., Dunn, G.P., Kim, A.H., 2014. Molecular and cellular heterogeneity: the hallmark of glioblastoma. *Neurosurg. Focus* 37, E11. <https://doi.org/10.3171/2014.9.FOCUS14521>.

- Avci, N.G., Fan, Y., Dragomir, A., Akay, Y.M., Akay, M., 2015. Investigating the influence of HUVECs in the formation of glioblastoma spheroids in high-throughput three-dimensional microwells. *IEEE Trans. Nanobioscience* 14, 790–796. <https://doi.org/10.1109/TNB.2015.2477818>.
- Ayuso, J.M., Virumbrales-Muñoz, M., Lacueva, A., Lanuza, P.M., Checa-Chavarria, E., Botella, P., Fernández, E., Doblaré, M., Allison, S.J., Phillips, R.M., Pardo, J., Fernandez, L.J., Ochoa, I., 2016. Development and characterization of a microfluidic model of the tumour microenvironment. *Sci. Rep.* 6, 36086. <https://doi.org/10.1038/srep36086>.
- Ayensa-Jiménez, J., Pérez-Aliacar, M., Randelovic, T., Oliván, S., Fernández, L., Sanz-Herrera, J.A., Ochoa, I., H. Doweidar, M., Doblaré, M., 2020. Mathematical formulation and parametric analysis of in vitro cell models in microfluidic devices: application to different stages of glioblastoma evolution. *Sci. Rep.* 10, 21193. <https://doi.org/10.1038/s41598-020-78215-3>.
- Ayuso, J.M., Monge, R., Martínez-González, A., Virumbrales-Muñoz, M., Llamazares, G. A., Berganzo, J., Hernández-Lain, A., Santolaria, J., Doblaré, M., Hubert, C., Rich, J. N., Sánchez-Gómez, P., Pérez-García, V.M., Ochoa, I., Fernández, L.J., 2017. Glioblastoma on a microfluidic chip: generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events. *Neuro. Oncol.* 19, 503–513. <https://doi.org/10.1093/neuonc/now230>.
- Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Bigner, D.D., Rich, J.N., 2006a. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 444, 756–760. <https://doi.org/10.1038/nature05236>.
- Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A.B., Shi, Q., McLendon, R.E., Bigner, D.D., Rich, J.N., 2006b. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. *Cancer Res.* 66, 7843–7848. <https://doi.org/10.1158/0008-5472.CAN-06-1010>.
- Bayat, N., Izadpanah, R., Ebrahimi-Barough, S., Javidan, A.N., Ai, A., Ardakan, M.M.M., Saberi, H., Ai, J., 2018. The anti-angiogenic effect of atorvastatin in glioblastoma spheroids tumor cultured in fibrin gel: in 3D in vitro model. *Asian Pac. J. Cancer Prev.* 19, 2553–2560. <https://doi.org/10.22034/APJCP.2018.19.9.2553>.
- Begley, D., 2004. ABC transporters and the blood-brain barrier. *Curr. Pharm. Des.* 10, 1295–1312. <https://doi.org/10.2174/1381612043384844>.
- Bell, H.S., Whittle, I.R., Walker, M., Leaver, H.A., Wharton, S.B., 2001. The development of necrosis and apoptosis in glioma: experimental findings using spheroid culture systems*. *Neuropathol. Appl. Neurobiol.* 27, 291–304. <https://doi.org/10.1046/j.0305-1846.2001.00319.x>.
- Belousov, A., Titov, S., Shved, N., Garbuz, M., Malykin, G., Gulaia, V., Kagansky, A., Kumeiko, V., 2019. The extracellular matrix and biocompatible materials in glioblastoma treatment. *Front. Bioeng. Biotechnol.* 7, 341. <https://doi.org/10.3389/fbioe.2019.00341>.
- Benson, K., Galla, H.J., Kehr, N.S., 2014. Cell adhesion behavior in 3D hydrogel scaffolds functionalized with D - or L -amino acids. *Macromol. Biosci.* 14, 793–798. <https://doi.org/10.1002/mabi.201300485>.
- Bernstein, J.J., Woodard, C.A., 1995. Glioblastoma cells do not intravasate into blood vessels. *Neurosurgery* 36, 124–132. <https://doi.org/10.1227/00006123-199501000-00016>.
- Berthier, S., Arnaud, J., Champelovier, P., Col, E., Garrel, C., Cottet, C., Boutonnat, J., Laporte, F., Faure, P., Hazane-Puch, F., 2017. Anticancer properties of sodium selenite in human glioblastoma cell cluster spheroids. *J. Trace Elem. Med. Biol.* 44, 161–176. <https://doi.org/10.1016/j.jtemb.2017.04.012>.
- Bhatia, S.N., Ingber, D.E., 2014. Microfluidic organs-on-chips. *Nat. Biotechnol.* 32 (8), 760–772. <https://doi.org/10.1038/nbt.2989>.
- Bicker, J., Alves, G., Fortuna, A., Falcão, A., 2014. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. *Eur. J. Pharm. Biopharm.* 87 (3), 409–432. <https://doi.org/10.1016/j.ejpb.2014.03.012>.
- Bighetti-Trevisan, R.L., Sousa, L.O., Castilho, R.M., Almeida, L.O., 2019. Cancer stem cells: powerful targets to improve current anticancer therapeutics. *Stem Cells Int.* 2019, 9618065. <https://doi.org/10.1155/2019/9618065>.
- Bjerkvig, R., Tonnesen, A., Laerum, O.D., Backlund, E.O., 1990. Multicenter tumor spheroids from human gliomas maintained in organ culture. *J. Neurosurg.* 72, 463–475. <https://doi.org/10.3171/jns.1990.72.3.0463>.
- Booth, R., Kim, H., 2012. Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB). *Lab Chip* 12, 1784–1792. <https://doi.org/10.1039/c2lc40094d>.
- Borgnia, M.J., Eytan, G.D., Assaraf, Y.G., 1996. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. *J. Biol. Chem.* 271, 3163–3171. <https://doi.org/10.1074/jbc.271.6.3163>.
- Borrego-Soto, G., Ortiz-López, R., Rojas-Martínez, A., 2015. Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer. *Genet. Mol. Biol.* 38 (4), 420–432. <https://doi.org/10.1590/S1415-475738420150019>.
- Böttger, K., Hatzikirou, H., Chauviere, A., Deutsch, A., 2012. Investigation of the migration/proliferation dichotomy and its impact on avascular glioma invasion. *Math. Model. Nat. Phenom.* 7, 105–135. <https://doi.org/10.1051/mmnp/20127106>.
- Brat, D.J., Castellano-Sanchez, A.A., Hunter, S.B., Pecot, M., Cohen, C., Hammond, E.H., Devi, S.N., Kaur, B., Van Meir, E.G., 2004. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. *Cancer Res.* 64, 920–927. <https://doi.org/10.1158/0008-5472.CAN-03-2073>.
- Bregenzner, M.E., Horst, E.N., Mehta, P., Novak, C.M., Raghavan, S., Snyder, C.S., Mehta, G., 2019. Integrated cancer tissue engineering models for precision medicine. *PLoS One* 14. <https://doi.org/10.1371/journal.pone.0216564>.
- Breznik, B., Motaln, H., Vittori, M., Rotter, A., Turnšek, T.L., 2017. Mesenchymal stem cells differentially affect the invasion of distinct glioblastoma cell lines. *Oncotarget* 8, 25482–25499.
- Brown, J.A., Pensabene, V., Markov, D.A., Allwardt, V., Diana Neely, M., Shi, M., Britt, C. M., Hoilett, O.S., Yang, Q., Brewer, B.M., Samson, P.C., McCawley, L.J., May, J.M., Webb, D.J., Li, D., Bowman, A.B., Reiserer, R.S., Wikswo, J.P., 2015. Recreating blood-brain barrier physiology and structure on chip: a novel neurovascular microfluidic bioreactor. *Biomicrofluidics* 9. <https://doi.org/10.1063/1.4934713>.
- Cahill, D.P., Levine, K.K., Betensky, R.A., Codd, P.J., Romany, C.A., Reavie, L.B., Batchelor, T.T., Futreal, P.A., Stratton, M.R., Curry, W.T., Lafrate, A.J., Louis, D.N., 2007. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. *Clin. Cancer Res.* 13, 2038–2045. <https://doi.org/10.1158/1078-0432.CCR-06-2149>.
- Calatrazzolo, C., Gelati, M., Ciusani, E., Sciacca, F.L., Pollo, B., Cajola, L., Marras, C., Silvani, A., Vitellaro-Zuccarello, L., Croci, D., Boiardi, A., Salmaggi, A., 2005. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 AND GST-π in human glioma. *J. Neurooncol.* 74, 113–121. <https://doi.org/10.1007/s11060-004-6152-7>.
- Caliari, S.R., Burdick, J.A., 2016. A practical guide to hydrogels for cell culture. *Nat. Methods* 13, 405. <https://doi.org/10.1038/NMETH.3839>.
- Capper, D., Gaiser, T., Hartmann, C., Habel, A., Mueller, W., Herold-Mende, C., von Deimling, A., Siegelin, M.D., 2009. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. *Acta Neuropathol.* 117, 445–456. <https://doi.org/10.1007/s00401-009-0494-3>.
- Cha, J., Kim, P., 2017. Biomimetic strategies for the glioblastoma microenvironment. *Front. Mater.* 4, 45. <https://doi.org/10.3389/fmats.2017.00045>.
- Charles, N., Ozawa, T., Squatrito, M., Bleau, A.-M., Brennan, C.W., Hambardzumyan, D., Holland, E.C., 2010. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. *Cell Stem Cell* 6, 141–152. <https://doi.org/10.1016/j.stem.2010.01.001>.
- Chen, Z., Htay, A., Dos Santos, W., Gillies, G.T., Fillmore, H.L., Sholley, M.M., Broadhus, W.C., 2009. In vitro angiogenesis by human umbilical vein endothelial cells (HUVEC) induced by three-dimensional co-culture with glioblastoma cells. *J. Neurooncol.* 92, 121–128. <https://doi.org/10.1007/s11060-008-9742-y>.
- Chen, Y., Meng, D., Wang, H., Sun, R., Wang, D., Wang, S., Fan, J., Zhao, Y., Wang, J., Yang, S., Huai, C., Song, X., Qin, R., Xu, T., Yun, D., Hu, L., Yang, J., Zhang, X., Chen, Haoming, Chen, J., Chen, Hongyan, Lu, D., 2015. VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells. *Neuro. Oncol.* 17, 407–418. <https://doi.org/10.1093/neuonc/nou219>.
- Cheng, V., Esteves, F., Chakrabarty, A., Cockle, J., Short, S., Brüning-Richardson, A., 2015. High-content analysis of tumour cell invasion in three-dimensional spheroid assays. *Oncoscience* 2, 596–606. <https://doi.org/10.18632/oncoscience.171>.
- Chin, E., Goh, E., 2018. Blood-brain barrier on a chip. In: Doh, J., Fletcher, D., Piel, M. (Eds.), *Methods in Cell Biology*. Academic Press Inc., pp. 159–182. <https://doi.org/10.1016/bbs.mcb.2018.06.003>.
- Chonan, Y., Taki, S., Sampetean, O., Saya, H., Sudo, R., 2017. Endothelium-induced three-dimensional invasion of heterogeneous glioma initiating cells in a microfluidic coculture platform. *Integr. Biol. (United Kingdom)* 9, 762–773. <https://doi.org/10.1039/c7ib00091j>.
- Chou, C.W., Wang, C.C., Wu, C.P., Lin, Y.J., Lee, Y.C., Cheng, Y.W., Hsieh, C.H., 2012. Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. *Neuro. Oncol.* 14, 1227–1238. <https://doi.org/10.1093/neuonc/nos195>.
- Christensen, K., Aaberg-Jessen, C., Andersen, C., Goplen, D., Bjerkvig, R., Kristensen, B. W., 2010. Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. *Neurosurgery* 66, 933–947. <https://doi.org/10.1227/01.NEU.0000368393.45935.46>.
- Civita, P., Leite, D.M., Pilkington, G.J., 2019. Pre-clinical drug testing in 2d and 3d human in vitro models of glioblastoma incorporating non-neoplastic astrocytes: tunneling nano tubules and mitochondrial transfer modulates cell behavior and therapeutic respons. *Int. J. Mol. Sci.* 20. <https://doi.org/10.3390/ijms20236017>.
- Colgan, O.C., Collins, N.T., Ferguson, G., Murphy, R.P., Birney, Y.A., Cahill, P.A., Cummins, P.M., 2008. Influence of basolateral condition on the regulation of brain microvascular endothelial tight junction properties and barrier function. *Brain Res.* 1193, 84–92. <https://doi.org/10.1016/j.brainres.2007.11.072>.
- Colwell, N., Larion, M., Giles, A.J., Seldomridge, A.N., Sizdahkhani, S., Gilbert, M.R., Park, D.M., 2017. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. *Neuro. Oncol.* 19, 887–896. <https://doi.org/10.1093/neuonc/now258>.
- Coniglio, S., Miller, I., Symons, M., Segall, J.E., 2016. Coculture assays to study macrophage and microglia stimulation of glioblastoma invasion. *J. Vis. Exp.* 116, 53990. <https://doi.org/10.3791/53990>.
- Coppola, S., Carnevale, I., Danen, E.H.J., Peters, G.J., Schmidt, T., Assaraf, Y.G., Giovannetti, E., 2017. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. *Drug Resist. Updat.* 31, 43–51. <https://doi.org/10.1016/j.drug.2017.07.001>.
- Crone, C., Olesen, S.P., 1982. Electrical resistance of brain microvascular endothelium. *Brain Res.* 241, 49–55. [https://doi.org/10.1016/0006-8993\(82\)91227-6](https://doi.org/10.1016/0006-8993(82)91227-6).
- Cui, Q., Wang, J.Q., Assaraf, Y.G., Ren, L., Gupta, P., Wei, L., Ashby, C.R., Yang, D.H., Chen, Z.S., 2018a. Modulating ROS to overcome multidrug resistance in cancer. *Drug Resist. Updat.* 41, 1–25. <https://doi.org/10.1016/j.drug.2018.11.001>.
- Cui, X., Morales, R.T.T., Qian, W., Wang, H., Gagner, J.P., Dolgalev, I., Placantonakis, D., Zagzag, D., Cimmino, L., Snuderl, M., Lam, R.H.W., Chen, W., 2018b. Hacking macrophage-associated immunosuppression for regulating glioblastoma

- angiogenesis. *Biomaterials* 161, 164–178. <https://doi.org/10.1016/j.biomaterials.2018.01.053>.
- Dai, X., Ma, C., Lan, Q., Xu, T., 2016. 3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility. *Biofabrication* 8, 045005. <https://doi.org/10.1088/1758-5090/8/4/045005>.
- Daneman, R., Zhou, L., Kebede, A.A., Barres, B.A., 2010. Pericytes are required for blood–brain barrier integrity during embryogenesis. *Nature* 468, 562–566. <https://doi.org/10.1038/nature09513>.
- Daniele, S., Pietrobono, D., Costa, B., Giustiniano, M., La Pietra, V., Giacomelli, C., La Regina, G., Silvestri, R., Taliani, S., Trincavelli, M.L., Da Settimo, F., Novellino, E., Martini, C., Marinelli, L., 2018. Bax activation blocks self-renewal and induces apoptosis of human glioblastoma stem cells. *ACS Chem. Neurosci.* 9, 85–99. <https://doi.org/10.1021/acschemneuro.7b00023>.
- de Almeida, L.C., Calil, F.A., Machado-Neto, J.A., Costa-Lotufo, L.V., 2021. DNA damaging agents and DNA repair: from carcinogenesis to cancer therapy. *Cancer Genet.* 252–253, 6–24. <https://doi.org/10.1016/j.cancergen.2020.12.002>.
- de Kruijff, R.M., van der Meer, A.J.G.M., Windmeijer, C.A.A., Kouwenberg, J.J.M., Morgenstern, A., Bruchertseifer, F., Sminia, P., Denkova, A.G., 2018. The therapeutic potential of polymersomes loaded with 225Ac evaluated in 2D and 3D in vitro glioma models. *Eur. J. Pharm. Biopharm.* 127, 85–91. <https://doi.org/10.1016/j.ejpb.2018.02.008>.
- de Trizio, I., Errede, M., d'Amati, A., Girolamo, F., Virgintino, D., 2020. Expression of P-gp in glioblastoma: what we can learn from brain development. *Curr. Pharm. Des.* 26, 1428–1437. <https://doi.org/10.2174/1381612826666200318130625>.
- De Witt Hamer, P.C., Leenstra, S., Van Noorden, C.J.F., Zwiderman, A.H., 2009. Organotypic glioma spheroids for screening of experimental therapies: how many spheroids and sections are required? *Cytom. Part A* 75, 528–534. <https://doi.org/10.1002/cyto.a.20716>.
- Declèves, X., Amiel, A., Delattre, J.-Y., Scherrmann, J.-M., 2006. Role of ABC transporters in the chemoresistance of human gliomas. *Curr. Cancer Drug Targets* 6, 433–445.
- DeCordova, S., Shastri, A., Tsolaki, A.G., Yasmin, H., Klein, L., Singh, S.K., Kishore, U., 2020. Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma. *Front. Immunol.* 11, 1402. <https://doi.org/10.3389/fimmu.2020.01402>.
- Deosarkar, S.P., Prabhakarandian, B., Wang, B., Sheffield, J.B., Krynska, B., Kiani, M.F., 2015. A novel dynamic neonatal blood–brain barrier on a chip. *PLoS One* 10. <https://doi.org/10.1371/journal.pone.0142725>.
- Dhermain, F.G., Hau, P., Lanfermann, H., Jacobs, A.H., van den Bent, M.J., 2010. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. *Lancet Neurol.* 9 (9), 906–920. [https://doi.org/10.1016/S1474-4422\(10\)70181-2](https://doi.org/10.1016/S1474-4422(10)70181-2).
- Dilnawaz, F., Sahoo, S.K., 2013. Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model. *Eur. J. Pharm. Biopharm.* 85, 452–462. <https://doi.org/10.1016/j.ejpb.2013.07.013>.
- Dirkx, A., Golebiewska, A., Buder, T., Nazarou, P.V., Muller, A., Poovathingal, S., Brons, N.H.C., Leite, S., Sauvageot, N., Sarkisjan, D., Seyfrid, M., Fritah, S., Stieber, D., Michelucci, A., Hertel, F., Herold-Mende, C., Azuaje, F., Skupin, A., Bjerkvig, R., Deutsch, A., Voss-Böhme, A., Niclou, S.P., 2019. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. *Nat. Commun.* 10, 1–16. <https://doi.org/10.1038/s41467-019-09853-z>.
- Doran, A., Obach, R.S., Smith, B.J., Hosea, N.A., Becker, S., Callegari, E., Chen, C., Chen, X., Choo, E., Cianfrogna, J., Cox, L.M., Gibbs, J.P., Gibbs, M.A., Hatch, H., Hop, C.E.C.A., Kasman, I.N., LaPerle, J., Liu, J.H., Liu, X., Logman, M., MacLain, D., Nedza, F.M., Nelson, F., Olson, E., Rahematpura, S., Raunig, D., Rogers, S., Schmidt, K., Spracklin, D.K., Szwed, M., Troutman, M., Tseng, E., Tu, M., Van Deusen, J.W., Venkatakrishnan, K., Walens, G., Wang, E.Q., Wong, D., Yaggar, A.S., Zhang, C., 2005. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. *Drug Metab. Dispos.* 33, 165–174. <https://doi.org/10.1124/dmd.104.001230>.
- Dore-Duffy, P., Katyshev, A., Wang, X., Van Buren, E., 2006. CNS microvascular pericytes exhibit multipotential stem cell activity. *J. Cereb. Blood Flow Metab.* 26, 613–624. <https://doi.org/10.1038/sj.cbfm.9600272>.
- Dyrna, F., Hanske, S., Krueger, M., Bechmann, I., 2013. The blood–brain barrier. *J. Neuroimmune Pharmacol.* 8 (4), 763–773. <https://doi.org/10.1007/s11481-013-9473-5>.
- Eigenmann, D.E., Xue, G., Kim, K.S., Moses, A.V., Hamburger, M., Oufir, M., 2013. Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood–brain barrier model for drug permeability studies. *Fluids Barriers CNS* 10, 33. <https://doi.org/10.1186/2045-8118-10-33>.
- Erickson, A.E., Lan Levengood, S.K., Sun, J., Chang, F.C., Zhang, M., 2018. Fabrication and characterization of chitosan–Hyaluronic acid scaffolds with varying stiffness for glioblastoma cell culture. *Adv. Healthc. Mater.* 7. <https://doi.org/10.1002/adhm.201800295>.
- Ezhilarasan, R., Mohanam, I., Govindarajan, Kathiravan, Mohanam, S., 2007. Glioma cells suppress hypoxia-induced endothelial cell apoptosis and promote angiogenic process. *Int. J. Oncol.* 30, 701–707.
- Fan, Y., Nguyen, D.T., Akay, Y., Xu, F., Akay, M., 2016. Engineering a brain Cancer chip for high-throughput drug screening. *Sci. Rep.* 6, 25062. <https://doi.org/10.1038/srep25062>.
- Fanfone, D., Idbaih, A., Mammi, J., Gabut, M., Ichim, G., 2020. Profiling anti-apoptotic bcl-xl protein expression in glioblastoma tumorspheres. *Cancers (Basel)* 12, 1–14. <https://doi.org/10.3390/cancers12102853>.
- Farace, C., Oliver, J.A., Melguizo, C., Alvarez, P., Bandiera, P., Rama, A.R., Malaguarnera, G., Ortiz, R., Madeddu, R., Prados, J., 2015. Microenvironmental modulation of decorin and lumican in temozolomide-resistant glioblastoma and neuroblastoma cancer stem-like cells. *PLoS One* 10, 1–18. <https://doi.org/10.1371/journal.pone.0134111>.
- Fayzullin, A., Sandberg, C.J., Spreadbury, M., Saberniak, B.M., Grieg, Z., Skaga, E., Langmoen, I.A., Vik-Mo, E.O., 2019. Phenotypic and expressional heterogeneity in the invasive glioma cells. *Transl. Oncol.* 12, 122–133. <https://doi.org/10.1016/j.tranon.2018.09.014>.
- Felsberg, J., Thon, N., Eigenbrod, S., Hentschel, B., Sabel, M.C., Westphal, M., Schackert, G., Kreth, F.W., Pietsch, T., Löffler, M., Weller, M., Reifenberger, G., Tonn, J.C., 2011. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. *Int. J. Cancer* 129, 659–670. <https://doi.org/10.1002/ijc.26083>.
- Feng, B., Mills, J.B., Davidson, R.E., Mireles, R.J., Janiszewski, J.S., Troutman, M.D., De Moraes, S.M., 2008. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. *Drug Metab. Dispos.* 36, 268–275. <https://doi.org/10.1124/dmd.107.017434>.
- Fernandez-Fuente, G., Mollinedo, P., Grande, L., Vazquez-Barquero, A., Fernandez-Luna, J.L., 2014. Culture dimensionality influences the resistance of glioblastoma stem-like cells to multikinase inhibitors. *Mol. Cancer Ther.* 13, 1664–1672. <https://doi.org/10.1158/1535-7163.MCT-13-0854>.
- Fessler, E., Borovski, T., Medema, J.P., 2015. Endothelial cells induce cancer stem cell features in differentiated glioblastoma cells via bFGF. *Mol. Cancer* 14, 157. <https://doi.org/10.1186/s12943-015-0420-3>.
- Florczyk, S.J., Wang, K., Jana, S., Wood, D.L., Sytsma, S.K., Sham, J.G., Kievit, F.M., Zhang, M., 2013. Porous chitosan–hyaluronic acid scaffolds as a mimic of glioblastoma microenvironment ECM. *Biomaterials* 34, 10143–10150. <https://doi.org/10.1016/j.biomaterials.2013.09.034>.
- Freeman, A.E., Hoffman, R.M., 1986. In vivo-like growth of human tumors in vitro. *Proc. Natl. Acad. Sci. U. S. A.* 83, 2694–2698. <https://doi.org/10.1073/pnas.83.8.2694>.
- Gacche, R.N., Assaraf, Y.G., 2018. Redundant angiogenic signaling and tumor drug resistance. *Drug Resist. Updat.* 36, 47–76. <https://doi.org/10.1016/j.drup.2018.01.002>.
- Garrido, W., Rocha, J.D., Jaramillo, C., Fernandez, K., Oyarzun, C., Martin, R.S., Quezada, C., 2014. Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme. *Curr. Drug Targets* 15, 931–942. <https://doi.org/10.2174/1389450115666140826122315>.
- Giese, A., Westphal, M., 1996. Glioma invasion in the central nervous system. *Neurosurgery* 39, 235–252.
- Gómez-Oliva, R., Domínguez-García, S., Carrascal, L., Abalos-Martínez, J., Pardillo-Díaz, R., Verástegui, C., Castro, C., Nunez-Abades, P., Geribaldi-Doldán, N., 2021. Evolution of experimental models in the study of glioblastoma: toward finding efficient treatments. *Front. Oncol.* 10, 3245. <https://doi.org/10.3389/fonc.2020.614295>.
- Gomez-Roman, N., Stevenson, K., Gilmour, L., Hamilton, G., Chalmers, A.J., 2016. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses. *Neuro. Oncol.* 19 (2), 229–241. <https://doi.org/10.1093/neuonc/nov164>.
- Gonen, N., Assaraf, Y.G., 2012. Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance. *Drug Resist. Updat.* 15, 183–210. <https://doi.org/10.1016/j.drup.2012.07.002>.
- Griep, L.M., Wolbers, F., De Wagenaar, B., Ter Braak, P.M., Weksler, B.B., Romero, I.A., Couraud, P.O., Vermes, I., Van Der Meer, A.D., Van Den Berg, A., 2013. BBB on CHiP: microfluidic platform to mechanically and biochemically modulate blood–brain barrier function. *Biomed. Microdevices* 15, 145–150. <https://doi.org/10.1007/s10544-012-9699-7>.
- Gritsenko, P., Leenders, W., Friedl, P., 2017. Recapitulating in vivo-like plasticity of glioma cell invasion along blood vessels and in astrocyte-rich stroma. *Histochem. Cell Biol.* 148, 395–406. <https://doi.org/10.1007/s00418-017-1604-2>.
- Grodecki, J., Short, A.R., Winter, J.O., Rao, S.S., Winter, J.O., Otero, J.J., Lannutti, J.J., Sarkar, A., 2015. Glioma-astrocyte interactions on white matter tract-mimetic aligned electrospun nanofibers. *Biotechnol. Prog.* 31, 1406–1415. <https://doi.org/10.1002/btpr.2123>.
- Grundy, T.J., De Leon, E., Griffin, K.R., Stringer, B.W., Day, B.W., Fabry, B., Cooper-white, J., Neill, G.M.O., 2016. Differential response of patient-derived primary glioblastoma cells to environmental stiffness. *Nat. Publ. Gr.* 4–13. <https://doi.org/10.1038/srep23353>.
- Guller, A.E., Grebenyuk, P.N., Shekhter, A.B., Zvyagin, A.V., Deyev, S.M., 2016. Bioreactor-based tumor tissue engineering. *Acta Naturae* 8, 44–58.
- Hamilton, J.D., Rapp, M., Schneiderhan, T.M., Sabel, M., Hayman, A., Scherer, A., Kröpel, P., Budach, W., Kretschmar, U., Arne Gerber, P., Prabhu, S., Ginsberg, L.E., Bölke, E., Matuschek, C., 2014. Glioblastoma multiforme metastasis outside the CNS: three case reports and possible mechanisms of escape. *J. Clin. Oncol.* 32, e80–e84. <https://doi.org/10.1200/JCO.2013.48.7546>.
- Han, J., Jun, Y., Kim, S.H., Hoang, H.-H., Jung, Y., Kim, S., Kim, J., Austin, R.H., Lee, S., Park, S., 2016. Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology. *Proc. Natl. Acad. Sci. U. S. A.* 113, 14283–14288. <https://doi.org/10.1073/pnas.1614898113>.
- Hartmann, C., Zozulya, A., Wegener, J., Galla, H.J., 2007. The impact of glia-derived extracellular matrices on the barrier function of cerebral endothelial cells: an in vitro

- study. *Exp. Cell Res.* 313, 1318–1325. <https://doi.org/10.1016/j.yexcr.2007.01.024>.
- Hatzikirou, H., Basanta, D., Simon, M., Schaller, K., Deutsch, A., 2012. “Go or grow”: the key to the emergence of invasion in tumour progression? *Math. Med. Biol.* 29, 49–65. <https://doi.org/10.1093/imammb/dqq011>.
- Haumann, R., Videira, J.C., Kaspers, G.J.L., van Vuurden, D.G., Hulleman, E., 2020. Overview of current drug delivery methods across the blood–brain barrier for the treatment of primary brain tumors. *CNS Drugs* 34 (11), 1121–1131. <https://doi.org/10.1007/s40263-020-00766-w>.
- Hayashi, K., Nakao, S., Nakaoke, R., Nakagawa, S., Kitagawa, N., Niwa, M., 2004. Effects of hypoxia on endothelial/pericytic co-culture model of the blood–brain barrier. *Regul. Pept.* 123, 77–83. <https://doi.org/10.1016/j.regpep.2004.05.023>.
- He, Weifeng, He, Weiqi, Kuang, Y., Xing, X., Simpson, R.J., Huang, H., Yang, T., Chen, J., Yang, L., Liu, E., Gu, J., 2014. Proteomic comparison of 3D and 2D glioma models reveals increased HLA-E expression in 3D models is associated with resistance to NK cell-mediated cytotoxicity. *J. Proteome Res.* 13, 2272–2281. <https://doi.org/10.1021/pr500064m>.
- He, Q., Liu, J., Liang, J., Liu, X., Li, W., Liu, Z., Ding, Z., Tuo, D., 2018. Towards improvements for penetrating the blood–brain barrier—recent progress from a material and pharmaceutical perspective. *Cells* 7, 24. <https://doi.org/10.3390/cells7040024>.
- Heddlston, J.M., Li, Z., McLendon, R.E., Hjelmeland, A.B., Rich, J.N., 2009. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. *Cell Cycle* 8, 3274–3284. <https://doi.org/10.4161/cc.8.20.9701>.
- Heffernan, J.M., Overstreet, D.J., Le, L.D., Vernon, B.L., Sirianni, R.W., 2015. Bioengineered scaffolds for 3D analysis of glioblastoma proliferation and invasion. *Ann. Biomed. Eng.* 43, 1965–1977. <https://doi.org/10.1007/s10439-014-1223-1>.
- Heinrich, M.A., Bansal, R., Lammers, T., Zhang, Y.S., Michel Schifferers, R., Prakash, J., 2019. 3D-bioprinted mini-brain: a glioblastoma model to study cellular interactions and therapeutics. *Adv. Mater.* 31 (14), 1806590. <https://doi.org/10.1002/adma.201806590>.
- Henderson, J.T., Piquette-Miller, M., 2015. Blood-brain barrier: an impediment to neuropharmaceuticals. *Clin. Pharmacol. Ther.* 97 (4), 308–313. <https://doi.org/10.1002/cpt.77>.
- Hermida, M.A., Kumar, J.D., Schwarz, D., Laverty, K.G., Di Bartolo, A., Ardron, M., Bogomolnys, M., Clavreul, A., Brennan, P.M., Wiegand, U.K., Melchels, F.P., Shu, W., Leslie, N.R., 2020. Three dimensional in vitro models of cancer: bioprinting multilineage glioblastoma models. *Adv. Biol. Regul.* 75, 100658. <https://doi.org/10.1016/j.jbior.2019.100658>.
- Herrera-Perez, M., Voytik-Harbin, S., Rickus, J.L., 2015. Extracellular matrix properties regulate the migratory response of glioblastoma stem cells in 3D culture. *Tissue Eng. Part A* 21, 2572–2582. <https://doi.org/10.1089/ten.TEA.2014.0504>.
- Hjelmeland, A.B., Wu, Q., Heddlston, J.M., Choudhary, G.S., MacSwords, J., Lathia, J. D., McLendon, R., Lindner, D., Sloan, A., Rich, J.N., 2011. Acidic stress promotes a glioma stem cell phenotype. *Cell Death Differ.* 18, 829–840. <https://doi.org/10.1038/cdd.2010.150>.
- Hoarau-Véhot, J., Rafii, A., Touboul, C., Pasquier, J., 2018. Halfway between 2D and animal models: are 3D cultures the ideal tool to study cancer-microenvironment interactions? *Int. J. Mol. Sci.* 19. <https://doi.org/10.3390/ijms19010181>.
- Hombach-Klonisch, S., Mehrpour, M., Shojai, S., Harlos, C., Pitz, M., Hamai, A., Siemianowicz, K., Likus, W., Wiehac, E., Toyota, B.D., Hoshy, R., Seyfoori, A., Sepehri, Z., Ande, S.R., Khadem, F., Akbari, M., Gorman, A.M., Samali, A., Klonisch, T., Ghavami, S., 2018. Glioblastoma and chemoresistance to alkylating agents: involvement of apoptosis, autophagy, and unfolded protein response. *Pharmacol. Ther.* 184, 13–41. <https://doi.org/10.1016/j.pharmthera.2017.10.017>.
- Hou, X., Jiang, J., Tian, Z., Wei, L., 2020. Autophagy and tumour chemotherapy. *Advances in Experimental Medicine and Biology*. Springer, pp. 351–374. https://doi.org/10.1007/978-981-15-4272-5_24.
- Hoyle, H.W., Smith, L.A., Williams, R.J., Przyborski, S.A., 2020. Applications of novel bioreactor technology to enhance the viability and function of cultured cells and tissues. *Interface Focus* 10. <https://doi.org/10.1098/rsfs.2019.0090>.
- Hu, B., Nandhu, M.S., Sim, H., Agudelo-Garcia, P.A., Saldivar, J.C., Dolan, C.E., Mora, M.E., Nuovo, G.J., Cole, S.E., Viapiano, M.S., 2012a. Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. *Cancer Res.* 72, 3873–3885. <https://doi.org/10.1158/0008-5472.CAN-12-1060>. Fibulin-3.
- Hu, Y.L., DeLay, M., Jahangiri, A., Molinaro, A.M., Rose, S.D., Carbonell, W.S., Aghi, M. K., 2012b. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. *Cancer Res.* 72, 1773–1783. <https://doi.org/10.1158/0008-5472.CAN-11-3831>.
- Huang, Y., Agrawal, B., Clark, P., Williams, J.C., Kuo, J.S., 2011. Evaluation of cancer stem cell migration using compartmentalizing microfluidic devices and live cell imaging. *J. Vis. Exp.* e3297. <https://doi.org/10.3791/3297>.
- Huang, Y., Tong, L., Yi, L., Zhang, C., Hai, L., Li, T., Yu, S., Wang, W., Tao, Z., Ma, H., Liu, P., Xie, Y., Yang, X., 2018. Three-dimensional hydrogel is suitable for targeted investigation of amoeboid migration of glioma cells. *Mol. Med. Rep.* 17, 250–256. <https://doi.org/10.3892/mmr.2017.7888>.
- Huang, S., Qi, P., Zhang, T., Li, F., He, X., 2019. The HIF-1 α /miR-224-3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia-induced protective autophagy in glioblastoma and astrocytoma. *Oncol. Rep.* 41, 1759–1768. <https://doi.org/10.3892/or.2018.6929>.
- Huang, R.X., Zhou, P.K., 2020. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. *Signal Transduct. Target. Ther.* 5 (1), 60. <https://doi.org/10.1038/s41392-020-0150-x>.
- Hubert, C.G., Rivera, M., Spangler, L.C., Wu, Q., Mack, S.C., Prager, B.C., Couce, M., McLendon, R.E., Sloan, A.E., Rich, J.N., 2016. A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. *Cancer Res.* 76, 2465–2477. <https://doi.org/10.1158/0008-5472.CAN-15-2402>.
- Iwasaki, K., Rogers, L.R., Barnett, G.H., Estes, M.L., Barna, B.P., 1993. Effect of recombinant tumor necrosis factor- α on three-dimensional growth, morphology, and invasiveness of human glioblastoma cells in vitro. *J. Neurosurg.* 78, 952–958.
- Jacob, F., Salinas, R.D., Zhang, D.Y., Nguyen, P.T.T., Schnoll, J.G., Wong, S.Z.H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., Liu, D.ao, Qian, X., Petrov, D., Lucas, T., Chen, H.I., Dorsey, J.F., Christian, K.M., Binder, Z.A., Nasrallah, M., Brem, S., O'Rourke, D.M., Ming, G., Song, H., 2020. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. *Cell* 180, 188–204. <https://doi.org/10.1016/j.cell.2019.11.036> e22.
- Jia, W., Lu, R., Martin, T.A., Jiang, W.G., 2014. The role of claudin-5 in blood-brain barrier (BBB) and brain metastases (Review). *Mol. Med. Rep.* 9, 779–785. <https://doi.org/10.3892/mmr.2013.1875>.
- Jia, Wei, Jiang, X., Liu, W., Wang, L., Zhu, B., Zhu, H., Liu, Xingdong, Zhong, M., Xie, D., Thokala, W., Jia, Wenting, Li, S., Liu, Xuxu, Zuo, X., Cheng, D., Dai, J., Ren, C., 2018. Effects of three-dimensional collagen scaffolds on the expression profiles and biological functions of glioma cells. *Int. J. Oncol.* 52, 1787–1800. <https://doi.org/10.3892/ijo.2018.4330>.
- Jiang, C., Cui, C., Li, L., Shao, Y., 2014. The anomalous diffusion of a tumor invading with different surrounding tissues. *PLoS One* 9, e109784. <https://doi.org/10.1371/journal.pone.0109784>.
- Jiang, W., Xia, J., Xie, S., Zou, R., Pan, S., Wang, Z., Assaraf, Y.G., Zhu, X., 2020. Long non-coding RNAs as a determinant of cancer drug resistance: towards the overcoming of chemoresistance via modulation of lncRNAs. *Drug Resist. Updat.* 50, 100683. <https://doi.org/10.1016/j.drug.2020.100683>.
- Jiguet Jiglaire, C., Baeza-Kalée, N., Denicola, E., Baret, D., Metellus, P., Padovani, L., Chino, O., Figarella-Branger, D., Fernandez, C., 2014. Ex vivo cultures of glioblastoma in three-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening. *Exp. Cell Res.* 321, 99–108. <https://doi.org/10.1016/j.yexcr.2013.12.010>.
- Jin, F., Zhao, L., Zhao, H.Y., Guo, S.G., Feng, J., Jiang, X.B., Zhang, S.L., Wei, Y.J., Fu, R., Zhao, J.S., 2008. Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes. *Neuroscience* 154, 541–550. <https://doi.org/10.1016/j.neuroscience.2008.03.054>.
- Jin, Y., Bin, Z.Q., Qiang, H., Liang, C., Hua, C., Jun, D., Dong, W.A., Qing, L., 2009. ABCG2 is related with the grade of glioma and resistance to mitoxantrone, a chemotherapeutic drug for glioma. *J. Cancer Res. Clin. Oncol.* 135, 1369–1376. <https://doi.org/10.1007/s00432-009-0578-4>.
- Jo, Y., Choi, N., Kim, H.N., Choi, J., 2018. Probing characteristics of cancer cells cultured on engineered platforms simulating different microenvironments. *Artif. Cells, Nanomedicine, Biotechnol.* 46, 1170–1179. <https://doi.org/10.1080/21691401.2018.1446970>.
- Johnson, J., Nowicki, M.O., Lee, C.H., Chiocia, E.A., Viapiano, M.S., Lawler, S.E., Lannutti, J.J., 2009. Quantitative analysis of complex glioma cell migration on electropun polycaprolactone using time-lapse microscopy. *Tissue Eng. - Part C Methods* 15, 531–549. <https://doi.org/10.1089/ten.tec.2008.0486>.
- Jung, S., Ackerley, C., Ivanchuk, S., Mondal, S., Becker, L.E., Rutka, J.T., 2001. Tracking the invasiveness of human astrocytoma cells by using green fluorescent protein in an organotypic brain slice model. *J. Neurosurg.* 94, 80–89. <https://doi.org/10.3171/jns.2001.94.1.0080>.
- Kaisar, M.A., Sajja, R.K., Prasad, S., Abhyankar, V.V., Liles, T., Cucullo, L., 2017. New experimental models of the blood-brain barrier for CNS drug discovery. *Expert Opin. Drug Discov.* 12 (1), 89–103. <https://doi.org/10.1080/17460441.2017.1253676>.
- Kalvass, J.C., Polli, J.W., Bourdet, D.L., Feng, B., Huang, S.M., Liu, X., Smith, Q.R., Zhang, L.K., Zamek-Gliszczyński, M.J., 2013. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. *Clin. Pharmacol. Ther.* 94 (1), 80–94. <https://doi.org/10.1038/clpt.2013.34>.
- Kaphle, P., Li, Y., Yao, L., 2019. The mechanical and pharmacological regulation of glioblastoma cell migration in 3D matrices. *J. Cell. Physiol.* 234, 3948–3960. <https://doi.org/10.1002/jcp.27209>.
- Kathagen-Buhmann, A., Schulte, A., Weller, J., Holz, M., Herold-Mende, C., Glass, R., Lamszus, K., 2016. Glycolysis and the pentose phosphate pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation. *Neuro. Oncol.* 18, 1219–1229. <https://doi.org/10.1093/neuonc/nov024>.
- Khaddour, K., Johans, T.M., Anstas, G., 2020. The landscape of novel therapeutics and challenges in glioblastoma multiforme: contemporary state and future directions. *Pharmacometrics* 13 (11), 1–26. <https://doi.org/10.3390/ph13110389>.
- Khain, E., Sander, L.M., 2006. Dynamics and pattern formation in invasive tumor growth. *Phys. Rev. Lett.* 96, 188103. <https://doi.org/10.1103/PhysRevLett.96.188103>.
- Khain, E., Katakowski, M., Hopkins, S., Szalad, A., Zheng, X., Jiang, F., Chopp, M., 2011. Collective behavior of brain tumor cells: the role of hypoxia. *Phys. Rev. E - Stat. Nonlinear, Soft Matter Phys.* 83, 031920. <https://doi.org/10.1103/PhysRevE.83.031920>.
- Khain, E., Katakowski, M., Charteris, N., Jiang, F., Chopp, M., 2012. Migration of adhesive glioma cells: front propagation and fingering. *Phys. Rev. E - Stat. Nonlinear, Soft Matter Phys.* 86, 011904. <https://doi.org/10.1103/PhysRevE.86.011904>.

- Kievit, F.M., Florczyk, S.J., Leung, M.C., Veisoh, O., Park, J.O., Disis, M.L., Zhang, M., 2010. Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment. *Biomaterials* 31, 5903–5910. <https://doi.org/10.1016/j.biomaterials.2010.03.062>.
- Kievit, F.M., Florczyk, S.J., Leung, M.C., Wang, K., Wu, J.D., Silber, J.R., Ellenbogen, R. G., Leef, J.S.H., Zhang, M., 2014. Proliferation and enrichment of CD133+ glioblastoma cancer stem cells on 3D chitosan-alginate scaffolds. *Biomaterials* 35, 9137–9143. <https://doi.org/10.1016/j.biomaterials.2014.07.037>.
- Kievit, F.M., Wang, K., Erickson, A.E., Lan Levegood, S.K., Ellenbogen, R.G., Zhang, M., 2016. Modeling the tumor microenvironment using chitosan-alginate scaffolds to control the stem-like state of glioblastoma cells. *Biomater. Sci.* 4, 610–613. <https://doi.org/10.1039/C5BM00514K>.
- Kijima, N., Kanemura, Y., 2017. Mouse models of glioblastoma. *Glioblastoma. Codon Publications*, pp. 131–139. <https://doi.org/10.15586/codon.glioblastoma.2017.ch7>.
- Kim, Y., Lawler, S., Nowicki, M.O., Chiocci, E.A., Friedman, A., 2009. A mathematical model for pattern formation of glioma cells outside the tumor spheroid core. *J. Theor. Biol.* 260, 359–371. <https://doi.org/10.1016/j.jtbi.2009.06.025>.
- Kim, J.W., Ho, W.J., Wu, B.M., 2011. The role of the 3D environment in hypoxia-induced drug and apoptosis resistance. *Anticancer Res.* 31, 3237–3245.
- Kim, Y., Jeon, H., Othmer, H., 2017. The role of the tumor microenvironment in glioblastoma: a mathematical model. *IEEE Trans. Biomed. Eng.* 64, 519–527. <https://doi.org/10.1109/TBME.2016.2637828>.
- Kingsmore, K.M., Logsdon, D.K., Floyd, D.H., Peirce, S.M., Purow, B.W., Munson, J.M., 2016. Interstitial flow differentially increases patient-derived glioblastoma stem cell invasion via CXCR4, CXCL12, and CD44-mediated mechanisms. *Integr. Biol. (Camb)* 8 (12), 1246–1260. <https://doi.org/10.1039/C6IB00167J>.
- Kinsella, P., Clynes, M., Amberger-Murphy, V., 2011. Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay. *J. Neurooncol.* 101, 189–198. <https://doi.org/10.1007/s11060-010-0246-1>.
- Klein, E., Hau, A.C., Oudin, A., Golebiewska, A., Niclou, S.P., 2020. Glioblastoma organoids: pre-clinical applications and challenges in the context of immunotherapy. *Front. Oncol.* 10, 604121. <https://doi.org/10.3389/fonc.2020.604121>.
- Knizhnik, A.V., Roos, W.P., Nikolova, T., Quiros, S., Tomaszewski, K.H., Christmann, M., Kaina, B., 2013. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. *PLoS One* 8, e55665. <https://doi.org/10.1371/journal.pone.0055665>.
- Koens, R., Tabata, Y., Serrano, J.C., Aratake, S., Yoshino, D., Kamm, R.D., Funamoto, K., 2020. Microfluidic platform for three-dimensional cell culture under spatiotemporal heterogeneity of oxygen tension. *APL Bioeng.* 4, 016106. <https://doi.org/10.1063/1.5127069>.
- Koh, I., Cha, J., Park, J., Choi, J., Kang, S.-G., Kim, P., 2018. The mode and dynamics of glioblastoma cell invasion into a decellularized tissue-derived extracellular matrix-based three-dimensional tumor model. *Sci. Rep.* 8, 4608. <https://doi.org/10.1038/s41598-018-22681-3>.
- Kolenda, J., Jensen, S.S., Aaberg-Jessen, C., Christensen, K., Andersen, C., Brünner, N., Kristensen, B.W., 2011. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. *J. Neurooncol.* 103, 43–58. <https://doi.org/10.1007/s11060-010-0357-8>.
- Kondo, T., 2021. Glioblastoma-initiating cell heterogeneity generated by the cell-of-origin, genetic/epigenetic mutation and microenvironment. *Semin. Cancer Biol.* <https://doi.org/10.1016/j.semcancer.2020.12.003>. In press.
- Krol, I., Castro-Giner, F., Maurer, M., Gkoutela, S., Szczepa, B.M., Scherrer, R., Coleman, N., Carreira, S., Bachmann, F., Anderson, S., Engelhardt, M., Lane, H., Jeffrey Evans, T.R., Plummer, R., Kristeleit, R., Lopez, J., Aceto, N., 2018. Detection of circulating tumour cell clusters in human glioblastoma. *Br. J. Cancer* 119, 487–491. <https://doi.org/10.1038/s41416-018-0186-7>.
- Kubo, A., Miyata, Y., 2017. Mathematical analysis of Glioblastoma invasion models from in vitro experiment. *WSEAS Trans. Math.* 16, 62–68.
- Lancaster, M.A., Knoblich, J.A., 2014. Organogenesis in a dish: modeling development and disease using organoid technologies. *Science* (80-) 345, 1247125. <https://doi.org/10.1126/science.1247125>.
- Lee, H.C., Kim, D.W., Jung, K.Y., Park, I.C., Park, M.J., Kim, M.S., Woo, S.H., Rhee, C.H., Yoo, H., Lee, S.H., Hong, S.I., 2004. Increased expression of antioxidant enzymes in radioresistant variant from U251 human glioblastoma cell line. *Int. J. Mol. Med.* 13, 883–887. <https://doi.org/10.3892/ijmm.13.6.883>.
- Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N.M., Pastorino, S., Purow, B. W., Christopher, N., Zhang, W., Park, J.K., Fine, H.A., 2006. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. *Cancer Cell* 9, 391–403. <https://doi.org/10.1016/j.ccr.2006.03.030>.
- Lee, Kwang Ho, Lee, Ki Hwa, Lee, J., Choi, H., Lee, D., Park, Y., Lee, S.H., 2014. Integration of microfluidic chip with biomimetic hydrogel for 3D controlling and monitoring of cell alignment and migration. *J. Biomed. Mater. Res. - Part A* 102, 1164–1172. <https://doi.org/10.1002/jbm.a.34772>.
- Lee, D.W., Lee, S.Y., Doh, I., Ryu, G.H., Nam, D.H., 2017. High-dose compound heat map for 3D-Cultured glioblastoma multiforme cells in a micropillar and microwell chip platform. *Biomed. Res. Int.* 2017, 7218707. <https://doi.org/10.1155/2017/7218707>.
- Lee, C., Abelseth, E., de la Vega, L., Willerth, S.M., 2019. Bioprinting a novel glioblastoma tumor model using a fibrin-based bioink for drug screening. *Mater. Today Chem.* 12, 78–84. <https://doi.org/10.1016/j.MTChem.2018.12.005>.
- Leite, D.M., Zvar Baskovic, B., Civita, P., Neto, C., Gumbleton, M., Pilkington, G.J., 2020. A human co-culture cell model incorporating microglia supports glioblastoma growth and migration, and confers resistance to cytotoxics. *FASEB J.* 34, 1710–1727. <https://doi.org/10.1096/fj.201901858RR>.
- Lenting, K., Verhaak, R., Laan, Mark Ter, Wesseling, P., Leenders, W., 2017. Glioma: experimental models and reality. *Acta Neuropathol.* 3, 263–282. <https://doi.org/10.1007/s00401-017-1671-4>.
- Leonetti, A., Assaraf, Y.G., Veltsista, P.D., El Hassouni, B., Tiseo, M., Giovannetti, E., 2019. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: current implications and future directions. *Drug Resist. Updat.* 42, 1–11. <https://doi.org/10.1016/j.drug.2018.11.002>.
- Lepeltier, E., Rijo, P., Rizzolio, F., Popovtzer, R., Petrikaite, V., Assaraf, Y.G., Passirani, C., 2020. Nanomedicine to target multidrug resistant tumors. *Drug Resist. Updat.* 52, 100704. <https://doi.org/10.1016/j.drug.2020.100704>.
- Levin, V.A., Panchabhai, S., Shen, L., Baggerly, K.A., 2012. Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures. *Proteome Sci.* 10, 5. <https://doi.org/10.1186/1477-5956-10-5>.
- Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Shi, Q., Cao, Y., Lathia, J., Mclendon, R.E., Hjelmeland, A.B., Rich, J.N., 2009. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. *Cancer Cell* 15, 501–513. <https://doi.org/10.1016/j.ccr.2009.03.018>. Hypoxia-Inducible.
- Li, Q., Lin, H., Wang, O., Qiu, X., Kidambi, S., Deleyrolle, L.P., Reynolds, B.A., Lei, Y., 2016a. Scalable production of glioblastoma tumor-initiating cells in 3 dimension thermoreversible hydrogels. *Sci. Rep.* 6. <https://doi.org/10.1038/srep31915>.
- Li, W., Zhang, H., Assaraf, Y.G., Zhao, K., Xu, X., Xie, J., Yang, D.H., Chen, Z.S., 2016b. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. *Drug Resist. Updat.* 27, 14–29. <https://doi.org/10.1016/j.drug.2016.05.001>.
- Li, Q., Lin, H., Rauch, J., Deleyrolle, L.P., Reynolds, B.A., Viljoen, H.J., Zhang, C., Zhang, C., Gu, L., Van Wyk, E., Lei, Y., 2018. Scalable culturing of primary human glioblastoma tumor-initiating cells with a cell-friendly culture system. *Sci. Rep.* 8, 3531. <https://doi.org/10.1038/s41598-018-21927-4>.
- Li Petri, G., El Hassouni, B., Sciarillo, R., Funel, N., Mantini, G., Zeeuw van der Laan, E. A., Cascioferro, S., Avan, A., Zucali, P.A., Zaffaroni, N., Lagerweij, T., Parrino, B., Smid, K., Deraco, M., Granchi, C., Braczkowski, A., Smolenski, R.T., Matherly, L.H., Jansen, G., Assaraf, Y.G., Diana, P., Cloos, J., Peters, G.J., Minutolo, F., Giovannetti, E., 2020. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. *Br. J. Cancer* 123, 644–656. <https://doi.org/10.1038/s41416-020-0912-9>.
- Lippmann, E.S., Azarin, S.M., Kay, J.E., Nessler, R.A., Wilson, H.K., Al-Ahmad, A., Palecek, S.P., Shusta, E.V., 2012. Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. *Nat. Biotechnol.* 30, 783–791. <https://doi.org/10.1038/nbt.2247>.
- Liu, W., Sun, P., Yang, L., Wang, Jinfeng, Li, L., Wang, Jinyi, 2010. Assay of glioma cell responses to an anticancer drug in a cell-based microfluidic device. *Microfluid. Nanofluidics* 9, 717–725. <https://doi.org/10.1007/s10404-010-0584-5>.
- Liu, C.J., Shamsan, G.A., Akkin, T., Odde, D.J., 2019. Glioma cell migration dynamics in brain tissue assessed by multimodal optical imaging. *Biophysj* 117, 1179–1188. <https://doi.org/10.1016/j.bpj.2019.08.010>.
- Logun, M., Zhao, W., Mao, L., Karumbaiah, L., 2018. Microfluidics in malignant glioma research and precision medicine. *Adv. Biosyst.* 2. <https://doi.org/10.1002/adbi.201700221>.
- Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W., 2016. The 2016 world health organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol.* 131, 803–820. <https://doi.org/10.1007/s00401-016-1545-1>.
- Luo, X., Weiss, W.A., 2020. Utility of human-derived models for glioblastoma. *Cancer Discov.* 10, 907–909. <https://doi.org/10.1158/2159-8290.CD-20-0493>.
- Lv, D., Yu, S., Ping, Y., Wu, H., Zhao, X., Zhang, H., Cui, Y., Chen, B., Zhang, X., Dai, J., Bian, X., Yao, X., 2016. A three-dimensional collagen scaffold cell culture system for screening anti-glioma therapeutics. *Oncotarget* 5. <https://doi.org/10.18632/oncotarget.10885>.
- Lv, D., Hu, Z., Lu, L., Lu, H., Xu, X., 2017. Three-dimensional cell culture: a powerful tool in tumor research and drug discovery (Review). *Oncol. Lett.* 14, 6999–7010. <https://doi.org/10.3892/ol.2017.7134>.
- Ma, J., Murphy, M., O'dwyer, P.J., Berman, E., Reed, K., Gallo, J.M., 2002. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. *Biochem. Pharmacol.* 63, 1219–1228.
- Ma, J., Zhang, X., Liu, Y., Yu, H., Liu, L., Shi, Y., Li, Y., Qin, J., 2016a. Patterning hypoxic multicellular spheroids in a 3D matrix - a promising method for anti-tumor drug screening. *Biotechnol. J.* 11, 127–134. <https://doi.org/10.1002/biot.201500183>.
- Ma, N.K.L., Lim, J.K., Leong, M.F., Sandanaraj, E., Ang, B.T., Tang, C., Wan, A.C.A., 2016b. Collaboration of 3D context and extracellular matrix in the development of glioma stemness in a 3D model. *Biomaterials* 78, 62–73. <https://doi.org/10.1016/j.biomaterials.2015.11.031>.
- Ma, L., Zhang, B., Zhou, C., Li, Y., Li, B., Yu, M., Luo, Y., Gao, L., Zhang, D., Xue, Q., Qiu, Q., Lin, B., Zou, J., Yang, H., 2018. The comparison genomics analysis with glioblastoma multiforme (GBM) cells under 3D and 2D cell culture conditions. *Colloids Surf. B Biointerfaces* 172, 665–673. <https://doi.org/10.1016/j.colsurfb.2018.09.034>.
- Maheparan, R., Tysnes, B.B., Read, T.A., Enger, P., Bjerkvig, R., Lund-Johansen, M., 1999. Extracellular matrix-induced cell migration from glioblastoma biopsy specimens in vitro. *Acta Neuropathol.* 97, 231–239. <https://doi.org/10.1007/s004010050979>.
- Mair, D.B., Ames, H.M., Li, R., 2018. Mechanisms of invasion and motility of high-grade gliomas in the brain. *Mol. Biol. Cell.* <https://doi.org/10.1091/mbc.E18-02-0123>.

- Maloney, E., Clark, C., Sivakumar, H., Yoo, K., Aleman, J., Rajan, S.A.P., Forsythe, S., Mazzocchi, A., Laxton, A.W., Tatter, S.B., Strowd, R.E., Votanopoulos, K.I., Skardal, A., 2020. Immersion bioprinting of tumor organoids in multi-well plates for increasing chemotherapy screening throughput. *Micromachines* 11. <https://doi.org/10.3390/mi11020208>.
- Maoz, B.M., Herland, A., Fitzgerald, E.A., Grevesse, T., Vidoudez, C., Pacheco, A.R., Sheehy, S.P., Park, T.E., Dauth, S., Mannix, R., Budnik, N., Shores, K., Cho, A., Nawroth, J.C., Segrè, D., Budnik, B., Ingber, D.E., Parker, K.K., 2018. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells. *Nat. Biotechnol.* 36, 865–877. <https://doi.org/10.1038/nbt.4226>.
- Marino, A., Tricinci, O., Battaglini, M., Filippeschi, C., Mattoli, V., Sinibaldi, E., Ciofani, G., 2018. A 3D real-scale, biomimetic, and biohybrid model of the blood-brain barrier fabricated through two-photon lithography. *Small* 14. <https://doi.org/10.1002/sml.201702959>.
- Marisol Herrera-Perez, R., Voytk-Harbin, S.L., Sarkaria, J.N., Pollok, K.E., Fishel, M.L., Rickus, J.L., 2018. Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition. *PLoS One* 13. <https://doi.org/10.1371/journal.pone.0194183>.
- Martin, I., Wendt, D., Heberer, M., 2004. The role of bioreactors in tissue engineering. *Trends Biotechnol.* 22 (2), 80–86. <https://doi.org/10.1016/j.tibtech.2003.12.001>.
- Martínez-Ramos, C., Lebourg, M., 2015. Three-dimensional constructs using hyaluronan cell carrier as a tool for the study of cancer stem cells. *J. Biomed. Mater. Res. - Part B Appl. Biomater.* 103, 1249–1257. <https://doi.org/10.1002/jbm.b.33304>.
- McCoy, M.G., Nanyo, D., Hung, C.K., Goerger, J.P., Zipfel, W.R., Williams, R.M., Nishimura, N., Fischbach, C., 2019. Endothelial cells promote 3D invasion of GBM by IL-8-dependent induction of cancer stem cell properties. *Sci. Rep.* 9 <https://doi.org/10.1038/s41598-019-45535-y>.
- Mei, X., Chen, Y.S., Chen, F.R., Xi, S.Y., Chen, Z.P., 2017. Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging. *Neuro. Oncol.* 19, 1109–1118. <https://doi.org/10.1093/neuonc/now016>.
- Merz, C., Strecker, A., Sykora, J., Hill, O., Fricke, H., Angel, P., Gieffers, C., Peterziel, H., 2015. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. *Anticancer Drugs* 26, 716–727. <https://doi.org/10.1097/CAD.0000000000000237>.
- Montaldi, A.P., Sakamoto-Hojo, E.T., 2013. Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide. *Clin. Exp. Med.* 13, 279–288. <https://doi.org/10.1007/s10238-012-0201-x>.
- Moore, K., Kim, L., 2010. Primary brain tumors: characteristics, practical diagnostic and treatment approaches. In: Ray, S.K. (Ed.), *Glioblastoma: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies*. Springer New York, New York, NY, pp. 43–75. https://doi.org/10.1007/978-1-4419-0410-2_2.
- Mosca, L., Ilari, A., Fazi, F., Assaraf, Y.G., Colotti, J.P., 2021. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. *Drug Resist. Updat.* 54 <https://doi.org/10.1016/j.drug.2020.100742>.
- Mouhieddine, T.H., Nakkari, A., Itani, M.M., Chamaa, F., Bahmad, H., Monzer, A., El-Merabhi, R., Daoud, G., Eid, A., Kobeissy, F.H., Abou-Kheir, W., 2015. Metformin and ara-a effectively suppress brain cancer by targeting cancer stem/progenitor cells. *Front. Neurosci.* 9 <https://doi.org/10.3389/fnins.2015.00442>.
- Mrugala, M.M., 2013. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. *Discov. Med.* 15, 221–230.
- Mrugala, M.M., Ruzevick, J., Zlomanczuk, P., Lukas, R.V., 2017. Tumor treating fields in neuro-oncological practice. *Curr. Oncol. Rep.* 19 (8), 53. <https://doi.org/10.1007/s11912-017-0611-8>.
- Munson, J.M., Bellamkonda, R.V., Swartz, M.A., 2013. Interstitial flow in a 3d microenvironment increases glioma invasion by a cxcr4-dependent mechanism. *Cancer Res.* 73, 1536–1546. <https://doi.org/10.1158/0008-5472.CAN-12-2838>.
- Musah-Eroje, A., Watson, S., 2019. A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia. *J. Neurooncol.* 142, 231–240. <https://doi.org/10.1007/s11060-019-03107-0>.
- Nakagawa, S., Deli, M.A., Nakao, S., Honda, M., Hayashi, K., Nakaoke, R., Kataoka, Y., Niwa, M., 2007. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. *Cell. Mol. Neurobiol.* 27, 687–694. <https://doi.org/10.1007/s10571-007-9195-4>.
- Nath, S., Devi, G.R., 2016. Three-dimensional culture systems in cancer research: focus on tumor spheroid model. *Pharmacol. Ther.* 163, 94–108. <https://doi.org/10.1016/j.pharmthera.2016.03.013>.
- Ngo, M.T., Harley, B.A., 2017. The influence of hyaluronic acid and glioblastoma cell coculture on the formation of endothelial cell networks in gelatin hydrogels. *Adv. Healthc. Mater.* 6 <https://doi.org/10.1002/adhm.201700687>.
- Nguyen, D., Fan, Y., Akay, Y., Akay, M., 2016a. TNP-470 reduces glioblastoma angiogenesis in three dimensional GelMA microwell platform. *IEEE Trans. Nanobioscience* 1241, 1. <https://doi.org/10.1109/TNB.2016.2600542>.
- Nguyen, D.T., Fan, Y., Akay, Y.M., Akay, M., 2016b. Investigating glioblastoma angiogenesis using a 3D in vitro GelMA microwell platform. *IEEE Trans. Nanobioscience* 15, 289–293. <https://doi.org/10.1109/TNB.2016.2528170>.
- Niewerth, D., Jansen, G., Assaraf, Y.G., Zweegman, S., Kaspers, G.J.L., Cloos, J., 2015. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. *Drug Resist. Updat.* 18, 18–35. <https://doi.org/10.1016/j.drup.2014.12.001>.
- Oh, H.C., Shim, J.K., Park, J., Lee, J.H., Choi, R.J., Kim, N.H., Kim, H.S., Moon, J.H., Kim, E.H., Chang, J.H., Yook, J.I., Kang, S.G., 2020. Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres. *J. Cancer Res. Clin. Oncol.* 1–12. <https://doi.org/10.1007/s00432-020-03330-7>.
- Oliva, C.R., Moellerling, D.R., Gillespie, G.Y., Griguer, C.E., 2011. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. *PLoS One* 6. <https://doi.org/10.1371/journal.pone.0024665>.
- Oliveira, A.I., Anjo, S.I., Vieira De Castro, J., Serra, S.C., Salgado, A.J., Manadas, B., Costa, B.M., 2017. Crosstalk between glial and glioblastoma cells triggers the “go-or-grow” phenotype of tumor cells. *Cell Commun. Signal* 15. <https://doi.org/10.1186/s12964-017-0194-x>.
- Oliveira Rodini, C., Benites Gonçalves da Silva, P., Faria Assoni, A., Melechco Carvalho, V., Keith Okamoto, O., 2018. Mesenchymal stem cells enhance tumorigenic properties of human glioblastoma through independent cell-cell communication mechanisms. *Oncotarget* 9, 24766–24777.
- Oraipoulou, M.E., Tzamali, E., Tzedakis, G., Liapis, E., Zacharakis, G., Vakis, A., Papamatheakis, J., Sakalis, V., 2018. Integrating in vitro experiments with in silico approaches for Glioblastoma invasion: the role of cell-to-cell adhesion heterogeneity. *Sci. Rep.* 8, 1–13. <https://doi.org/10.1038/s41598-018-34521-5>.
- Ostrom, Q.T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., Barnholtz-Sloan, J.S., 2019. CEBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. *Neuro. Oncol.* 21, V1–V100. <https://doi.org/10.1093/neuonc/now150>.
- Paguirigan, A.L., Beebe, D.J., 2008. Microfluidics meet cell biology: bridging the gap by validation and application of microscale techniques for cell biological assays. *Bioessays* 30, 811–821. <https://doi.org/10.1002/bies.20804>.
- Panchalingam, K.M., Paramchuk, W.J., Chiang, C.-Y.K., Shah, N., Madan, A., Hood, L., Foltz, G., Behie, L.A., 2010. Bioprocessing of human glioblastoma brain Cancer tissue. *Tissue Eng. Part A* 16, 1169–1177. <https://doi.org/10.1089/ten.tea.2009.0490>.
- Pang, L., Liu, W., Tian, C., Xu, J., Li, T., Chen, S., Wang, J., 2016. Construction of single-cell arrays and assay of cell drug-resistance in an integrated microfluidics. *Lab Chip* 16, 4612–4620. <https://doi.org/10.1039/C6LC01000H>.
- Paolillo, M., Schinelli, S., 2016. Brain infiltration by cancer cells: different roads to the same target? *J. Cancer Metastasis Treat.* 2, 90–100. <https://doi.org/10.4103/2394-4722.172661>.
- Park, T.E., Mustafaoglu, N., Herland, A., Hasselkus, R., Mannix, R., FitzGerald, E.A., Prantil-Baun, R., Watters, A., Henry, O., Benz, M., Sanchez, H., McCrea, H.J., Goumnerova, L.C., Song, H.W., Palecek, S.P., Shusta, E., Ingber, D.E., 2019. Hypoxia-enhanced blood-brain barrier chip recapitulates human barrier function and shuttling of drugs and antibodies. *Nat. Commun.* 10, 1–12. <https://doi.org/10.1038/s41467-019-10588-0>.
- Pawlowska, E., Szczepanska, J., Szatkowska, M., Blasiak, J., 2018. An interplay between senescence, apoptosis and autophagy in glioblastoma multiforme-role in pathogenesis and therapeutic perspective. *Int. J. Mol. Sci.* 19 <https://doi.org/10.3390/ijms19030889>.
- Pedron, S., Harley, B.A.C., 2013. Impact of the biophysical features of a 3D gelatin microenvironment on glioblastoma malignancy. *J. Biomed. Mater. Res. - Part A* 101, 3404–3415. <https://doi.org/10.1002/jbm.a.34637>.
- Pedron, S., Becka, E., Harley, B.A.C., 2013. Regulation of glioma cell phenotype in 3D matrices by hyaluronic acid. *Biomaterials* 34, 7408–7417. <https://doi.org/10.1016/j.biomaterials.2013.06.024>.
- Pedron, S., Hanselman, J.S., Schroeder, M.A., Sarkaria, J.N., Harley, B.A.C., 2017. Extracellular hyaluronic acid influences the efficacy of EGFR tyrosine kinase inhibitors in a biomaterial model of glioblastoma. *Adv. Heal. Mater.* 6, 1–20. <https://doi.org/10.1002/adhm.201700529>.
- Perel, P., Roberts, I., Sena, E., Wheble, P., Briscoe, C., Sandercock, P., Macleod, M., Mignini, L.E., Jayaram, P., Khan, K.S., 2007. Comparison of treatment effects between animal experiments and clinical trials: systematic review. *Br. Med. J.* 334, 197–200. <https://doi.org/10.1136/bmj.39048.407928.BE>.
- Pérez-García, V.M., Calvo, G.F., Bosque, J.J., León-Triana, O., Jiménez, J., Pérez-Beteta, J., Belmonte-Beitia, J., Valiente, M., Zhu, L., García-Gómez, P., Sánchez-Gómez, P., Hernández-San Miguel, E., Hortigüela, R., Azimzade, Y., Molina-García, D., Martínez, A., Acosta Rojas, A., Ortiz de Mendivil, A., Vallette, F., Schucht, P., Murek, M., Pérez-Cano, M., Albillo, D., Honguero Martínez, A.F., Jiménez Londoño, G.A., Arana, E., García Vicente, A.M., 2020. Universal scaling laws rule explosive growth in human cancers. *Nat. Phys.* 1–6. <https://doi.org/10.1038/s41567-020-0978-6>.
- Perrin, S.L., Samuel, M.S., Koszyca, B., Brown, M.P., Ebert, L.M., Oksdath, M., Gomez, G. A., 2019. Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments. *Biochem. Soc. Trans.* 47 (2), 625–638. <https://doi.org/10.1042/BST20180444>.
- Phan, D.T.T., Bender, R.H.F., Andrejcsk, J.W., Sobrino, A., Hachey, S.J., George, S.C., Hughes, C.C.W., 2017. Blood-brain barrier-on-a-chip: microphysiological systems that capture the complexity of the blood-central nervous system interface. *Exp. Biol. Med.* 242 (17), 1669–1678. <https://doi.org/10.1177/1535370217694100>.
- Pine, A.R., Cirigliano, S.M., Nicholson, J.G., Hu, Y., Linkous, A., Miyaguchi, K., Edwards, L., Singhania, R., Schwartz, T.H., Ramakrishna, R., Pisapia, D.J., Snuderl, M., Elemento, O., Fine, H.A., 2020. Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas. *Cancer Discov.* 10, 964–979. <https://doi.org/10.1158/2159-8290.CD-20-0057>.
- Polewski, M.D., Reveron-Thornton, R.F., Cherryholmes, G.A., Marinov, G.K., Cassady, K., Abody, K.S., 2016. Increased expression of system x c-in glioblastoma confers an altered metabolism and chemoresistance. *Mol. Cancer Res.* 14, 1229–1242. <https://doi.org/10.1158/1541-7786.MCR-16-0028>.
- Prabhakarandian, B., Shen, M.C., Nichols, J.B., Mills, I.R., Sidoryk-Wegrzynowicz, M., Aschner, M., Pant, K., 2013. SyM-BBB: a microfluidic blood brain barrier model. *Lab Chip* 13, 1093–1101. <https://doi.org/10.1039/c2lc41208j>.
- Qazi, H., Shi, Z.-D., Tarbell, J.M., 2011. Fluid shear stress regulates the invasive potential of glioma cells via modulation of migratory activity and matrix metalloproteinase expression. *PLoS One* 6, e20348. <https://doi.org/10.1371/journal.pone.0020348>.

- Quereda, V., Hou, S., Madoux, F., Scampavia, L., Spicer, T.P., Duckett, D., 2018. A cytotoxic three-dimensional-Spheroid, high-throughput assay using patient-derived glioma stem cells. *SLAS Discov.* 23, 842–849. <https://doi.org/10.1177/2472555218775055>.
- Rabé, M., Dumont, S., Álvarez-Arenas, A., Janati, H., Belmonte-Beitia, J., Calvo, G.F., Thibault-Carpentier, C., Séry, Q., Chauvin, C., Joalland, N., Briand, F., Blandin, S., Scotet, E., Pecqueur, C., Clairambault, J., Oliver, L., Perez-Garcia, V., Nadaradjane, A., Cartron, P.F., Gratas, C., Vallette, F.M., 2020. Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. *Cell Death Dis.* 11, 1–14. <https://doi.org/10.1038/s41419-019-2200-2>.
- Ramalho, M.J., Andrade, S., Coelho, M.A.N., Loureiro, J.A., Pereira, M.C., 2019. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: the relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. *Eur. J. Pharm. Biopharm.* 136, 156–163. <https://doi.org/10.1016/j.ejpb.2019.01.015>.
- Rao, S.S., DeJesus, J., Short, A.R., Otero, J.J., Sarkar, A., Winter, J.O., 2013a. Glioblastoma behaviors in three-dimensional collagen-hyaluronan composite hydrogels. *ACS Appl. Mater. Interfaces* 5, 9276–9284. <https://doi.org/10.1021/am402097j>.
- Rao, S.S., Nelson, M.T., Xue, R., DeJesus, J.K., Viapiano, M.S., Lannutti, J.J., Sarkar, A., Winter, J.O., 2013b. Mimicking white matter tract topography using core-shell electrospun nanofibers to examine migration of malignant brain tumors. *Biomaterials* 34, 5181–5190. <https://doi.org/10.1016/j.biomaterials.2013.03.069>.
- Ravi, M., Ramesh, A., Pattabhi, A., 2017. Human brain malignant glioma (BMG-1) 3D aggregate morphology and screening for cytotoxicity and anti-proliferative effects. *J. Cell. Physiol.* 232, 685–690. <https://doi.org/10.1002/jcp.25603>.
- Raz, S., Sheban, D., Gonen, N., Stark, M., Berman, B., Assaraf, Y.G., 2014. Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest. *Cell Death Dis.* 5 <https://doi.org/10.1038/cddis.2014.39>.
- Rezk, R., Jia, B.Z., Wendler, A., Dimov, I., Watts, C., Markaki, A.E., Franze, K., Kabla, A. J., 2020. Spatial heterogeneity of cell-matrix adhesive forces predicts human glioblastoma migration. *Neuro-Oncology Adv.* 2, 1–11. <https://doi.org/10.1093/naojnl/vdaa081>.
- Rosenberg, T., Aaberg-Jessen, C., Pettersen, S.A., Kristensen, B.W., 2018. Heterogenic expression of stem cell markers in patient-derived glioblastoma spheroid cultures exposed to long-term hypoxia. *CNS Oncol.* 7, CNS15. <https://doi.org/10.2217/cns-2017-0034>.
- Ruano, Y., Mollejo, M., Camacho, F.I., De Lope, A.R., Fiaño, C., Ribalta, T., Martínez, P., Hernández-Moneo, J.L., Meléndez, B., 2008. Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme. *Cancer* 112, 1575–1584. <https://doi.org/10.1002/cncr.23338>.
- Russo, M., Russo, G.L., 2018. Autophagy inducers in cancer. *Biochem. Pharmacol.* 153, 51–61. <https://doi.org/10.1016/j.bcp.2018.02.007>.
- Saji Joseph, J., Tebogo Malindisa, S., Ntwasa, M., 2019. Two-dimensional (2D) and Three-dimensional (3D) cell culturing in drug Discovery. In: Mehanna, R.A. (Ed.), *Cell Culture*. IntechOpen. <https://doi.org/10.5772/intechopen.81552>.
- Saleh, A., Marhuenda, E., Fabre, C., Hassani, Z., Weille, Jde, Boukhaddaoui, H., Guelfi, S., Maldonado, I.L., Hugnot, J.P., Duffau, H., Bauchet, L., Cornu, D., Bakalar, N., 2019. A novel 3D nanofibre scaffold conserves the plasticity of glioblastoma stem cell invasion by regulating galectin-3 and integrin- β 1 expression. *Sci. Rep.* 9 <https://doi.org/10.1038/s41598-019-51108-w>.
- Samiei, E., Seyfoori, A., Toyota, B., Ghavami, S., Akbari, M., 2020. Investigating programmed cell death and tumor invasion in a three-dimensional (3d) microfluidic model of glioblastoma. *Int. J. Mol. Sci.* 21, 3162. <https://doi.org/10.3390/ijms21093162>.
- Sanzey, M., Abdul Rahim, S.A., Oudin, A., Dirkse, A., Kaoma, T., Vallar, L., Herold-Mende, C., Bjerkvig, R., Golebiewska, A., Niclou, S.P., 2015. Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma. *PLoS One* 10. <https://doi.org/10.1371/journal.pone.0123544>.
- Sarisozen, C., Dhokai, S., Tsikudo, E.G., Luther, E., Rachman, I.M., Torchilin, V.P., 2016. Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: in vitro evaluation on 2D and 3D tumor models. *Eur. J. Pharm. Biopharm.* 108, 54–67. <https://doi.org/10.1016/j.ejpb.2016.08.013>.
- Sarkar, S., Yong, V.W., 2009. Inflammatory cytokine modulation of matrix metalloproteinase expression and invasiveness of glioma cells in a 3-dimensional collagen matrix. *J. Neurooncol.* 91, 157–164. <https://doi.org/10.1007/s11060-008-9695-1>.
- Selden, C., Fuller, B., 2018. Role of bioreactor technology in tissue engineering for clinical use and therapeutic target design. *Bioengineering* 5 (2), 32. <https://doi.org/10.3390/bioengineering5020032>.
- Serra, M., Brito, C., Correia, C., Alves, P.M., 2012. Process engineering of human pluripotent stem cells for clinical application. *Trends Biotechnol.* 30 (6), 350–359. <https://doi.org/10.1016/j.tibtech.2012.03.003>.
- Shafiee, A., Atala, A., 2016. Printing technologies for medical applications. *Trends Mol. Med.* 22, 254–265. <https://doi.org/10.1016/j.jmolmed.2016.01.003>.
- Shannon, S., Jia, D., Enters, I., Beelen, P., Yu, M., Carcione, C., Carcione, J., Mahtabfar, A., Vaca, C., Weaver, M., Shreiber, D., Zahn, J.D., Liu, L., Lin, H., Foty, R. A., 2017. Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901. *BMC Cancer* 17. <https://doi.org/10.1186/s12885-017-3107-x>.
- Sharifzad, F., Ghavami, S., Mardpour, S., Mollapour, M., Azizi, Z., Taghikhani, A., Łos, M.J., Verdi, J., Fakharian, E., Ebrahimi, M., Hamidieh, A.A., 2019. Glioblastoma cancer stem cell biology: potential theranostic targets. *Drug Resist. Updat.* 42, 35–45. <https://doi.org/10.1016/j.drug.2018.03.003>.
- Sharma, P., Sheets, K., Elankumaran, S., Nain, A.S., 2013. The mechanistic influence of aligned nanofibers on cell shape, migration and blebbing dynamics of glioma cells. *Integr. Biol. (Camb)* 5, 1036–1044. <https://doi.org/10.1039/c3ib40073e>.
- Shojaei, S., Koleini, N., Samiei, E., Aghaei, M., Cole, L.K., Alizadeh, J., Islam, M.I., Vosoughi, A., Albokashy, M., Butterfield, Y., Marzban, H., Xu, F., Thliveris, J., Kardami, E., Hatch, G.M., Eftekharpour, E., Akbari, M., Hombach-Klonisch, S., Klonisch, T., Ghavami, S., 2020. Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes. *FEBS J.* 287, 1005–1034. <https://doi.org/10.1111/febs.15069>.
- Siddharthan, V., Kim, Y.V., Liu, S., Kim, K.S., 2007. Human astrocytes/astrocyte-conditioned medium and shear stress enhance the barrier properties of human brain microvascular endothelial cells. *Brain Res.* 1147, 39–50. <https://doi.org/10.1016/j.brainres.2007.02.029>.
- Simonetti, G., Silvani, A., Fariselli, L., Hottinger, A.F., Pesce, G.A., Prada, F., Gaviani, P., 2017. Extra central nervous system metastases from glioblastoma: a new possible trigger event? *Neurol. Sci.* 38, 1873–1875. <https://doi.org/10.1007/s10072-017-3036-0>.
- Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D., Dirks, P.B., 2004. Identification of human brain tumor initiating cells. *Nature* 432, 396–401. <https://doi.org/10.1038/nature03128>.
- Smits, I.P.M., Blaschuk, O.W., Willerth, S.M., 2020. Novel N-cadherin antagonist causes glioblastoma cell death in a 3D bioprinted co-culture model. *Biochem. Biophys. Res. Commun.* 529, 162–168. <https://doi.org/10.1016/j.bbrc.2020.06.001>.
- Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R.D., Engh, J., Iwama, T., Kunisada, T., Kassam, A.B., Pollack, I.F., Park, D.M., 2009. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 α . *Oncogene* 28, 3949–3959. <https://doi.org/10.1038/ncr.2009.252>.
- Son, B., Lee, S., Youn, H.S., Kim, E.G., Kim, W., Youn, B.H., 2017. The role of tumor microenvironment in therapeutic resistance. *Oncotarget* 8, 3933–3945. <https://doi.org/10.18632/oncotarget.13907>.
- Stein, A.M., Demuth, T., Mobley, D., Berens, M., Sander, L.M., 2007. A mathematical model of glioblastoma tumor spheroid invasion in a three-dimensional in vitro experiment. *Biophys. J.* 92, 356–365. <https://doi.org/10.1529/biophysj.106.093468>.
- Stein, S., Zhao, R., Haeno, H., Vivanco, I., Michor, F., 2018. Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. *PLoS Comput. Biol.* 14 <https://doi.org/10.1371/journal.pcbi.1005924>.
- Stojković, S., Podolski-Renić, A., Dinić, J., Pavković, Z., Ayuso, J.M., Fernández, L.J., Ochoa, I., Pérez-García, V.M., Pešić, V., Pešić, M., 2016. Resistance to DNA Damaging agents produced invasive phenotype of rat glioma cells-characterization of a new in vivo model. *Molecules* 21, 1–16. <https://doi.org/10.3390/molecules21070843>.
- Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J.B., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J.G., Eisenhauer, E., Mirimanoff, R.O., 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N. Engl. J. Med.* 352, 987–996. <https://doi.org/10.1056/NEJMoa043330>.
- Sumi, N., Nishiohoku, T., Takata, F., Matsumoto, J., Watanabe, T., Shuto, H., Yamauchi, A., Dohgu, S., Kataoka, Y., 2010. Lipopolydisaccharide-activated microglia induce dysfunction of the blood-brain barrier in rat microvascular endothelial cells co-cultured with microglia. *Cell. Mol. Neurobiol.* 30, 247–253. <https://doi.org/10.1007/s10571-009-9446-7>.
- Sun, S., Lee, D., Leung, G.K.K., 2013. Chemoresistance in glioma. *New Advances on Disease Biomarkers and Molecular Targets in Biomedicine*. Humana Press Inc., pp. 243–270. https://doi.org/10.1007/978-1-62703-456-2_14.
- Suvà, M.L., Rheinbay, E., Gillespie, S.M., Patel, A.P., Wakimoto, H., Rabkin, S.D., Riggi, N., Chi, A.S., Cahill, D.P., Nahed, B.V., Curry, W.T., Martuza, R.L., Rivera, M. N., Rossetti, N., Kasif, S., Beik, S., Kadri, S., Tirosh, I., Wortman, I., Shalek, A.K., Rozenblatt-Rosen, O., Regev, A., Louis, D.N., Bernstein, B.E., 2014. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. *Cell* 157, 580–594. <https://doi.org/10.1016/j.cell.2014.02.030>.
- Tamura, R., Tanaka, T., Akasaki, Y., Murayama, Y., Yoshida, K., Sasaki, H., 2020. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. *Med. Oncol.* 37 (1), 2. <https://doi.org/10.1007/s12032-019-1329-2>.
- Tang, M., Xie, Q., Gimple, R.C., Zhong, Z., Tam, T., Tian, J., Kidwell, R.L., Wu, Q., Prager, B.C., Qiu, Z., Yu, A., Zhu, Z., Mesci, P., Jing, H., Schimelman, J., Wang, P., Lee, D., Lorenzini, M.H., Dixit, D., Zhao, L., Bhargava, S., Miller, T.E., Wan, X., Tang, J., Sun, B., Cravatt, B.F., Muotri, A.R., Chen, S., Rich, J.N., 2020. Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. *Cell Res.* 1–21. <https://doi.org/10.1038/s41422-020-0338-1>.
- Tataranu, L.G., Ciubotaru, V., Cazac, T.L., Alexandru, O., Purcaru, O.S., Tache, D.E., Artene, S.A., Dricu, A., 2018. Current trends in glioblastoma treatment. In: Agrawal, A., Moscote-Salazar, L.R. (Eds.), *Brain Tumors - An Update*. Intech. <https://doi.org/10.5772/intechopen.75049>.
- Tektonidis, M., Hatzikirou, H., Chauvière, A., Simon, M., Schaller, K., Deutsch, A., 2011. Identification of intrinsic in vitro cellular mechanisms for glioma invasion. *J. Theor. Biol.* 287, 131–147. <https://doi.org/10.1016/j.jtbi.2011.07.012>.
- Tiek, D.M., Rone, J.D., Graham, G.T., Pannkuk, E.L., Haddad, B.R., Riggins, R.B., 2018. Alterations in cell motility, proliferation, and metabolism in novel models of acquired temozolomide resistant glioblastoma. *Sci. Rep.* 8 <https://doi.org/10.1038/s41598-018-25588-1>.
- Trejo-Solis, C., Serrano-Garcia, N., Escamilla-Ramírez, Á., Castillo-Rodríguez, R.A., Jimenez-Farfan, D., Palencia, G., Calvillo, M., Alvarez-Lemus, M.A., Flores-

- Nájera, A., Cruz-Salgado, A., Sotelo, J., 2018. Autophagic and apoptotic pathways as targets for chemotherapy in glioblastoma. *Int. J. Mol. Sci.* 19 (12), 3773. <https://doi.org/10.3390/ijms19123773>.
- Truong, D., Fiorelli, R., Barrientos, E.S., Melendez, E.L., Sanai, N., Mehta, S., Nikkhah, M., 2019. A three-dimensional (3D) organotypic microfluidic model for glioma stem cells – vascular interactions. *Biomaterials* 198, 63–77. <https://doi.org/10.1016/j.biomaterials.2018.07.048>.
- Ulrich, T.A., De Juan Pardo, E.M., Kumar, S., 2009. The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. *Cancer Res.* 69, 4167–4174. <https://doi.org/10.1158/0008-5472.CAN-08-4859>.
- Ulrich, T.A., Jain, A., Tanner, K., MacKay, J.L., Kumar, S., 2010. Probing cellular mechanobiology in three-dimensional culture with collagen-agarose matrices. *Biomaterials* 31, 1875–1884. <https://doi.org/10.1016/j.biomaterials.2009.10.047>.
- Unal, S., Arslan, S., Karademir Yilmaz, B., Kazan, D., Oktar, F.N., Gunduz, O., 2020. Glioblastoma cell adhesion properties through bacterial cellulose nanocrystals in polycaprolactone/gelatin electrospun nanofibers. *Carbohydr. Polym.* 233 <https://doi.org/10.1016/j.carbpol.2019.115820>.
- Uribe, D., Torres, A., Rocha, J.D., Niechi, I., Oyarzún, C., Sobrevia, L., San Martín, R., Quezada, C., 2017. Multidrug resistance in glioblastoma stem-like cells: role of the hypoxic microenvironment and adenosine signaling. *Mol. Aspects Med.* 55, 140–151. <https://doi.org/10.1016/j.mam.2017.01.009>.
- Vadivelu, R., Kamble, H., Shiddiki, M., Nguyen, N.-T., 2017. Microfluidic technology for the generation of cell spheroids and their applications. *Micromachines* 8, 94. <https://doi.org/10.3390/mi8040094>.
- Valdés-Rives, S.A., Casique-Aguirre, D., Germán-Castelán, L., Velasco-Velázquez, M.A., González-Arenas, A., 2017. Apoptotic signaling pathways in glioblastoma and therapeutic implications. *Biomed Res. Int.* 2017, 7403747 <https://doi.org/10.1155/2017/7403747>.
- Vatine, G.D., Al-Ahmad, A., Barriga, B.K., Svendsen, S., Salim, A., Garcia, L., Garcia, V.J., Ho, R., Yucer, N., Qian, T., Lim, R.G., Wu, J., Thompson, L.M., Spivia, W.R., Chen, Z., Van Eyk, J., Palecek, S.P., Refetoff, S., Shusta, E.V., Svendsen, C.N., 2017. Modeling psychomotor retardation using iPSCs from MCT8-Deficient patients indicates a prominent role for the blood-brain barrier. *Cell Stem Cell* 20, 831–843. <https://doi.org/10.1016/j.stem.2017.04.002> e5.
- Virga, J., Szemcsák, C.D., Reményi-Puskár, J., Tóth, J., Hortobágyi, T., Csász, É., Zahuczky, G., Szivos, L., Bognár, L., Klekner, A., 2017. Differences in extracellular matrix composition and its role in invasion in primary and secondary intracerebral malignancies. *Anticancer Res.* 37, 4119–4126. <https://doi.org/10.21873/anticancer.11799>.
- Wang, C., Tong, X., Yang, F., 2014. Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-Based hydrogels. *Mol. Pharm.* 11, 2115–2125. <https://doi.org/10.1021/mp5000828>.
- Wang, K., Kievit, F.M., Erickson, A.E., Silber, J.R., Ellenbogen, R.G., Zhang, M., 2016. Culture on 3D chitosan-hyaluronic acid scaffolds enhances stem cell marker expression and drug resistance in human glioblastoma Cancer stem cells. *Adv. Healthc. Mater.* 5, 3173–3181. <https://doi.org/10.1002/adhm.201600684>.
- Wang, C., Tong, X., Jiang, X., Yang, F., 2017a. Effect of matrix metalloproteinase-mediated matrix degradation on glioblastoma cell behavior in 3D PEG-based hydrogels. *J. Biomed. Mater. Res. Part A* 105A, 770–778. <https://doi.org/10.1002/jbm.a.35947>.
- Wang, Y.I., Abaci, H.E., Shuler, M.L., 2017b. Microfluidic blood–brain barrier model provides in vivo-like barrier properties for drug permeability screening. *Biotechnol. Bioeng.* 114, 184–194. <https://doi.org/10.1002/bit.26045>.
- Wang, X., Dai, X., Zhang, X., Li, X., Xu, T., Lan, Q., 2018a. Enrichment of glioma stem cell-like cells on 3D porous scaffolds composed of different extracellular matrix. *Biochem. Biophys. Res. Commun.* 498, 1052–1057. <https://doi.org/10.1016/j.bbrc.2018.03.114>.
- Wang, X., Li, X., Dai, X., Zhang, X., Zhang, J., Xu, T., Lan, Q., 2018b. Bioprinting of glioma stem cells improves their endothelial potential. *Colloids Surf. B Biointerfaces* 171, 629–637. <https://doi.org/10.1016/j.colsurfb.2018.08.006>.
- Wang, C., Li, J., Sinha, S., Peterson, A., Grant, G.A., Yang, F., 2019a. Mimicking brain tumor-vascular microanatomical architecture via co-culture of brain tumor and endothelial cells in 3D hydrogels. *Biomaterials* 202, 35–44. <https://doi.org/10.1016/j.biomaterials.2019.02.024>.
- Wang, X., Dai, X., Zhang, X., Ma, C., Li, X., Xu, T., Lan, Q., 2019b. 3D bioprinted glioma cell-laden scaffolds enriching glioma stem cells via epithelial-mesenchymal transition. *J. Biomed. Mater. Res. - Part A* 107, 383–391. <https://doi.org/10.1002/jbm.a.36549>.
- Wang, B., Wang, Z., Chen, T., Zhao, X., 2020a. Development of novel bioreactor control systems based on smart sensors and actuators. *Front. Bioeng. Biotechnol.* 8, 7. <https://doi.org/10.3389/fbioe.2020.00007>.
- Wang, C., Sinha, S., Jiang, X., Murphy, L., Fitch, S., Wilson, C., Grant, G., Yang, F., 2020b. Matrix stiffness modulates patient-derived glioblastoma cell fates in 3D hydrogels. *Tissue Eng. Part A*. <https://doi.org/10.1089/ten.tea.2020.0110> ahead of print.
- Wang, X., Li, X., Ding, J., Long, X., Zhang, H., Zhang, X., Jiang, X., Xu, T., 2020c. 3D bioprinted glioma microenvironment for glioma vascularization. *J. Biomed. Mater. Res. Part B Appl. Biomater.* <https://doi.org/10.1002/jbm.b.37082>.
- Wang, J.Q., Yang, Y., Cai, C.Y., Teng, Q.X., Cui, Q., Lin, J., Assaraf, Y.G., Chen, Z.S., 2021. Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance. *Drug Resist. Updat.* 54 <https://doi.org/10.1016/j.drup.2021.100743>.
- Weiswald, L.B., Bellet, D., Dangles-Marie, V., 2015. Spherical Cancer models in tumor biology. *Neoplasia (United States)* 17 (1), 1–15. <https://doi.org/10.1016/j.neo.2014.12.004>.
- Wen, P.Y., Weller, M., Lee, E.Q., Alexander, B.M., Barnholtz-Sloan, J.S., Barthel, F.P., Batchelor, T.T., Bindra, R.S., Chang, S.M., Chiocca, E.A., Cloughesy, T.F., DeGroot, J. F., Galanis, E., Gilbert, M.R., Hegi, M.E., Horbinski, C., Huang, R.Y., Lassman, A.B., Le Rhun, E., Lim, M., Mehta, M.P., Mellinger, I.K., Minniti, G., Nathanson, D., Platten, M., Preusser, M., Roth, P., Sanson, M., Schiff, D., Short, S.C., Taphoorn, M.J. B., Tonn, J.-C., Tsang, J., Verhaak, R.G.W., von Deimling, A., Wick, W., Zadeh, G., Reardon, D.A., Aldape, K.D., van den Bent, M.J., 2020. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. *Neuro. Oncol.* 22, 1073–1113. <https://doi.org/10.1093/neuonc/noaa106>.
- Wesseling, P., Capper, D., 2018. WHO 2016 Classification of gliomas. *Neuropathol. Appl. Neurobiol.* 44, 139–150. <https://doi.org/10.1111/nan.12432>.
- Whitesides, G.M., 2006. The origins and the future of microfluidics. *Nature* 442, 368–373. <https://doi.org/10.1038/nature05058>.
- Wiedeman, M.P., 1963. Dimensions of blood vessels from distributing artery to collecting vein. *Circ. Res.* 12, 375–378. <https://doi.org/10.1161/01.RES.12.4.375>.
- Wijdeven, R.H., Pang, B., Assaraf, Y.G., Neefjes, J., 2016. Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics. *Drug Resist. Updat.* 28, 65–81. <https://doi.org/10.1016/j.drug.2016.07.001>.
- Wolff, A., Antfolk, M., Brodin, B., Tenje, M., 2015. In vitro blood-brain barrier models - an overview of established models and new microfluidic approaches. *J. Pharm. Sci.* 104 (9), 2727–2746. <https://doi.org/10.1002/jps.24329>.
- Woods, D., Turchi, J.J., 2013. Chemotherapy induced DNA damage response Convergence of drugs and pathways. *Cancer Biol. Ther.* 14 (5), 379–389. <https://doi.org/10.4161/cbt.23761>.
- Xiao, W., Sohrabi, A., Seidlits, S.K., 2017. Integrating the glioblastoma microenvironment into engineered experimental models. *Futur. Sci. OA.* 3 (3), FSO189. <https://doi.org/10.4155/fsoa-2016-0094>.
- Xiao, M., Li, X., Song, Q., Zhang, Q., Lazzarino, M., Cheng, G., Ulloa Severino, F.P., Torre, V., 2018a. A fully 3D interconnected graphene–Carbon nanotube web allows the study of glioma infiltration in bioengineered 3D cortex-like networks. *Adv. Mater.* 30, 1806132 <https://doi.org/10.1002/adma.201806132>.
- Xiao, W., Zhang, R., Sohrabi, A., Ehsanipour, A., Sun, S., Liang, J., Walther, C.M., Ta, L., Nathanson, D.A., Seidlits, S.K., 2018b. Brain-mimetic 3D culture platforms allow investigation of cooperative effects of extracellular matrix features on therapeutic resistance in glioblastoma. *Cancer Res.* 78, 1358–1370. <https://doi.org/10.1158/0008-5472.can-17-2429>.
- Xiao, W., Wang, S., Zhang, R., Sohrabi, A., Yu, Q., Liu, S., Ehsanipour, A., Liang, J., Bierman, R.D., Nathanson, D.A., Seidlits, S.K., 2019. Bioengineered scaffolds for 3D culture demonstrate extracellular matrix-mediated mechanisms of chemotherapy resistance in glioblastoma. *Matrix Biol.* 85–86, 128–146. <https://doi.org/10.1016/j.matbio.2019.04.003>.
- Xu, H., Rahimpour, S., Nesvick, C.L., Zhang, X., Ma, J., Zhang, M., Zhang, G., Wang, L., Yang, C., Hong, C.S., Germanwala, A.V., Elder, J.B., Ray-Chaudhury, A., Yao, Y., Gilbert, M.R., Lonser, R.R., Heiss, J.D., Brady, R.O., Mao, Y., Qin, J., Zhuang, Z., 2015. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy. *Oncotarget* 6, 11882–11893. <https://doi.org/10.18632/oncotarget.3592>.
- Xu, H., Li, Z., Yu, Y., Sizdahkhani, S., Ho, W.S., Yin, F., Wang, L., Zhu, G., Zhang, M., Jiang, L., Zhuang, Z., Qin, J., 2016. A dynamic in vivo-like organotypic blood-brain barrier model to probe metastatic brain tumors. *Sci. Rep.* 6 <https://doi.org/10.1038/srep36670>.
- Yahyanejad, S., King, H., Iglesias, V.S., Granton, P.V., Barbeau, L.M.O., van Hoof, S.J., Groot, A.J., Habets, R., Prickaerts, J., Chalmers, A.J., Ekers, D.B.P., Theys, J., Short, S.C., Verhaegen, F., Vooijs, M., 2016. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. *Oncotarget* 7. <https://doi.org/10.18632/oncotarget.9275>.
- Yamada, K., Tso, J., Ye, F., Choe, J., Liu, Y., Liau, L.M., Tso, C.L., 2011. Essential gene pathways for glioblastoma stem cells: clinical implications for prevention of tumor recurrence. *Cancers (Basel)*. 3 (2), 1975–1995. <https://doi.org/10.3390/cancers3021975>.
- Yang, N., Yan, T., Zhu, H., Liang, X., Leiss, L., Sakariassen, P.Ø., Skafnesmo, K.O., Huang, B., Costea, D.E., Enger, P.Ø., Li, X., Wang, J., 2014. A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma. *J. Transl. Med.* 12 <https://doi.org/10.1186/s12967-014-0278-y>.
- Yang, M.Y., Chiao, M.T., Lee, H.T., Chen, C.M., Yang, Y.C., Shen, C.C., Ma, H.I., 2015. An innovative three-dimensional gelatin foam culture system for improved study of glioblastoma stem cell behavior. *J. Biomed. Mater. Res. B Appl. Biomater.* 103, 618–628. <https://doi.org/10.1002/jbm.b.33214>.
- Yang, H., Villani, R.M., Wang, H., Simpson, M.J., Roberts, M.S., Tang, M., Liang, X., 2018. The role of cellular reactive oxygen species in cancer chemotherapy. *J. Exp. Clin. Cancer Res.* 37, 266. <https://doi.org/10.1186/s13046-018-0909-x>.
- Yi, H., Jeong, Y.H., Kim, Y., Choi, Y., Moon, H.E., Cho, D., 2019. A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses. *Nat. Biomed. Eng.* 3, 509–519. <https://doi.org/10.1038/s41551-019-0363-x>.
- Zhang, M., Ye, G., Li, J., Wang, Y., 2015. Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy. *Brain Tumor Pathol.* 32, 229–236. <https://doi.org/10.1007/s10014-015-0233-5>.
- Zhang, L., Cui, Y., Amiri, A., Ding, Y., Campbell, R.E., Maysinger, D., 2016. Pharmacological inhibition of lipid droplet formation enhances the effectiveness of curcumin in glioblastoma. *Eur. J. Pharm. Biopharm.* 100, 66–76. <https://doi.org/10.1016/j.ejpb.2015.12.008>.
- Zhang, C., Jin, M., Zhao, J., Chen, J., Jin, W., 2020. Organoid models of glioblastoma: advances, applications and challenges. *Am. J. Cancer Res.* 10, 2242–2257.

- Zhang, H., Xu, H., Ashby, C.R., Assaraf, Y.G., Chen, Z.S., Liu, H.M., 2021. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). *Med. Res. Rev.* 41 (1), 525–555. <https://doi.org/10.1002/med.21739>.
- Zhitomirsky, B., Assaraf, Y.G., 2016. Lysosomes as mediators of drug resistance in cancer. *Drug Resist. Updat.* 24, 23–33. <https://doi.org/10.1016/j.drug.2015.11.004>.
- Zhu, T.S., Costello, M.A., Talsma, C.E., Flack, C.G., Jessica, G., Hamm, L.L., He, X., Hervey-j, S.L., Heth, J.A., Muraszko, M., Dimeco, F., Vescovi, A.L., Fan, X., 2012. Endothelial cells create a stem cell niche in glioblastoma by providing Notch ligands that nurture self-renewal of cancer stem-like cells. *Cancer Res.* 71, 6061–6072. <https://doi.org/10.1158/0008-5472.CAN-10-4269.Endothelial>.
- Zhu, D., Trinh, P., Li, J., Grant, G., Yang, F., 2020. Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in <scp>3D</scp>. *J. Biomed. Mater. Res. Part B Appl. Biomater.* 1–9. <https://doi.org/10.1002/jbm.b.37093>.
- Zustiak, S.P., Dadhwal, S., Medina, C., Steczina, S., Chehrehganzabi, Y., Ashraf, A., Asuri, P., 2016. Three-dimensional matrix stiffness and adhesive ligands affect cancer cell response to toxins. *Biotechnol. Bioeng.* 113, 443–452. <https://doi.org/10.1002/bit.25709>.